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ABSTRACT 
 
EVASION OF HOST RECOGNITION BY PHASE VARIATION IN HAEMOPHILUS INFLUENZAE 
Sarah E. Clark 
Jeffrey N. Weiser 
 
Haemophilus influenzae colonizes the human respiratory tract, and is a major 
source of disease. Antibody and complement contribute to the limitation of H. 
influenzae colonization. This work explores bacterial factors that aid in the 
evasion of antibody recognition and subsequent complement-mediated lysis. 
Antibody recognition of H. influenzae is affected by the phase variation of 
lipopolysaccharide (LPS) structures. Phase variation refers to the stochastic, high 
frequency on/off switching in gene expression. One phase variable gene, lic1A, 
controls the attachment of the small molecule phosphorylcholine (ChoP) to the 
LPS. We found that ChoP-expressing bacteria had reduced antibody binding and 
increased survival in the presence of complement. Also, ChoP attachment to the 
LPS increased the stability of the outer membrane, reducing accessibility to host 
molecules including antibodies. Next, we conducted a screen of genes required 
for complement resistance in H. influenzae. We found that several LPS phase 
variable biosynthesis genes are critical for survival in the presence of human 
antibody and complement. In addition to these, we identified vacJ and the 
associated yrb genes, which encode an ABC transporter that increases 
membrane stability and reduces antibody binding. These findings present two 
different examples of how alterations in outer membrane stability can affect 
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antibody binding to bacterial surface structures. Finally, we examined the 
dynamics of the contributions of multiple phase variable LPS biosynthesis genes 
to bacterial survival. We found that exposure to antibody and complement drives 
selection for phase variants expressing ChoP, di-galactoside (galα1-4gal), and 
an alternative glucose structure. Each of these LPS structures, in addition to the 
phase variable molecule sialic acid, had an independent effect on bacterial 
survival, and these effects were additive in combination. Bacteria with the 
maximum number of LPS modifications had the greatest survival, and this 
correlated with reduced recognition of conserved inner core LPS structures. In 
summary, LPS phase variation in H. influenzae contributes to bacterial evasion of 
antibody binding and complement-mediated killing. The expression of several 
LPS phase variable modifications shields conserved surface structures on H. 
influenzae from host recognition to contribute to the successful colonization of 
this extracellular pathogen. 
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CHAPTER 1 
	  
Introduction, Part 1: Haemophilus influenzae colonization and the role of 
oligosaccharide phase variation 
 
Sarah E. Clark 
 
Department of Microbiology, University of Pennsylvania, Philadelphia, 
Pennsylvania, United States of America 
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H. influenzae colonization and disease 
 
Haemophilus influenzae is a gram-negative coccobacillus that colonizes 
the human respiratory tract. H. influenzae was first described by Richard Pfeiffer, 
working with Shibasaburo Kitasato under Robert Koch in 1892 (380). At the time, 
Pfeiffer and his colleagues identified what they called Bacillus influenzae from 
patients with influenza. While H. influenzae was initially described as the 
causative agent of influenza, this theory was disproved by filtration of infectious 
material from influenza patients during the 1918 pandemic. Since then, it has 
become clear that H. influenzae is an important human pathogen in its own right, 
and we continue to investigate both asymptomatic colonization and disease 
caused by this bacterium. The name Haemophilus, or ‘heme-loving,’ is derived 
from the nutrient requirements of H. influenzae, which is dependent on an 
environmental source of hemin, as well as nicotinamide adenine dinucleotide 
(NAD), for growth (87). Humans are the only known reservoir and natural host for 
H. influenzae, and it is therefore important to understand the associations 
between this bacterium and its native environment, the human nasopharynx. 
 Colonization with H. influenzae occurs early in life, often within the first few 
months of age, and carriage rates are highest (up to 80%) in infants and children 
under six years old (89, 113). While individual colonization events are transient, 
lasting weeks to a few months, exposure to other H. influenzae strains in the 
population can lead to serial colonization.  A study comparing healthy patients to 
those with H. influenzae bronchiectasis found that all subjects, including healthy 
patients, had detectable levels of antibody reactive against several different H. 
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influenzae strains, supporting the notion that most people have been exposed to 
H. influenzae by adulthood (201). Transient, asymptomatic colonization can be 
studied using the murine nasopharyngeal model, where bacteria are introduced 
intranasally without anesthetics. This model has been used to study the host 
immune factors that are important for limiting bacterial colonization (440). An 
experimental human colonization model was recently developed by M. Apicella 
and colleagues at the University of Iowa, where healthy volunteers were 
intranasally inoculated with H. influenzae, and following six days of colonization 
all subjects were treated with antibiotics to clear remaining bacteria (303).  Study 
of the commensal state of H. influenzae is important to better understand the 
subsequent processes of disease development and transmission, which are 
discussed below. Limitation of H. influenzae carriage is a critical step toward 
reducing H. influenzae-associated disease. 
 Infection with H. influenzae can lead to invasive diseases including 
septicemia and meningitis, as well as more localized respiratory tract infections 
(272, 382). H. influenzae is one of the primary pathogens associated with otitis 
media, which is especially common in children, as well as pneumonia and 
chronic bronchitis (14, 275). H. influenzae is also the bacterial agent most 
frequently associated with exacerbations of chronic obstructive pulmonary 
disease (COPD), which is currently the third leading cause of death worldwide 
(271, 296). Antimicrobials are commonly used to treat patients with H. influenzae 
infections, although many strains carry antibiotic resistance determinants, such 
as β-lactamase, or express mutant penicillin binding proteins, making bacterial 
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clearance more difficult (200, 259, 337). It has been suggested that H. influenzae 
can ‘hide’ inside epithelial cells, reducing antibiotic accessibility (14). However, 
while there is evidence for metabolic activity in intracellular H. influenzae, these 
bacteria do not grow, and there is no evidence for continued replication following 
cell invasion (258). 
There are several studies supporting the proposition that colonization with 
H. influenzae is directly linked to the development of H. influenzae-associated 
disease. For example, a study following infections in COPD patients over time 
demonstrated that colonization with H. influenzae correlated with the timing of 
disease exacerbations as well as markers of inflammation (296). Also, in children 
with recurrent otitis media, the frequency of H. influenzae colonization matched 
the frequency of otitis media events (148). For the development of otitis media, it 
has been suggested that H. influenzae spreads to the middle ear through the 
Eustachian tube, which is shorter in young children (325). An infant rat model of 
invasive infection showed evidence for direct spread of H. influenzae from the 
nasopharynx to the bloodstream, which was independent of regional lymph 
nodes (326). Colonization with H. influenzae is also thought to be critical for 
transmission to new hosts. In a study of strain diversity in children, caregivers 
were colonized by the same H. influenzae isolates as the children they cared for 
(337). Also, high levels of H. influenzae DNA can be isolated from both middle 
ear effusion samples and, importantly for transmission, nasopharyngeal samples 
(390). These studies highlight the importance of considering both asymptomatic 
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and disease-related states of H. influenzae infection, as the two are intricately 
linked. 
Different types of H. influenzae strains are associated with the 
development of separate disease states: invasive disease versus more localized 
respiratory tract infections. The separation between these manifestations of H. 
influenzae infections is due to the presence and type of capsule, which is a thick 
polysaccharide that surrounds the outer membrane of encapsulated strains (57). 
H. influenzae strains with a type-b capsule (Hib) are the most virulent compared 
to other capsule types, and Hib infection can lead to septicemia and meningitis 
(10, 441). The advent of conjugate vaccines for Hib, the first of which was 
licensed in 1987, has led to a dramatic reduction in invasive H. influenzae 
disease (2). Hib vaccines involve conjugation of the type-b polyribosyl ribitol 
phosphate (PRP) capsule to a protein carrier (61, 119). Conjugation to a protein 
carrier is necessary because capsule polysaccharide is a T-cell independent 
antigen, and therefore will not stimulate protective immunity (with memory) in 
infants (192, 306). The Hib vaccine is highly effective at preventing Hib disease 
(over 80%), induces long-term antibodies capable of recognizing Hib, and 
reduces carriage of Hib (119, 233, 260). H. influenzae strains without capsule are 
called non-typeable H. influenzae (NTHi), and these are most frequently 
associated with respiratory tract infections (275). There are other capsule types, 
from type-a through type-f, although carriage and infections from these are less 
frequent than for Hib and NTHi strains (156). Of note, the avirulent strain Rd is a 
capsule-negative derivative of a type-d strain, and is a commonly used laboratory 
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strain. Rd was the first organism to have its genome fully sequenced, and is very 
amenable to transformation (102). NTHi strains contain abundant intra- and 
interstrain diversity, and are genetically distinct from Hib and other encapsulated 
strains (86, 280, 337). 
 The burden of disease caused by NTHi strains has necessitated the 
development of vaccine strategies to target these bacteria. In the absence of a 
capsule, alternative vaccination approaches are required for NTHi strains. 
Several methods have been explored, including vaccination with outer 
membrane vesicles, conjugation of the lipopolysaccharide (LPS) to a protein 
carrier, and immunization with purified, conserved outer membrane proteins or 
LPS structures (140, 304, 321, 379). There is one currently licensed vaccine with 
efficacy against NTHi disease. This vaccine was developed to protect against 
Streptococcus pneumoniae strains, with 10 S. pneumoniae capsule types 
conjugated to protein D, which is a conserved outer membrane protein in H. 
influenzae (105). In addition to protecting against S. pneumoniae-associated 
disease, the protein D conjugate vaccine has 33.5% efficacy for protection 
against NTHi acute otitis media (307). However, the protein D vaccine does not 
prevent NTHi colonization (395). Despite the limited efficacy of the protein D 
vaccine, its ability to reduce NTHi disease serves as a proof-of-principle for the 
potential to protect against infection through vaccination targeting conserved 
surface structures. The inclusion of additional targets, or alternative outer 
membrane structures such as the LPS, are some of the strategies currently being 
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explored to develop a more successful NTHi vaccine to prevent respiratory tract 
infections associated with H. influenzae infection. 
 
Host defenses against H. influenzae in the respiratory tract 
 
Mucociliary clearance 
Successful colonization of the human respiratory tract requires multiple strategies 
for the subversion of host defenses at the mucosal surface. One of the first 
challenges is simply remaining at the site of colonization; airway epithelial cells 
provide the means to literally sweep away a large number of microbes through 
mucociliary clearance (424). The thick mucus layer present throughout the 
respiratory tract is the first barrier against infection. Also, exposure to gram-
negative bacteria can cause the up-regulation of genes responsible for mucin 
production (76). To circumvent mucociliary clearance, many microbes have 
adhesive molecules designed to bind (non-specifically or through direct receptor-
ligand interactions) to the host epithelium (21). H. influenzae strains express 
several adhesive proteins, including the HMW1 and HMW2 adhesins, the Hap 
autotransporter adhesin, protein E, the fimbriae protein P5, and pili (96, 125, 187, 
251, 323, 356). Carriage of these adhesins varies between different strains of H. 
influenzae, and some, including the HMW1 and HMW2 adhesins, are only found 
in NTHi isolates (79). Some adhesins have dynamic interactions with their 
receptors. For example, P5 binding to one of its epithelial cell receptors, 
intracellular adhesion molecule 1 (ICAM-1), up-regulates receptor expression 
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(11). Adhesins can also have dual roles, such as the Hap adhesin, which 
increases binding to respiratory tract epithelial cells and contains a domain that 
enables bacterial cell-cell adhesion (249). The aggregation of receptor-bound 
bacteria has been proposed to be important for the development of 
microcolonies, which could aid bacterial persistence in the respiratory tract. 
Multiple adhesins, with different host receptor targets, contribute to the ability of 
H. influenzae to associate with the respiratory tract surface and avoid mucociliary 
clearance.   
 
Antimicrobial peptides 
In addition to mucus itself, the respiratory tract contains a number of antimicrobial 
peptides, both secreted by epithelial cells and present within phagocytic immune 
cells such as neutrophils (420). Antimicrobial peptides with bactericidal activity 
have been isolated from human nasal tissue, nasal secretions, and lung airway 
fluid (56, 229, 355). Members of the two main antimicrobial peptide classes, 
defensins and cathelicidins, have lytic activity against H. influenzae strains (214, 
229). Many antimicrobial peptides are positively charged, as their mechanism of 
action involves binding to and invasion of the negatively charged bacterial cell 
envelope. A study comparing the binding properties of different antimicrobial 
peptides found that all peptides that could bind NTHi strains contained positively 
charged residues (27). Bacterial strategies for antimicrobial resistance, therefore, 
include protease digestion as well as membrane modifications that reduce the 
9 
negative charge of the bacterial surface (75). Examples of membrane charge 
modifications include the addition of lysine to the cell wall of Staphylococcus 
aureus, and the attachment of aminoarabinose to the lipid A portion of the LPS of 
Salmonella enterica, which both reduce the negative surface charge and 
increase antimicrobial peptide resistance (142, 300). In H. influenzae, an 
alternative strategy to evade killing by defensins is to import them to the 
cytoplasm for degradation, through the Sap ABC transporter (242, 349). 
Antimicrobial peptides can also affect the immune response against invading 
microbes indirectly. For example, the human cathelicidin LL-37 can down-
regulate macrophage activity, and other antimicrobial peptides affect recruitment 
of neutrophils and T cells (147, 341).   
  
Cell-mediated immunity 
In addition to cell-free antimicrobial factors, cell-mediated immune responses 
limit bacterial colonization of the respiratory tract. Alveolar macrophages are the 
first line of cellular immune defense encountered by microbes at the mucosal 
surface, and are capable of killing H. influenzae (350). Alveolar macrophages 
from COPD patients have impaired phagocytosis of NTHi strains, suggesting the 
reduced function of this cell type contributes to H. influenzae disease (25). The 
other major cell type involved in airway immunity is the neutrophil. While 
neutrophils are initially present in low numbers in respiratory tract tissue, they are 
recruited to high levels from the respiratory tract vasculature following infection 
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(439). It has been shown in a murine model of nasopharyngeal colonization that 
neutrophils help reduce H. influenzae colonization (440). Neutrophil recruitment 
and pro-inflammatory responses induced by H. influenzae are initiated in part by 
the toll-like receptor TLR4, which binds LPS, on epithelial cells and alveolar 
macrophages (406). TLR4 and TLR2, which recognizes lipoproteins, contribute 
to the stimulation of a pro-inflammatory immune response and limit H. influenzae 
colonization (22).  Other immune cell types, including T and B cell subtypes, are 
important for the development of protective immunity against H. influenzae, such 
as that observed in patients who have received the Hib conjugate vaccine (192). 
B cells secrete antibody, establish immunological memory, and undergo affinity 
maturation to make more antigen-specific antibodies (265). T cells help activate 
B cells to produce antibody and stimulate phagocytic cells (265). Also, Th17 cells 
can activate neutrophil recruitment, and were shown to be important in an acute 
pneumonia model of S. pneumoniae infection (205, 237). While it has been 
shown that adaptive immune cell types are not required for initial recognition and 
clearance of H. influenzae in the naïve host, cell-mediated immune responses 
may be more important during disease development (108, 440). 
 
Complement defenses 
In addition to cell-mediated immune clearance, H. influenzae is susceptible to 
direct complement-dependent lysis. There are three main pathways of 
complement-mediated killing of bacterial pathogens (summarized in Figure 1) 
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(403). The classical complement pathway involves antibody binding to the 
bacterial surface, followed by the deposition of complement proteins that form the 
C1 complex (containing the C1q, C1r, C1s proteins), which cleaves C4 and C2 to 
form the classical pathway C3 convertase (a C4b2a complex). The mannose-
binding lectin complement pathway is initiated by mannose-binding lectin (MBL) 
and MBL associated proteases binding to the bacterial surface, which leads to 
the formation of the lectin pathway C3 convertase (a C4b2a complex). It is 
unclear how much the mannose-binding lectin pathway contributes to control of 
H. influenzae infection, as MBL binding has been observed in very few H. 
influenzae strains (283, 347). Finally, the alternative complement pathway results 
from the direct binding of C3b (from spontaneous C3 cleavage) to the bacterial 
surface, which then binds factor B. Factor B is cleaved by factor D to form the 
alternative pathway C3 convertase (a C3bBb complex). The three complement 
pathways converge at the level of the formation of a C3 convertase, which 
cleaves C3 to C3a and C3b. The C3b cleavage fragments bind to the bacterial 
surface and initiate the formation of the membrane attack complex (MAC) (403). 
The MAC, which is assembled after cleavage of C5 to make C5a and C5b, 
contains the complement components C5b, C6, C7, C8, and C9, and together 
these proteins insert into the bacterial membrane to form a pore, resulting in cell 
lysis. In addition to direct cell lysis, complement is important for 
opsonophagocytosis, as C3b deposition acts as an opsonin to increase bacterial 
recognition and uptake (288). Also, circulating complement cleavage products 
including C3a and C5a are pro-inflammatory (352).  
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Several host proteins can interact with components of the complement 
pathway and affect their activity. For example, C-reactive protein can bind 
bacteria and initiate classical pathway complement-mediated lysis (in place of 
antibody binding) (132). Other host proteins, discussed below, can bind the 
bacterial surface and reduce sensitivity to complement-mediated lysis. The 
complement system is incredibly complex, involving over 30 proteins, and is a 
key component of the host immune response to H. influenzae infection. 
Complement proteins are present on the mucosal surface, and levels increase 
significantly during inflammation (146). Complement depletion experiments in 
animal models have demonstrated the importance of complement in reducing H. 
influenzae colonization and invasive disease (440, 442). These data are 
consistent with clinical observations, as people with deficiencies in the activation 
and regulation of complement have recurrent infections with bacteria including H. 
influenzae (78, 301).  
Different strains of H. influenzae have varying levels of complement 
susceptibility based on their repertoire of complement-resistance determinants 
(423). For example, different capsular types of H. influenzae have separate 
complement resistance profiles (371, 373). Within the same capsular type, 
duplication of the capsule-encoding locus, which increases the amount of 
capsule expressed, reduces deposition of C3 and increases survival in the 
presence of complement (287). For NTHi strains, one example of a complement-
resistance mechanism is binding to host C4b-binding protein (C4BP), which 
reduces susceptibility to classical pathway complement-mediated lysis through 
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degradation of C3b and C4b (145). While the bacterial receptor is unknown, 
C4BP binding has been observed for several clinical NTHi isolates (compared to 
the absence of binding to encapsulated strains). H. influenzae protein E binds the 
host protein vitronectin, which protects against complement-mediated lysis by 
reducing deposition of MAC proteins on the bacterial surface (354). Also, some 
NTHi strains bind serum amyloid protein (SAP), which reduces C1q deposition, 
increasing resistance to classical pathway complement-mediated lysis (70). 
Other bacteria use similar strategies for the reduction of complement-mediated 
lysis. For example, sialic acid attached to the outer membrane can bind the host 
protein factor H, which promotes inactivation of the C3 convertase and C3b 
proteins, although this does not occur following sialylation in H. influenzae (95, 
313).  
 
Antibody recognition of H. influenzae 
Antibodies are another cell-free immune factor critical to the host defense against 
H. influenzae. Antibody recognition of bacteria can lead to the deposition of 
complement components, resulting in classical pathway complement-mediated 
killing (404). In addition to complement-mediated cell lysis, antibody binding 
contributes to the phagocytosis of H. influenzae by acting as an opsonin to 
enhance bacterial uptake, as with some complement proteins (386). Also, 
antibody binding can cause the agglutination of bacterial cells, which aids in the 
mucociliary clearance of bacteria not bound to epithelial cells (381). Even without 
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the Fc-activating portion of antibody, which is required for C1q deposition, 
antibody-mediated agglutination of H. influenzae enhances complement-
dependent lysis, likely through increased C3b deposition (65). The importance of 
antibody for protection against H. influenzae has been demonstrated in the 
murine nasopharyngeal colonization model, where antibody-deficient (µMT) mice 
have higher levels of bacteria that wild-type mice (440). As mice are not a natural 
host of H. influenzae, the antibodies important for controlling colonization are 
natural antibodies.  
Natural antibodies refer to those produced in the absence of specific 
antigen stimulation, and typically have poly-reactivity with host and non-host 
epitopes (12). Natural antibodies present on the mucosal surface provide 
immediate protection against a wide range of pathogens, although in order to 
limit potentially damaging responses against self epitopes, these antibodies are 
not capable of affinity maturation (19). In addition to pre-existing natural 
antibodies, some antibodies raised in response to other bacteria can cross-react 
with H. influenzae (118). Exposure to H. influenza also results in production of 
antigen-specific antibodies, such as antibodies that bind the outer membrane 
proteins P6 and protein D (194). While IgA is the most abundant antibody 
present on the respiratory tract mucosal surface, IgG and IgM are also present 
and can be detected in human nasal secretions (202). IgG and IgM contribute to 
killing of H. influenzae through classical pathway complement-mediated lysis (53, 
282). While IgA does not activate the classical pathway of complement, it can 
affect bacterial survival by interfering with bacterial adherence and increasing 
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phagocytosis (198). Although less well characterized, IgD can bind type-b H. 
influenzae strains and is also present in the upper airways (50).  
Clinical evidence supports a role for antibody in the defense against H. 
influenzae infection in humans. For example, people with IgM deficiencies have 
increased susceptibility to NTHi compared to those capable of IgM production 
and secretion (253). Also, people deficient in the production of all antibody types 
have persistent infections with H. influenzae (330). There are many outer 
membrane structures of H. influenzae that are targets of antibody. For example, 
antibodies that recognize the HMW1 and HMW2 adhesins increase 
opsonophagocytic killing in the presence of complement and neutrophils (425). 
Antibodies against outer membrane proteins including P2, P4, and P6 have been 
thoroughly investigated due to interest in conserved vaccination targets (32, 175, 
386). In addition to these, there are also many bactericidal antibodies targeting 
LPS structures (85). One important defense mechanism against antibody binding 
in H. influenzae is the expression of IgA1 protease genes, including iga and igaB 
(93). However, even with IgA1 protease digestion, H. influenzae remains 
susceptible to IgG and IgM antibody recognition during colonization. Additional 
defenses against antibody recognition of H. influenzae outer membrane 
structures are the subject of ongoing work and a focus of this thesis.  
 
Surface variation in H. influenzae 
 
16 
 Host recognition of H. influenzae is dependent on the repertoire of surface 
structures on the bacterial outer membrane. Understanding the composition and 
variation of these structures is critical to the development of strategies to 
enhance bacterial clearance. The two main categories of surface structures in H. 
influenzae are the outer membrane proteins and the LPS. The six most prevalent 
outer membrane proteins in H. influenzae are designated P1 through P6, in order 
of descending molecular weight (221). Of these, the porin P2 is the most 
abundant outer membrane protein on the surface of H. influenzae, and is also a 
target of bactericidal antibodies (273, 386). Several of these proteins perform 
critical functions for H. influenzae. For example, the lipoprotein P6, which is 
highly conserved, helps to maintain the stability of the outer membrane (276). 
Another highly conserved lipoprotein, P4, aids in the utilization of NAD for 
bacterial growth (315). Other outer membrane proteins include protein D and the 
multiple adhesins mentioned previously (4). The conservation of these proteins 
make them good vaccine targets, and several studies have shown that 
immunization with outer membrane proteins leads to the production of an 
antibody response against H. influenzae (175, 176, 304). However, several outer 
membrane proteins contain variable domains, and minor outer membrane 
proteins are often not conserved among H. influenzae strains, making 
vaccination coverage more difficult (79, 123). 
 The second major surface structure on the outer membrane of H. 
influenzae is the LPS. The LPS of H. influenzae is also referred to as the 
lipooligosaccharide (LOS), because unlike most gram-negative bacteria it does 
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not contain the extended chain of O-antigen oligosaccharide units (421). Instead, 
the LPS of H. influenzae consists of a truncated oligosaccharide core, similar to 
that of rough mutants of other bacteria, such as Salmonella (402). The LPS of H. 
influenzae has several variable structures, and these provide a major source of 
surface antigenic variation. As shown in Figure 2, the LPS is composed of a 
conserved inner core, which is identical among all strains, and a variable outer 
core (169, 225). The inner core contains the lipid A portion of the LPS, which has 
hydrophobic acyl chains that insert into the outer leaflet of the outer membrane. 
Attached to lipid A is a single 2-keto-3-deoxyoctulosonic acid (KDO) group, with a 
pyrophosphoethanolamine residue on it. Extending outward (away from the 
bacterial surface) from the KDO group are three conserved heptose residues, 
which are referred to as HepI, HepII, and HepIII. Aside from the conserved 
phosphoethanolamine that is attached to the HepII residue, the remaining LPS 
extensions from the three inner core heptoses comprise the variable outer core 
of H. influenzae LPS. Outer core LPS structures differ both among separate 
strains of H. influenzae and within a single population of the same isolate (339, 
375).  
 LPS modifications in many bacteria are important for host-pathogen 
interactions. For example, bacteria with O-antigen extensions have several 
survival advantages compared to O-antigen-deficient isogenic mutants. In 
Francisella tularensis, O-antigen reduces complement-mediated lysis, and in 
Brucella melitensis the presence of O-antigen aids intracellular survival (54, 94). 
Also, in Salmonella, O-antigen contributes to the reduction of early innate 
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immune responses stimulated by bacterial invasion of epithelial cells (77). 
Modification of lipid A is a mechanism to increase to bacterial survival in the 
presence of antimicrobial peptides, through reduction of the negative charge of 
the bacterial membrane, as previously mentioned (82). An additional example of 
this type of resistance is the de-phosphorylation of lipid A, which increases 
resistance to cationic antimicrobial peptides in Helicobacter pylori and 
Porphyromonas gingivalis (55, 62). Alteration of core oligosaccharide structures 
can also affect bacterial evasion of host immunity. For example, core 
oligosaccharide structures, not O-antigen, are required for adherence and 
invasion of epithelial cells by S. enterica (40). In Escherichia coli, dendritic cells 
phagocytose rough LPS mutants more readily than wild-type or deep-rough 
mutants. Rough mutants contain the oligosaccharide core but no O-antigen, 
suggesting targeting of core LPS structures (203). LPS modifications affecting 
host recognition of H. influenzae occur primarily in the oligosaccharide core. 
 
Phase variation of oligosaccharide structures in H. influenzae 
 
 The diversity of core oligosaccharide structures in H. influenzae is largely 
due to the phase variation of LPS biosynthesis genes. Phase variation is defined 
by high frequency, reversible, switching (off ↔ on) in gene expression. In 
contrast to spontaneous mutation, which occurs at a frequency of 10-8 to 10-6 per 
generation, phase variation happens at a rate of 10-4 or higher per generation, 
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depending on the mechanism (426). There are several mechanisms for phase 
variation of gene expression. Some of these include gene conversion, which 
involves gene recombination, site-specific conversion, where recombinases swap 
out genes at inverted repeat sites, duplication, insertion-excision, and gene 
deletion. One example from these mechanisms is the duplication of the capsule-
encoding locus of H. influenzae. The cap locus in type b H. influenzae is flanked 
by an insertion element, allowing amplification through locus duplication, which 
increases the amount of capsule expressed (207). Another mechanism of phase 
variation is called slipped-strand mispairing (215). Slipped-strand mispairing is 
caused by the presence of short DNA repeats either within the coding sequence 
of a gene or in the promoter region. During DNA replication, slipped-strand 
mispairing can result in either the addition or deletion of DNA repeats, shifting the 
reading frame of the product. Therefore, slipped-strand mispairing creates a 
translational on/off switch. Importantly, phase variation is distinct from other 
forms of gene regulation because it is a stochastic process; rather than 
responding to an external stimulant, phase variation ensures continuous 
reversals in gene expression (396). The maintenance of a heterogeneous 
population is a specific survival strategy for H. influenzae, allowing rapid 
enrichment of the most-fit phase variants amidst constantly changing host 
conditions.  
 There are several examples of phase variation by slipped-strand 
mispairing in different bacterial systems. In Neisseria gonorrhoeae, pentamaric 
repeats in two genes within the opaE1 locus are responsible for the phase 
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variation of opacity proteins (368). In Neisseria meningitidis, the presence of a 
homopolymeric guanosine tract in the gene pptA causes phase variation of pili 
modification with phosphorylcholine (referred to as ChoP) (407). There are also 
homopolymeric repeat tracts in genes encoding adhesins in Yersinia 
pseudotuberculosis and Bordetella pertussis (324, 422). Homopolymeric tracts in 
the LPS biosynthesis genes of Campylobacter jejuni (wlaN), H. pylori (futA and 
futB), and Neisseria species (lgt genes) are responsible for phase variation of 
LPS structures in these bacteria (7, 182, 218).  
 In H. influenzae, there are several LPS biosynthesis genes with 
tetranucleotide repeats, causing phase variation by slipped-strand mispairing 
(171). The rate of phase variation for genes containing tetranucleotide repeats in 
H. influenzae is 10-2 to 10-3 per generation, and this rate is higher for longer 
repeat tracts (69, 413). The phase variation of LPS biosynthesis genes affects 
the attachment of structures to the outer core region of the LPS, and these 
structures include hexose and non-oligosaccharide modifications. The 
expression of some outer core LPS structures is dependent on the attachment of 
proximal structures, which can also be phase variable. As a result, there are 
examples where the sequential addition of several LPS residues is dependent on 
the phase variant status of each LPS biosynthesis gene involved in the full 
extension (136, 339). Phase variation of the outer core creates a mixture of 
different LPS structures expressed within a single population from the same 
strain of H. influenzae.  
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Not every strain of H. influenzae contains the same repertoire of phase 
variable LPS biosynthesis genes, so there are different structural possibilities 
between separate H. influenzae strains (305). Also, some phase variable LPS 
biosynthesis genes have multiple alleles. For example, different alleles of the 
phosphorylcholine transferase, lic1D, control attachment to extensions from 
separate heptose residues (228). Allelic polymorphisms in the gene lex2B 
determine whether glucose or galactose is attached to the LPS when the 
associated phase variable gene lex2A is expressed (73). Finally, LPS 
heterogeneity in H. influenzae is not solely influenced by phase variation. Several 
LPS biosynthesis genes compete for substrates, creating another source of 
random structural variation (340). Unlike phase variation, this type of structural 
diversity is not heritable, although both are stochastic processes. 
 H. influenzae phase variable LPS biosynthesis genes with tetranucleotide 
repeats, where the LPS structure affected by phase variation has been 
characterized, are summarized in Table 1 and discussed below. Aside from the 
genes listed in Table 1, there are also LPS phase variable genes with other 
length repeats, such as the losA1 gene, which has an octonucleotide repeat and 
controls attachment of a fourth heptose to the outer core of the LPS (84). Phase 
variation also occurs in genes controlling expression of outer membrane proteins. 
For example, there is phase variation of the HMW1 and HMW2 adhesins, caused 
by heptanuclotide repeats in the promoter regions of the hmw1A and hmw2A 
genes, and of fimbriae, from dinuclotide repeats in the promoter region of the hifA 
and hifB genes (67, 397). Additional genes with repeat tracts of various lengths 
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have been identified in screens of H. influenzae genomes, but these genes 
remain largely uncharacterized (264, 305). Four of the phase variable genes with 
tetranucleotide repeats not listed in Table 1 encode hemoglobin-binding proteins, 
involved in the acquisition of hemin, an essential nutrient required for H. 
influenzae growth (261, 305). There are several host factors involved in 
sequestering iron, which makes hemin a limited nutrient at the mucosal surface 
(43, 410). The remaining tetranucleotide repeat-containing gene that has been 
characterized in H. influenzae but is not included in Table 1 is mod, which is a 
type III DNA methyltransferase (69). Phase variation of mod affects the 
expression of two other DNA methyltransferases, which remain uncharacterized, 
in addition to genes involved in metabolism and hemoglobin acquisition (361).  
 The phase variable genes with tetranucleotide repeats listed in Table 1 
control the attachment of LPS outer core structures. The phase variant status of 
some of these genes can be determined phenotypically using monoclonal 
antibodies (mAbs). One of these genes is lic1A, which controls the attachment of 
phosphorylcholine (ChoP) to the LPS of H. influenzae (413). ChoP can be 
detected with the mAb TEPC-15 (417), allowing for the identification of lic1A 
phase-on bacteria. Colony immunoblots using TEPC-15 to distinguish between 
lic1A phase-on and lic1A phase-off bacteria are shown in Figure 3. Another pair 
of LPS phase variable genes, lic2A and lgtC, controls the attachment of a di-
galactoside structure, galα1-4gal, to the LPS (171, 415). This di-galactoside can 
be detected with the mAb 4C4 (401). Each component of the di-galactoside 
structure is added separately; lic2A controls attachment of the proximal galactose 
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and lgtC controls attachment of the distal galactose (169). Additional phase 
variable LPS biosynthesis genes included in Table 1 are oafA, which controls the 
addition of O-acetyl groups to the LPS, and lic3A, which is associated with LPS 
sialylation (107, 168). lic3A and at least two other non-phase variable genes 
determine the attachment of sialic acid to different regions of the LPS outer core 
(173, 186). H. influenzae requires an environmental source of sialic acid for 
expression (345). Finally, lex2A expression results in the attachment of glucose 
or galactose to the LPS, depending on the allele of the associated gene lex2B 
(73).  
While all H. influenzae strains analyzed to date contain lic1A, lic2A, lgtC, 
and lic3A, several do not encode oafA or lex2A (305). Also, the location of 
attachment for each of these LPS structures differs between H. influenzae strains 
(81, 170, 225, 245). In these ways, phase variation of LPS structures creates 
both intra- and interstrain diversity in the outer core LPS of H. influenzae. All of 
the phase variable genes listed in Table 1 contribute to bacterial survival in 
serum (107, 138, 168, 415). However, the mechanisms of these effects remain 
undefined in most cases. One exception to this is lic3A, as sialic acid attachment 
to the LPS reduces deposition of complement components (95). Therefore, 
expression of lic3A increases bacterial survival in the presence of complement. 
Further research is necessary to characterize the individual and combined effects 
of LPS phase variable structures on host recognition of bacteria during 
colonization and disease establishment. 
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Concluding remarks 
 
 H. influenzae is an extracellular bacterium that successfully colonizes the 
human respiratory tract. Understanding the bacterial factors that aid in evasion of 
mucosal host immune responses is important for the control of H. influenzae-
associated disease as well as the development of NTHi vaccines. Ideally, 
vaccination would reduce carriage of NTHi strains in order to prevent the 
development of diseases including otitis media and chronic bronchitis. However, 
the effect of eliminating H. influenzae, which is carried asymptomatically in a 
significant portion of the population, remains unknown.  
 Critical to understanding how the immune system recognizes H. 
influenzae is a thorough knowledge of the bacterial surface. Many structures in 
the outer membrane of H. influenzae are variable, including several LPS outer 
core structures. Phase variation of LPS structures could influence bacterial 
survival in the presence of multiple host factors, including antibody and 
complement. Antibody and complement both limit H. influenzae colonization in 
animal models, and are important for control of H. influenzae infections in people. 
The primary bacterial targets of antibody and complement, however, remain 
unclear. Antigenic variation of surface structures, including LPS modifications, 
may help bacteria escape immune recognition by constantly changing the targets 
of host antibody and complement. Alternatively, phase variable outer core LPS 
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structures could shield conserved inner core structures from recognition. 
Understanding the dynamics of LPS phase variation in H. influenzae may shed 
light on how this bacterium evades the host immune system during colonization. 
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Table 1. Phase variable LPS biosynthesis genes in H. influenzae 
Genea Repeat sequence Structure   
lic1A CAAT ChoPb  
lic2A CAAT Galc  
lgtC GACA Gal   
lic3A CAAT Neu5Acd  
oafA GCAA OAce  
lex2A GCAA Gal or Glcf  
a. Includes only phase variable LPS structures with tetranucleotide 
repeats for which the LPS modification affected by phase variation is 
known 
b. ChoP, phosphorylcholine   
c. Gal, galactose    
d. Neu5Ac, sialic acid   
e. OAC, acetyl group   
f. Glc, glucose; Gal or Glc dependent on the associated lex2B allele  
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Figure 1. Diagram of complement pathways leading to bacterial lysis. Summary 
of the classical, mannose-binding lectin, and alternative pathways of 
complement. All three of these pathways converge at the formation of a C3 
convertase, which leads to the formation of the membrane attack complex 
(MAC), shown in the bottom right, which forms pores in the cell membrane, 
causing bacterial lysis. (Reproduced with permission from: Walport, M. J., 2001, 
Complement: first of two parts, The New England Journal of Medicine, 344(14), 
pg 1058-1066, Copyright Massachusetts Medical Society) 
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Figure 2. H. influenzae LPS structural diagrams. Proposed LPS structures for the 
H. influenzae type-d, capsule- strain Rd (A) and the NTHi clinical isolate R2846 
(B). Conserved inner core structures are shown in blue, and are separated by a 
dotted line from variable outer core structures, shown in black. In B, arrows 
designate the point of attachment for the two alternative oligosaccharide 
extensions shown. 
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Figure 3. Colony immunoblots of ChoP phase variants. Colony immunoblots, 
using the mAb TEPC-15 to detect lic1A phase-on variants (purple), compared to 
lic1A phase-off variants (light pink). Shown are colony immunoblots of ChoP+ 
(lic1A phase-on) variants, designated H418, and ChoP- (lic1A phase-off) 
variants, designated H419. Also shown are revertants of these, isolated by 
selective enrichment from the original phase variant populations, designated as 
H418R (ChoP-) and H419R (ChoP+). 
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Abstract 
 
All microorganisms dependent on persistence in a host for survival rely on either 
hiding from or modulating host responses to infection. The small molecule 
phosphorylcholine, or ChoP, is used for both of these purposes by a wide array 
of bacterial and parasitic microbes. While the mechanisms underlying ChoP 
acquisition and expression are diverse, a unifying theme is the use of ChoP to 
reduce the immune response to infection, creating an advantage for ChoP-
expressing microorganisms. In this Minireview, we discuss several benefits of 
ChoP expression during infection as well as how the immune system fights back 
against ChoP-expressing pathogens. 
 
Introduction 
 
Phosphorylcholine [(CH3)3N+CH2CH2P04-] is a small (0.18 kD) zwitterionic 
molecule expressed by a number of microbes, across taxonomic kingdoms, 
which infect humans and other eukaryotic hosts (23, 99, 151, 417). 
Phosphorylcholine will be referred to here as ChoP, for choline phosphate. Most 
microbes that express ChoP acquire choline from their host.  While choline is not 
required for growth in most prokaryotes, it is an essential nutrient in eukaryotes. 
Furthermore, choline is readily available to microbes during infection, as ChoP is 
a component of the most abundant eukaryotic membrane phospholipid, 
phosphatidylcholine. The turnover of phosphatidylcholine results in the release of 
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glycerophospholipids containing choline (44). While microbes can use choline as 
a nutrient source (328) or as an osmoprotectant in the form of glycine betaine 
(101, 212) many also modify proteins or glycoconjugates with ChoP. ChoP may 
be either attached to the surface of the microbe or secreted on modified 
products. 
The advantages of ChoP modification have been explored in both 
bacterial and parasitic systems. For extracellular bacteria that colonize the 
respiratory tract, where ChoP-expressing microbes are particularly common, 
ChoP is always attached to the bacterial surface (99, 120, 411). Surface 
expression of ChoP can affect epithelial cell adhesion and immune recognition. 
The intracellular bacteria Legionella pneumophila, in contrast, modifies a host 
protein with ChoP, aiding bacterial survival within host cells (267). In filarial 
nematodes, a secreted product that contains ChoP moderates the host 
inflammatory response, creating an environment amenable to parasite 
persistence (152). Despite the vast differences between these systems, a 
common theme is the use of ChoP to modulate the host response in order to 
support microbial survival. 
The identification of ChoP on pathogenic microbes has led to the 
investigation of vaccine approaches to aid the recognition and clearance of 
ChoP-expressing pathogens. However, these efforts have been limited by the 
ability of ChoP to stimulate protective immunity, which is affected by the molecule 
to which it is attached, as well as its accessibility within that molecule. The 
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prevalence of ChoP expression, both in microbes and their host, demonstrates 
its importance in the constant interplay between these organisms. In this 
Minireview, we discuss how bacteria and parasites use ChoP expression to 
promote survival in their respective hosts. Figure 1 summarizes the most well 
characterized pathways of ChoP-dependent host modulation during infection. 
The links between these different mechanisms may provide new avenues of 
investigation on the role of ChoP expression and how it can be targeted 
therapeutically.   
 
Microbial Acquisition and Expression of ChoP 
 
 Choline is an essential nutrient in humans, as it is required for the 
synthesis of several molecules including cell membrane lipids, methionine, 
platelet activating factor receptor, and the neurotransmitter acetylcholine (436). 
Choline turnover occurs continuously in eukaryotic cells during the synthesis and 
recycling of the major membrane lipid phosphatidylcholine (44). As a 
consequence, many microbes have adapted strategies to take advantage of 
host-accessible choline for use as a nutrient source, osmoprotectant, and as a 
mechanism for the evasion of host immune responses. The phosphorylated 
choline molecule ChoP is associated with a wide range of microorganisms. The 
two most well characterized groups include bacterial species that colonize the 
upper respiratory tract and parasitic nematodes that secrete ChoP-modified 
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products (120, 126, 178, 411). Importantly, ChoP is associated with commensal 
as well as pathogenic microbes. A summary of the microorganisms that express 
ChoP-modified molecules can be found in Table 1.  
Choline is required for growth in some, but not all, bacterial species. The 
human respiratory pathogen Streptococcus pneumoniae, which cannot 
synthesize choline, is dependent on choline for growth (312). While S. 
pneumoniae can grow without choline in the presence of a choline structural 
analog, bacteria under these conditions form extended chains and are unable to 
autolyse or undergo transformation (383). When environmental choline is 
available, it is transported into the cell, transformed to ChoP, and incorporated 
into the cell wall teichoic acid (TA) or lipoteichoic acid (LTA) through the genes 
encoded by the lic operon (437). The lic operon was first identified in another 
respiratory tract bacterial pathogen, Haemophilus influenzae, and is also present 
in commensal Neisseria strains (342, 412). The lic operon allows for molecular 
thievery, whereby microbes utilize a host resource to their own advantage. 
Parasites, in contrast, utilize the Kennedy pathway for phosphatidylcholine 
synthesis, similar to most eukaryotes (36, 177, 329). Some bacterial species can 
also synthesize phosphatidylcholine, either through the Kennedy pathway or by 
methylation of phosphatidylethanolamine, which is an alternative method for 
phosphatidylcholine synthesis also used by eukaryotes (1, 9, 223). Pathogenic 
Neisseria strains contain enzymes that are homologous to those used in the 
methylation pathway to synthesize ChoP (1).  
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 Most microbes with ChoP-modified molecules have evolved mechanisms 
to vary ChoP expression and its location. In Pseudomonas aeruginosa, for 
example, ChoP is attached to the elongation factor Tu in a temperature-
dependent manner (15). For S. pneumoniae, where ChoP is attached to the TA 
and LTA of the cell wall, the number of ChoP groups per cell wall repeating unit 
as well as the amount of TA itself are both variable (190, 199). Also, S. 
pneumoniae contains several choline-binding proteins, which can attach to 
ChoP-modified cell wall (144). While the choline-binding proteins of S. 
pneumoniae are diverse, from the cell wall hydrolytic enzyme LytA to the 
abundant surface molecule PspA, all have the potential to obscure antibody 
recognition of the ChoP epitope when bound to the pneumococcal cell wall (331, 
433). In a S. pneumoniae PspA mutant, for example, there is increased binding 
of anti-ChoP antibodies as well as serum proteins that recognize ChoP (266).   
The location of ChoP attachment itself is variable between different 
Neisseria species. In the pathogenic species N. meningitidis and N. 
gonorrhoeae, ChoP is covalently linked to serine residues on the bacterial pilus, 
while in commensal species including N. lactima and N. subflava it is found on 
the lipopolysaccharide (LPS) (157, 342). Pilus modification is a rare example of 
the direct attachment of ChoP to a protein residue, as opposed to linkage 
through glycans, as for the majority of cases. ChoP attachment to the pilus in N. 
gonorrhoeae is in competition with attachment of phosphoethanolamine, and the 
“winner” is determined by the expression level of the protein PilV (157). In N. 
meningitidis, pilin modification is variable due to the presence of an unstable 
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homopolymeric repeat in the ChoP transferase gene, pptA (407). The on-off 
switching in expression due to the repeating sequence in pptA is an example of 
phase variation. ChoP attachment to the LPS in commensal Neisseria species 
and to the LPS in H. influenzae is also determined by phase variation.  
Phase variation in commensal Neisseria and H. influenzae is due to the 
presence of a track of tetranucleotide repeats in the first gene of the lic locus 
(412, 413). Phase variation in these bacteria occurs through slipped-strand 
mispairing, resulting in stochastic variation in ChoP attachment (159).  Rather 
than controlling expression in response to an external stimulus, phase variation 
allows for rapid on-off switching of ChoP expression within the population. This 
strategy for regulation, or rather the absence of it, allows for the rapid selection of 
advantageous traits within a heterogeneous population exposed to new 
environments. In addition, there are multiple alleles of the ChoP transferase 
gene, licD, in H. influenzae strains. The licD allele carried by a given strain 
determines the location of attachment to the LPS (228). Finally, some strains of 
H. influenzae contain a duplication of the lic locus, resulting in the attachment of 
two ChoPs per LPS molecule (106). 
 Parasitic expression of the levels of several ChoP-modified molecules is 
also variable, albeit through different mechanisms than those found in bacterial 
species. While there exists a range of different molecules modified by ChoP in 
Caenorhabditis elegans, stage-specific ChoP modification of glycosphingolipids 
occurs in this as well as other nematodes (220). For example, in the filarial 
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nematode Acanthocheilonema viteae, ChoP is attached to the secretory product 
ES-62. Secretion of ES-62 is stage-specific, restricted to the latest larval stage 
and adult worms, and occurs through post-translational control of ES-62 
production (367).  
The acquisition and control of ChoP expression by so many diverse 
microorganisms alludes to the importance of this small molecule. This is 
especially true during host infection, where choline is readily available. Even the 
human host itself can undergo stage-specific modification of proteins with ChoP, 
such as during pregnancy. It has been shown that placental polypeptides are 
modified with ChoP, which has been proposed to help shield the fetus from 
immune recognition (224). In the following sections the advantages as well as 
disadvantages of microbial ChoP expression in different host environments are 
highlighted. 
 
ChoP Affects Host Recognition 
 
  ChoP is found on the surface of several bacterial species, both 
commensal and pathogenic, that colonize the upper respiratory tract. Despite the 
constant phase variation of ChoP, ChoP-expressing phase variants of H. 
influenzae are the dominant population isolated from humans and from colonized 
mice (239, 415, 416). In a six-day colonization study in healthy human adults, 
inoculation with mixed phase variant populations resulted in selection for ChoP-
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expressing phase variant dominant populations following colonization (303). 
While ChoP is important during colonization, it also plays a role during disease. 
For example, ChoP-expressing H. influenzae are more strongly associated with 
the development of otitis media in chinchillas (384). Correspondingly, ChoP-
expressing H. influenzae are correlated with increased persistence in children 
with otitis media (110). H. influenzae expressing ChoP also have delayed 
clearance from the lungs of infected mice (295). ChoP expression is 
advantageous for other bacteria as well. S. pneumoniae without ChoP-modified 
TA are unable to colonize the upper respiratory tract in mice and are less virulent 
in a murine sepsis model (195). ChoP expression in Histophilus somni has also 
been shown to increase colonization of its bovine host (80). 
One of the advantages of ChoP expression for survival in the respiratory 
tract is the ability of ChoP to increase bacterial adhesion to the epithelial cell 
surface. ChoP is part of the recognition domain of the host protein platelet-
activating factor (PAF), which binds to host platelet-activating factor receptor, or 
PAFr, on epithelial cells. Bacterial species including H. influenzae, S. 
pneumoniae, Aggregatibacter actinomycetemcomitans, H. somni, P. aeruginosa, 
and commensal Neisseria strains exhibit this version of molecular mimicry, 
allowing binding to PAFr in vitro (64, 335, 343, 374). PAFr binding also increases 
cell invasion for several bacterial species, including S. pneumoniae, P. 
aeruginosa, A. actinomycetemcomitans, and Acinetobacter baumannii (15, 64, 
335, 357). Invasion of epithelial cells allows bacteria to avoid extracellular 
immune responses, although intracellular survival is dependent on evasion of 
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anti-bacterial intracellular immunity. Invasion of epithelial cells could also aid 
bacterial access to the bloodstream, exposing bacteria to yet another host 
environment. In support of a role for PAFr during bacterial infection, PAFr 
knockout mice are less susceptible to S. pneumoniae-induced pneumonia (317). 
S. pneumoniae also exhibits ChoP-dependent binding to the epithelial receptor 
asialo-GM1. (370). Although the mechanism for this binding remains unclear, this 
suggests that S. pneumoniae adheres to epithelial cells by binding multiple host 
receptors through ChoP. A role for ChoP in adhesion has also been proposed for 
some parasitic species. In the parasite Plasmodium falciparum, a var family 
protein involved in parasite adhesion is modified with ChoP, although whether 
binding is dependent on ChoP has not been investigated (133). In contrast, a 
ChoP-modified glycoprotein in Dictyocaulus viviparus may inhibit, rather than aid, 
attachment to the host (206). While several bacterial species have increased 
adhesion to host cells through ChoP expression, this is not the only example of 
how ChoP contributes to microbial survival. Also, the in vivo impact of PAFr 
binding remains unclear for some species. For example, the role of PAFr is not 
always ChoP dependent, as PAFr has also been shown to be important in 
infection models with bacteria that do not express ChoP (103, 174, 359). In 
addition, there are examples of ChoP-expressing bacterial infections that are not 
affected by the absence of PAFr, such as colonization with H. influenzae (39).  
ChoP expression by microbes can also affect survival in the presence of 
host immune factors including antibody, complement, and antimicrobial peptides. 
It was recently shown that ChoP expression in H. influenzae reduces antibody 
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binding to the bacterial surface, resulting in increased survival in the presence of 
complement (53). ChoP attachment to the LPS in H. influenzae alters the 
physical properties of the outer membrane, resulting in decreased membrane 
accessibility, reduced membrane permeability, and an altered membrane melting 
temperature (53).  ChoP expression in H. influenzae also increases resistance to 
antimicrobial peptides such as human cathelicidin LL-37 (229). ChoP-expressing 
Pasteurella multocida are also more resistant to cathelicidins produced by their 
natural host, chickens (153). Increased resistance to antimicrobial peptides has 
been observed for other phosphorylated amine molecules, including 
phosphoethanolamine (PEtn) attached to lipopolysaccharide (LPS). When PEtn 
is expressed on lipid A or the LPS outer core, bacterial species including 
Salmonella enterica and Citrobacter rodentium have increased resistance to the 
antimicrobial peptide polymyxin B (270, 400). These effects may extend beyond 
LPS modification, as similar effects on polymyxin B sensitivity were also 
observed for PEtn attachment to flagella in Campylobacter jejuni (63). It is 
possible that phospho-amine associated modifications serve to increase 
membrane stability in a number of bacterial strains, and the impact of these 
modifications on host recognition has only recently begun to be explored. ChoP-
expressing H. influenzae are also associated with biofilms in vitro, (418) and in a 
chinchilla model of otitis media biofilm persistence was correlated with ChoP 
expression (166). While a cause-and-effect relationship between biofilms and 
ChoP expression in H. influenzae has not been established, these data suggest 
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that ChoP-expressing phase variants have an advantage during biofilm 
establishment in the development of otitis media.  
 
ChoP Modulation of the Host Response 
 
In addition to altering host recognition, ChoP is used by microbes to 
modify host responses during infection. Recently, a mechanism for ChoP-
dependent host modification was identified in the intracellular bacteria Legionella 
pneumophila. In this pathogen, a secreted protein reversibly 
phosphorylcholinates the host GTPase Rab1 (378). The bacterial secreted 
protein, ankX, is a ChoP transferase, and ChoP modification of Rab1 results in 
host cell defects in endosome formation (267). It has been proposed that 
Legionella uses ankX and the dephosphorylcholinase Lem3 as an alternative to 
the GTP/GDP exchange system used in human cells (131). It is possible that 
other intracellular bacteria use ChoP to modify the activity of host proteins, 
although whether this phenomenon is limited to the decoration of host GTPases 
is unclear. Alteration of endosome processing creates an advantage for L. 
pneumophila during intracellular survival, much as the increased epithelial cell 
adherence and reduced immune recognition aid extracellular bacteria during host 
colonization.  
 Microbes also use ChoP to modify the host immune response. 
Interestingly, all examples to date of ChoP-mediated immune modulation occur in 
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parasites. However, there may be common links between the role of ChoP in 
parasites and in bacteria that have not yet been explored. The most thoroughly 
studied example of a ChoP-modified immunomodulatory molecule is ES-62, a 
secretory product of parasitic nematodes. Several of the immunomodulatory 
properties of ES-62 are dependent on the presence of ChoP. In A. viteae, ES-62 
induces a Th2 immune response while reducing Th1 immunity. As part of the 
induction of a Th2-skewed immune response, macrophage and dendritic cell 
exposure to ES-62 reduces the production of IL-12 and TNF-alpha in response to 
classic inflammatory signals such as LPS (129). Also, exposure to ES-62 results 
in the maturation of dendritic cells that promote IL-4 and reduced IFN-gamma 
cytokine production in T cells (419). ES-62 exposure additionally desensitizes B 
cell activation and proliferation through the traditional PI3K and Ras MAP kinase 
signaling pathways (74, 150). Finally, ES-62 can induce a Th2-skewed antibody 
response, resulting in production of increased IgG1 and decreased IgG2a (238). 
The filarial nematode B. malayi also produces ChoP-modified antigens which 
suppress B and T cell signaling in a ChoP-dependent manner (208). The 
suppression of Th1 inflammation allows for parasite persistence within the host.  
The phenotypes described above have also been replicated using ChoP-
conjugated OVA peptide. ChoP-OVA exposure alone results in the induction of 
Th2 immunity, demonstrating that ChoP is essential for the immune modulation 
observed during ES-62 exposure (130). Indeed, even the synthetic oxidized 1-
palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine, or oxPAPC, molecule, 
which contains ChoP, has been shown to bind TLR4 and induce IL-8 secretion 
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(405). Interestingly, PAFr has been found on the surface of macrophages as well 
as B and T cells, raising the possibility that ChoP-mediated immune modulation 
occurs through PAFr binding (46, 284). However, while PAFr is functional on 
macrophages, it is not on B and T cells, suggesting the presence of additional 
immune activators responsible for ChoP-dependent effects on the immune 
system (353). 
While the exposure or secretion of ChoP-modified molecules creates an 
advantage for microbes, the immune modulation that results also has the 
potential to affect immune homeostasis in the host. For example, the anti-
inflammatory effect of ES-62 exposure also reduces arthritis in a ChoP-
dependent manner (149). Additionally, the importance of ChoP-mediated effects 
on the immune response to concurrent or subsequent microbial infections 
remains to be explored.  
 
Host Responses to ChoP 
 
Microbial expression of ChoP-modified molecules provides several 
potential advantages during host infection. However, the ability to vary ChoP 
expression in most microbes suggests that ChoP-modified molecules may only 
be advantageous in certain host environments. The acute phase reactant protein 
C-reactive protein (CRP) recognizes ChoP and can initiate classical pathway, 
complement-mediated killing of H. influenzae and increase phagocytosis of S. 
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pneumoniae (255, 415). Even the position of ChoP on the LPS of H. influenzae 
affects the level of CRP-mediated bacterial killing (228). A role for CRP has also 
been demonstrated in vivo, as transgenic mice expressing human CRP have 
increased survival and reduced bacteremia following infection with S. 
pneumoniae, and the majority of these effects are dependent on complement 
(376, 377). Also, CRP binding to ChoP-modified pilin increases uptake of N. 
meningitidis by phagocytes (48). It was recently shown that in S. pneumoniae, 
CRP binding is inhibited by the surface protein PspA, which is anchored to ChoP 
(266). Inhibition of CRP binding also reduces complement deposition on the 
bacterial surface. CRP levels are initially low in both the blood and at the 
mucosal surface, although these increase dramatically during inflammation (132).  
When CRP is readily available, such as in rat or human serum during infection, 
ChoP-expressing H. influenzae are more sensitive to complement-mediated 
killing than bacteria not expressing ChoP (180, 417). In contrast, ChoP-
expressing bacteria have the advantage in mouse and rabbit models of 
bloodstream infection, where CRP levels remain low (85, 116). The pentraxin 
serum amyloid protein (SAP) can also bind ChoP, although no bactericidal effect 
has been demonstrated (52). Instead, SAP binding inhibits classical pathway 
complement activity (70). The difference in the impact of CRP versus SAP 
binding highlights the concept that ChoP expression may only be advantageous 
in the presence of certain host conditions.  
The second major host factor involved in ChoP recognition is the 
expression of anti-ChoP antibodies. Anti-ChoP antibodies are B1-lineage, natural 
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antibodies. B1 antibodies are part of the repertoire of IgM synthesized prior to 
microbial exposure, and have lower affinity than antibodies induced following 
infection (19). The major idiotype of anti-ChoP antibodies is T15, originally 
identified in mice (193, 216). While ChoP modification of host molecules 
including the major cell membrane lipid phosphatidylcholine is very common, it 
has been shown that T15 antibodies don’t recognize the ChoP epitope in intact 
human membrane lipids (60, 392). Anti-ChoP antibodies do, however, recognize 
ChoP on intact or digested microbes, and it has been shown that there are 
detectable levels of circulating ChoP-containing antigens following infection with 
ChoP-expressing parasites in the bloodstream (209). 
While anti-ChoP antibodies play a role in the recognition of microbes with 
ChoP-modified surfaces (127), they also are important during clearance of 
apoptotic cells and may be beneficial during atherosclerosis (348). As a case-in-
point, anti-ChoP antibodies that bind to dental plaque bacteria cross-react with 
oxidized low-density lipoprotein (oxLDL), which contains ChoP (336). Reduced 
anti-ChoP IgM levels in patients with acute cardiovascular disease corresponds 
with increased risk of a new cardiovascular event (45, 100). Also, higher anti-
ChoP IgM levels correlate with decreased symptomology for systemic lupus 
erythematosus (SLE) patients (139). These effects, however, aren’t limited to 
anti-ChoP antibodies. CRP, known to play an important role in killing ChoP-
expressing microbes, binds to oxLDL as well as apoptotic cells in a ChoP-
dependent manner (49). However, ChoP-dependent recognition of LDL may not 
always be beneficial. A study investigating the effect of anti-ChoP antibodies on 
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atherosclerosis found that opsonization of minimally modified LDL increased 
inflammation generated by DCs and NK cells (197). These studies suggest that 
infection with ChoP-expressing microbes can impact non-infectious disease 
processes in the host.  
Evasion of host recognition is critical for microbial survival during infection. 
However, microbes must also defend themselves, such as bacteria from infection 
with phages. It has been shown that choline-modified TA in S. pneumoniae 
increases susceptibility to certain phages (222). Several pneumococcal phages 
contain proteins homologous to the CBPs of S. pneumoniae, and choline-binding 
interactions have been demonstrated for some of these (160, 327). As LPS 
molecules can serve as phage receptors (181, 432), it is possible ChoP 
attachment to the LPS affects phage susceptibility in other bacteria as well. In 
this way, ChoP expression could also impact inter-microbial competition in 
addition to the ongoing competition between microbe and host. 
 
ChoP-Based Vaccines 
 
 Vaccines that successfully stimulate a protective anti-ChoP response have 
the potential to be used for immunization against a wide range of ChoP-
expressing microbes. Even though B1 anti-ChoP antibodies are low affinity, they 
provide some protection, as B1-deficient Xid mice (333) are more susceptible to 
S. pneumoniae infection (433). Beyond pre-existing anti-ChoP B1 antibodies, 
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stimulation of anti-ChoP antibody production occurs during exposure to ChoP-
expressing microbes. Carriage of S. pneumoniae in young children is associated 
with increased levels of anti-ChoP antibodies (134). It remains unclear, however, 
whether these antibodies are able to protect children from additional infections 
with S. pneumoniae or other ChoP-expressing microbes.  
While there is no vaccine currently in use that targets ChoP directly, there 
is one example of a licensed vaccine that induces a response against a protein 
involved in choline acquisition. One of the vaccines for S. pneumoniae contains 
10 pneumococcal polysaccharide serotypes conjugated to Protein D. Protein D is 
a glycerophodiester phosphodiesterase from H. influenzae that scavenges host 
choline (269). In human children, the Protein D-containing vaccine has 35% 
efficacy against otitis media caused by H. influenzae (307). Passive transfer of 
sera from children immunized with this vaccine also protects chinchillas against 
H. influenzae otitis media with similar efficacy (290). The Protein D-containing 
conjugate vaccine induces antibodies that inhibit the glpQ activity of Protein D 
(385), suggesting its efficacy is related to its ability to repress choline scavenging 
in vivo. In recent work it was shown that abrogation of Protein D activity results in 
reduced ChoP expression and decreased epithelial cell adherence and fitness in 
vivo (185). The success of the Protein D-containing conjugate vaccine against H. 
influenzae infection, while limited, demonstrates the potential for targeting ChoP 
expression to protect against other ChoP-expressing microbes.  
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More direct approaches to target ChoP, such as inducing anti-ChoP 
antibodies, may have a greater impact on stimulating immunity to ChoP-
expressing microbes. While the majority of ChoP-specific antibodies are IgM 
natural antibodies (351), human ChoP-specific IgG is protective against H. 
influenzae and S. pneumoniae in mouse models of infection (127). Patients with 
specific antibody defects, such as IgA-deficient patients, also have elevated 
levels of anti-ChoP IgG (111). Several vaccine formulations have demonstrated 
promise for the induction of ChoP-specific responses in animal models of 
infection with S. pneumoniae (387), N. meningitidis (20), and H. influenzae (379). 
In S. pneumoniae, the level of protection with anti-ChoP IgG is dependent on 
capsule type (41). ChoP vaccine formulations often involve conjugation of ChoP 
to a protein carrier, such as keyhole limpet hemocyanin (13, 97). ChoP is an 
example of a T cell-independent antigen, as with polysaccharides. Conjugation to 
a protein carrier allows for a repertoire shift in the anti-ChoP idiotype, resulting in 
the involvement of T cells and the development of higher affinity antibodies (42). 
The induction of anti-ChoP antibodies may also provide protection against other 
ChoP-expressing bacteria, including A. actinomycetemcomitans and Treponema 
pallidum (29, 308). Interestingly, vaccination with S. pneumoniae induces T15 
IgM that binds oxLDL, resulting in reduced atherosclerosis (26).  
Targeting ChoP surface molecules is an attractive option as a strategy to 
immunize against multiple pathogens simultaneously. However, this would also 
affect ChoP-expressing commensal bacteria, and depletion of normal flora due to 
vaccination is a potential concern. Also, the variable expression of ChoP in many 
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microbes suggests that even in the presence of protective anti-ChoP antibodies, 
phase variation or covering the ChoP epitope would allow infection to continue. 
Given the diversity in ChoP expression, additional targets may be required for 
vaccines targeting ChoP to have the most significant impact.  
  
Concluding Remarks 
 
 The use of choline beyond a nutrient source has proven to be a useful 
strategy for microbes as a way to hide from (molecular mimicry), or alter host 
immune responses. The role of ChoP-modified molecules varies by microbe, 
although there may be undiscovered functional links. It is unclear, for example, 
whether ChoP-modified glycans or pilin in bacteria can modulate the immune 
response like ES-62 does during nematode infection. ChoP modulation of host 
immune responses may be dependent on the context in which it is presented. 
Additional studies should give insight to the development of ChoP-targeted 
vaccines and immune therapies using ChoP-modified molecules. Likewise, 
surface expression of ChoP on bacteria as demonstrated for H. influenzae could 
impact survival in the presence of antibody, complement, and antimicrobial 
peptides. ChoP itself may not be the only molecule capable of these and other 
effects, as other phospho-amine molecule modifications of the LPS increase 
resistance to antimicrobial peptides. Finally, there may be additional examples of 
related microbial products that can modify the activity of host proteins, as 
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highlighted by the discovery of the ChoP transferase of L. pneumophila. 
Regardless of the interplay between different systems, the ability to manipulate 
ChoP has a marked effect on host recognition and response to microbes during 
infection. 
 There has been extensive interest in stimulating immune responses 
targeting ChoP-expressing microbes. However, the effects of anti-ChoP immunity 
also impact non-infectious disease conditions, including arthritis, SLE, and 
atherosclerosis. There is clearly a dual role for anti-ChoP immune responses, 
which target ChoP-expressing microbes but also respond to host molecules with 
an exposed ChoP epitope, such as oxLDL. Even in the context of an effective 
anti-ChoP immune response, the seemingly universal capacity of microbes to 
vary either ChoP expression or accessibility limits the effectiveness of anti-ChoP 
immunity in eradicating infections. This Minireview highlights ChoP as a key 
player in the constant battle between host and microbe during infection. The 
contribution of this dynamic molecule to microbial survival occurs through several 
different mechanisms, and the interplay between these and the host response to 
ChoP-expressing microbes is an important area for ongoing research. 
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Table 1. Microbes that use ChoP for structural modification* 
    
Organism 
group 
Taxonomic 
classification 
ChoP-modified 
structure Reference 
Gram-
positive  
Streptococcus 
pneumoniae TA, LTA (99) 
bacteria Streptococcus oralis TA (121) 
 Streptococcus mitis TA (121) 
    
Gram-
negative  Haemophilus influenzae LPS (417) 
bacteria 
Haemophilus 
haemolyticus LPS (248) 
 
Pseudomonas 
aeruginosa 
Elongation factor 
Tu (15, 411) 
 Neisseria meningitidis Pilus (411) 
 Neisseria gonorrhoeae Pilus (411) 
 Neisseria lactima LPS (343) 
 Neisseria subflava LPS (343) 
 Neisseria flavescens LPS (343) 
 Histophilus somni LPS (59) 
 
Aggregatibacter 
actinomycetemcomitans 
LPS 
 
(126) 
 
 
Acinetobacter 
baumannii porinD (357) 
 Pasteurella multocida LPS (362) 
 Legionella pneumophila 
Host Rab1 
GTPase  (267) 
 Proteus mirabilis LPS (109) 
 Treponema pallidum Membrane lipid (29)  
 Morganella morganii O-antigen (434) 
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Mollicutes 
Mycoplasma 
fermentans 
Membrane 
proteins  (23) 
    
    
Nematode Caenorhabditis elegans ASP-6, Glycolipids (117, 220) 
 
Acanthocheilonema 
viteae ES-62 (151) 
 Brugia pahangi Secreted proteins (232) 
 Brugia malayi Secreted proteins (162) 
 Dictyocaulus viviparus GP300 (206) 
 Ascaris suum Glycolipids (219) 
 Ascaris lumbricoides Glycolipids (398) 
 Haemonchus contortus GP300 (206) 
 Cooperia oncophora GP300 (206) 
 Onchocerca volvulus 
Glycolipids, 
glycoproteins (154, 430) 
 Onchocerca gibsoni Glycolipids (154) 
 Trichinella spiralis Tsp, Glycolipids (217, 256)  
 
Nippostrongylus 
brasiliensis C substance (299) 
 Wuchereria bancrofti PC-Ag (68) 
    
Protozoa Plasmodium falciparum 
Surface, secreted 
proteins (133) 
 Eimeria bovis Polypeptides (158) 
    
*Table does not include microorganisms that contain ChoP-modified phospholipids or those 
for which the ChoP-modified structure has not been elucidated 
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Figure 1. Schematic of the mechanisms used by microbes to modulate host 
immune responses with phosphorylcholine. In bacteria such as S. pneumoniae, 
the attachment of ChoP to the outer membrane allows for adhesion to the 
eukaryotic platelet-activating factor receptor (PAFr). This is an example of 
adhesion through molecular mimicry; in this case mimicry of the natural PAFr 
binding partner PAF, which also contains ChoP. In H. influenzae, ChoP 
expression reduces binding of bactericidal antibody. In L. pneumophila, the 
secreted protein ankX attaches phosphorylcholine to host Rab1 GTPase in order 
to modify its activity. The secretion of ES-62 in nematodes results in ChoP-
dependent inhibition of pro-inflammatory Th1 immunity. 
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DISSERTATION AIMS 
 
 H. influenzae is an extracellular bacterial pathogen that must evade host 
immune components present in the respiratory tract. Antibody and complement 
are present on the mucosal surface, and contribute to the limitation of H. 
influenzae colonization and disease. The overall aim of this study is to 
understand how H. influenzae evades host recognition and complement-
mediated killing. Our hypothesis is that the phase variation of LPS structures 
contributes to bacterial resistance against antibody binding and complement-
mediated lysis by shielding inner core structures from host recognition.  
Specific Aim 1: Determine the role of phosphorylcholine (ChoP) expression in 
bacterial evasion of antibody recognition 
We hypothesize that the attachment of ChoP to the LPS reduces binding of 
human antibody to the bacterial surface, and increases survival in the presence 
of complement. We use flow cytometry to compare antibody binding to the 
surface of ChoP-expressing and non-expressing phase variants. The mechanism 
for the effect of ChoP on antibody binding is investigated by comparing outer 
membrane stability between ChoP-expressing and non-expressing bacteria, with 
the hypothesis that ChoP attachment to the LPS increases the stability of the 
outer membrane, which reduces membrane accessibility.  
Specific Aim 2: Identify new genes that contribute to bacterial resistance to 
complement-mediated killing 
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We hypothesize that multiple LPS biosynthesis genes are critical for survival of 
H. influenzae in the presence of antibody and complement. We use mariner 
transposon mutagenesis to screen for genes that are required for bacterial 
survival in human serum as a source of antibody and complement. Following the 
identification of critical genes, we investigate the mechanism of the effect of a 
previously uncharacterized set of genes that contribute to bacterial evasion of 
complement-mediated killing. 
Specific Aim 3: Determine the collective contribution of multiple LPS phase 
variable genes to protection against antibody and complement-mediated lysis 
We hypothesize that individual LPS phase variable modifications have 
independent effects on bacterial survival, and that these effects are additive in 
combination. We passage bacteria in human antibody and complement and 
determine whether serial exposure selects for resistant phase variant 
populations. Also, we determine the effect of single versus multiple LPS 
modifications on bacterial survival in the presence of human antibody and 
complement using a series of H. influenzae mutants and phase variant enriched 
populations. 
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Abstract  
 
The human pathogen Haemophilus influenzae has the ability to quickly adapt to 
different host environments through phase variation of multiple structures on its 
lipooligosaccharide (LPS), including phosphorylcholine (ChoP). During 
colonization with H. influenzae, there is a selection for ChoP+ phase variants. In 
a murine model of nasopharyngeal colonization, this selection is lost in the 
absence of adaptive immunity. Based on previous data highlighting the 
importance of natural antibody in limiting H. influenzae colonization, the effect of 
ChoP expression on antibody binding and its bactericidal activity was 
investigated. Flow cytometric analysis revealed that ChoP+ phase variants had 
decreased binding of antibody to LPS epitopes compared to ChoP- phase 
variants. This difference in antibody binding correlated with increased survival of 
ChoP+ phase variants in the presence of antibody-dependent, complement-
mediated killing. ChoP+ phase variants were also more resistant to trypsin 
digestion, suggesting a general effect on the physical properties of the outer 
membrane. Moreover, ChoP-mediated protection against antibody binding 
correlated with increased resilience of outer membrane integrity. Collectively, 
these data suggest that ChoP expression provides a selective advantage during 
colonization through ChoP-mediated effects on the accessibility of bactericidal 
antibody to the cell surface.  
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Author Summary 
 
The bacterial pathogen Haemophilus influenzae evades immune responses 
during colonization in its human host. Decoration of the bacterial surface with 
different structures is one way that Haemophilus avoids host recognition. In this 
study, we show that the attachment of the small molecule phosphorylcholine, or 
ChoP, to the lipopolysaccharide covering the bacterial surface allows H. 
influenzae to avoid the immune response by inhibiting antibody binding. The 
presence of ChoP alters the bacterial surface to reduce its accessibility. The 
ability of ChoP to affect antibody binding is dependent on the positive charge of 
the molecule, which changes the physical properties of the bacterial membrane. 
The increased survival of bacteria with ChoP attached to their surface enriches 
ChoP+ bacteria during colonization. This study reveals a novel mechanism for 
bacterial evasion of a host immune response. 
 
Introduction 
 
Haemophilus influenzae is an extracellular, gram-negative pathogen that is a 
primary causative agent of otitis media in children and is also frequently isolated 
from adults with pneumonia and exacerbations of chronic obstructive pulmonary 
disease (COPD) (18, 71, 274, 275, 278). Colonization of the upper respiratory 
tract with H. influenzae is common and is the first step in disease development, 
as H. influenzae carriage is associated with recurrent otitis media episodes in 
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children (88, 148). While the Hib conjugate vaccine has greatly reduced the 
burden of disease caused by type b H. influenzae (119, 188), non-typeable H. 
influenzae (NTHi) strains, which are unencapsulated, remain a common source 
of respiratory tract infections. Vaccine strategies targeting NTHi strains are 
complicated by the high variability of outer membrane antigens (17, 123). One of 
the structurally diverse molecules on the surface of H. influenzae is the 
lipopolysaccharide (LPS).  
 The LPS of H. influenzae is truncated compared to the LPS of other gram-
negative bacteria. It contains no repetitive O antigen side chains and is also 
referred to as lipooligosaccharide (LOS) (184, 298). H. influenzae LPS consists 
of lipid A attached to 3-deoxy-D-manno-oct-2-ulosonic acid (KDO), with three 
conserved inner core heptoses to which various oligosaccharide extensions, and 
other non-carbohydrate molecules, can be attached (339). Mass spectrometry 
(MS) analysis of different H. influenzae isolates has revealed a significant level of 
diversity in LPS structures (81, 225, 227, 235, 236, 244, 319). For example, the 
length and composition of the hexose extensions from the inner core heptoses, 
as well as the attachment of molecules such as sialic acid and glycine, varies 
both between different strains and within glycoforms of the same isolate. A major 
source of LPS variability in H. influenzae is on-off switching, or phase variation, 
involving LPS biosynthesis genes (305, 375). One of the phase variable 
molecules expressed on H. influenzae LPS is phosphorylcholine.  
60 
Phosphorylcholine [(CH3)3N+CH2CH2PO4 -], or ChoP, is a small, 
zwitterionic molecule that is covalently attached to the LPS through its phosphate 
group. ChoP is a surface structure of a number of bacteria in addition to H. 
influenzae, particularly those found in the respiratory tract, including 
Streptococcus pneumoniae, Pseudomonas aeruginosa, and Neisseria species 
(120, 204, 411). ChoP is also a component of eukaryotic membrane lipids in the 
form of phosphatidylcholine. H. influenzae must acquire choline from the 
environment, and turnover of host lipids can be a major source of choline during 
colonization (44, 91).  Choline import, phosphorylation, and attachment to H. 
influenzae LPS is controlled by genes in the lic1 locus.  The choline kinase gene 
lic1A contains a tetranucleotide repeat that is responsible for ChoP phase 
variation.  Slipped-strand mispairing within the repeat region of lic1A creates a 
translational on-off switch controlling ChoP expression (414).  As a result, the 
control of ChoP attachment to the LPS is stochastic, and phase variation occurs 
at a high frequency (69).   
Phase variation of ChoP expression may provide a mechanism for 
Haemophilus to display a variety of phenotypes, allowing rapid adaptation to 
different host environments. ChoP attachment to the LPS enables recognition by 
C-reactive protein (CRP), which binds to ChoP and initiates classical pathway 
complement-mediated killing (416).  In host environments with high levels of 
CRP, such as in the blood, there is a selective advantage for ChoP- phase 
variants (180). In addition, an antibody response can be initiated against LPS 
epitopes containing ChoP (41, 379).  However, the maintenance of phase 
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variable ChoP expression predicts that there are also advantages for ChoP+ 
bacteria in select host environments. During H. influenzae colonization there is a 
strong selection for ChoP+ phase variants.  This selection has been observed in 
several animal models of Haemophilus colonization, as well as during human 
carriage (239, 295, 384, 416). ChoP expression increases adherence to epithelial 
cells through interaction with platelet-activating factor receptor (rPAF), which 
normally binds the ChoP-containing molecule PAF. While in vitro experiments 
have demonstrated the capacity of ChoP+ bacteria to bind rPAF, mice deficient 
in rPAF have no colonization defect (39, 374). These data suggest that there are 
additional host factors involved in the selection for ChoP+ bacteria during 
colonization. Here, we show that ChoP attachment to the LPS alters the physical 
properties of the outer membrane and reduces antibody binding to the surface of 
H. influenzae. 
 
Results 
 
Adaptive immunity is required for the selection of ChoP+ phase variants during 
colonization 
The role of adaptive immunity in the selection of ChoP+ phase variants was 
examined in vivo using a murine model of nasopharyngeal colonization. The 
percentage of ChoP+ phase variants was determined by colony immunoblotting 
following colonization with a mixture of ChoP+/- variants of strain H632, an NTHi 
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strain that is able to colonize mice (440). The proportion of ChoP+ phase variants 
in the output (colonizing) population was substantially greater than that in the 
input (inoculum) after challenge of immune competent, (wild-type) BALB/c mice 
(Figure 1). In contrast, there was no evidence for a selection of ChoP+ phase 
variants following colonization in BALB/c mice lacking an adaptive immune 
system (severe combined immune deficiency, or SCID) (35). These results 
demonstrate that adaptive immunity is important for the selection of ChoP+ 
phase variants during colonization. 
 
ChoP expression reduces antibody binding to the surface of H. influenzae 
The importance of natural, or pre-existing, antibody in limiting H. influenzae 
colonization has been demonstrated previously (440). These data led to an 
examination of the impact of ChoP expression on antibody binding by flow 
cytometry. It was found that ChoP+ variants had reduced antibody binding to 
their surface compared to ChoP- variants (Figure 2). The ChoP+ phase variant of 
NTHi strain H233 had decreased binding of natural IgG using both serum from 
(wild-type) BALB/c mice (Figure 2A) and normal human serum (NHS; Figure 2C). 
Revertants of the originally selected phase variants of strain H233, as well as 
ChoP+/- phase variants in another NTHi strain, H729, showed a similar effect 
(Figure 2A, C). The ChoP-mediated reduction of the binding of natural antibody 
in serum (naïve control) was also observed in the serum of mice previously 
intranasally immunized with H. influenzae (Figure 2B). To confirm the difference 
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in antibody binding was not dependent on other serum components, the effect of 
ChoP on binding of IgG purified from NHS was also examined, with the same 
result (Figure 2D). This binding assay was also conducted using a mutant strain 
of Rd with constitutive ChoP+ expression (phase locked ChoP+), H491. This 
strain was grown in chemically defined medium (CDM) with or without choline. 
The binding of IgG in NHS to H491 was reduced when choline was added to the 
CDM, compared to CDM without choline (Figure 2E). ChoP expression also 
reduced binding of IgA from NHS (Figure 2F), from human nasal secretions 
(Figure 2G), and IgM purified from NHS (Figure 2H).   
To examine whether there was an additional effect of ChoP expression on 
binding of complement component C3, baby rabbit serum (BRS) was used as a 
source of complement without natural antibody to H. influenzae. While there was 
no difference C3 binding to ChoP+/- phase variants in BRS alone, the ChoP+ 
phase variant of strain H233 had reduced C3 binding in the presence of BRS 
with purified IgG from NHS (Figure 2I). Collectively, these data demonstrate that 
ChoP expression results in decreased antibody binding, which limits complement 
deposition, on the surface of H. influenzae. 
 
ChoP expression reduces binding of LPS-specific, bactericidal antibody 
The classical pathway of complement-mediated killing can be initiated by binding 
of CRP or bactericidal antibody to H. influenzae. In order to determine if ChoP 
expression affects classical pathway complement-mediated killing following 
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antibody binding, NHS depleted of C-reactive protein (CRP) was used as an 
antibody and complement source for bactericidal assays. ChoP+ phase variants 
had increased survival in CRP-depleted NHS compared to ChoP- variants of 
strain H233, as well as revertants of the originally selected phase variants 
(Figure 3A). There was also increased survival of the ChoP+ phase variant of 
H233 using IgG purified from NHS (in the same concentration as that used for 
flow cytometry in Figure 2D) with BRS as a complement source (Figure 3B). The 
increased survival of ChoP+ bacteria in the presence of CRP-depleted NHS was 
observed for multiple other NTHi strains, constitutive ChoP+ and ChoP- mutants 
in Rd, and an H. influenzae type b strain (Eagan) (Figure 3C).  Serum was IgG-
depleted to determine whether the difference in survival of ChoP variants was 
dependent on antibody. In IgG-depleted NHS there was a recovery of survival for 
the ChoP- variant of H233, while the addition of purified IgG restored killing 
(Figure 3D). No differences in survival were detected for bactericidal assays 
conducted in BRS as a source of complement without antibody, or in NHS with 
MgEGTA buffer, which allows alternative pathway complement-mediated killing 
only (not shown). Collectively, these results suggest that ChoP expression 
increases survival in the presence of bactericidal antibody. 
 The potential targets on the surface of H. influenzae that are protected 
from antibody binding by ChoP expression were examined using antibody-
depleted NHS and mAbs. Purified LPS was used to absorb LPS–specific 
antibodies from NHS prior to conducting bactericidal assays. LPS antibody pre-
absorption with wt, constitutive ChoP- LPS resulted in increased survival of the 
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constitutive ChoP- mutant in Rd, H446 (Figure 4B). In contrast, there was no 
increase in survival of the constitutive ChoP- mutant after pre-absorption with 
ChoP- LPS from the Rd opsX mutant strain, which is highly truncated with no 
KDO heptose extensions (Figure 4A, B). To confirm that the LPS pre-absorbed 
serum retained complement activity, purified IgG was added back to the LPS pre-
absorbed serum, and killing was observed (not shown). These results indicate 
that the majority of the bactericidal antibody affected by ChoP expression in NHS 
is LPS oligosaccharide-specific. Of note, that there was a greater increase in the 
survival of the Rd constitutive ChoP- mutant H446 following NHS pre-absorption 
with ChoP- LPS, compared to pre-absorption with ChoP+ LPS, a result that 
correlated with the effect of ChoP on antibody binding (Figure 4B). While purified 
LPS may not accurately mimic the environment of the outer membrane, this 
result demonstrates that the same decrease in antibody binding observed in 
ChoP+ whole bacteria is also observed for ChoP+ LPS. 
 The mAb 6E4, which binds H. influenzae LPS (360), was used to examine 
the effect of ChoP on antibody binding to a specific LPS epitope. ChoP 
expression reduced 6E4 binding and increased survival following incubation in 
6E4 with BRS as a complement source (Figure 4C, D). This was observed for 
NTHi strain H729 and for the constitutive ChoP+ mutant in Rd, H491. These 
results confirmed that ChoP expression provides protection against bactericidal 
antibody binding to LPS oligosaccharide epitopes.  
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LPS structural requirements for the effect of ChoP on antibody binding 
A selection of LPS mutants in Rd was used to investigate the importance of the 
LPS molecular environment for ChoP-mediated protection against antibody 
binding (Figure 4A). The ChoP+ phase variant of the lpsA mutant strain, which no 
longer has HepIII hexose extensions, maintained reduced antibody binding and 
increased survival in the presence of CRP-depleted NHS (Figure 5). In contrast, 
there was no longer a protective effect of ChoP expression on antibody binding 
and complement-mediated killing for the orfH and lpt6 mutant strains. The orfH 
mutation results in a lack of HepIII, while the lpt6 mutation prevents attachment of 
a conserved phosphoethanolamine molecule to HepII.  
 ChoP can be attached to hexose extensions from multiple heptose 
residues, most commonly HepI and HepIII (318-320).  The importance of the 
position of ChoP for its effect on antibody binding was examined using lic1D 
exchange mutants, as the lic1D allele dictates the position of ChoP attachment 
(228).  In Rd, ChoP is attached to a hexose extension on HepI (HI). Alteration of 
the position of ChoP in Rd from H1 to a hexose extension on HepIII (H3) resulted 
in the loss of ChoP-mediated protection against antibody binding and antibody-
dependent bactericidal activity (Figure 6). Collectively, these data demonstrate 
that the constituents of the oligosaccharide and the molecular environment of 
ChoP are both important for the effect of ChoP on antibody binding and 
resistance to antibody-dependent, complement-mediated killing. 
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ChoP expression alters the physical properties of the outer membrane 
We next investigated the mechanism for ChoP-mediated protection against 
antibody binding, considering two possibilities; 1) steric hindrance, where ChoP 
obscures key epitope(s) and 2) ChoP alteration of the physical properties of the 
outer membrane, resulting in decreased membrane accessibility. In order to test 
the effect of ChoP expression on the ability of molecules other than antibodies to 
access the membrane, trypsin sensitivity was compared for ChoP+ and ChoP- 
phase variants. The fluorescent dye Cy5, which labels lysine residues, was used 
to quantify the exposure of outer membrane surface proteins by flow cytometry. 
Following trypsin digestion, there was decreased Cy5 binding to the ChoP- 
phase variant of strain H233, as well as the ChoP- revertant of the original 
ChoP+ phase variant (Figure 7A). The same effect was observed for the 
constitutive ChoP- mutant in Rd, H446 (Figure 7A). The reduction in Cy5 binding 
following trypsin digestion suggests that ChoP expression affects the general 
accessibility of molecules, including antibodies, to outer membrane targets. 
In order to further examine the effect of ChoP on the physical properties of 
the outer membrane, membrane barrier function was compared in ChoP+ and 
ChoP- phase variants. Bacterial uptake of the dye ethidium bromide (EtBr) was 
used to measure the effect of ChoP on the permeability of the outer membrane. 
The rate-limiting step for EtBr uptake is transversal of the outer membrane (270). 
In the presence of a low concentration of polymyxin B, there was an increased 
rate of EtBr uptake in the ChoP-, compared to the ChoP+, phase variants of 
H233 (Figure 7B). The same effect was observed for the revertants of the original 
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variants of strain H233 as well as the constitutive ChoP+ and ChoP- mutants in 
Rd (Figure 7B). It was necessary to include polymyxin B to cause initial 
membrane destabilization for dye uptake. While ChoP expression does not affect 
killing by polymyxin B alone (not shown), the difference in EtBr uptake rates may 
reflect a difference in outer membrane susceptibility to polymyxin B. The 
alteration of polymyxin B-induced EtBr uptake demonstrates that ChoP 
expression strengthens the barrier function of the outer membrane.   
Differences in membrane barrier function often correlate with changes in 
the gel-to-liquid crystalline phase transition temperature, or Tm, which can be 
determined by differential scanning calorimetry (DSC) (289). In order to test the 
effect of ChoP expression on the Tm of H. influenzae LPS, DSC was performed 
on LPS purified from ChoP+ and ChoP- bacteria. The Tm of LPS from the Rd 
constitutive ChoP+ strain H491 was determined to be 29.8±.2°C, while the Tm of 
the constitutive ChoP- mutant strain H446 was significantly higher, at 34.3±.1°C 
(p<.0001). Phase transition temperatures were independent of Mg2+ 
concentration.  
The effect of ChoP on the integrity of the outer membrane was examined 
by comparing EDTA sensitivity in ChoP+ and ChoP- phase variants. EDTA 
treatment chelates the divalent cations that are important for maintaining LPS 
interactions and membrane stability (58). The ChoP+ variant of strain H233 had 
increased resistance to EDTA, compared to the ChoP- variant (Figure 8A). ChoP 
revertants of these variants showed the same trend (not shown). Growth of the 
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Rd constitutive ChoP+ strain H491 in CDM with choline also resulted in 
increased EDTA resistance, compared to survival following growth in CDM 
without choline (Figure 8B). In contrast, the expression of a digalactoside residue 
(Galα1-4Gal) in strain H233, detected by the mAb 4C4, had no impact on EDTA 
resistance (Figure 8A).  
The importance of the position of ChoP for its effect on outer membrane 
integrity was also investigated. For the Rd lic1D exchange mutant strains, only 
ChoP in the H1, but not H3, position resulted in increased EDTA resistance 
(Figure 8C, D). These results correlate with the effect of ChoP position on 
antibody binding, suggesting that the same structural requirements for ChoP-
mediated reduction of antibody binding are necessary for its effect on the 
integrity of the outer membrane. Next, the effect of divalent cation concentration 
on antibody binding was explored. Increasing the Mg2+ concentration (up to 50 
mM) resulted in reduced antibody binding to the ChoP- phase variant of H233 
(Figure 8E). These results demonstrate that excess Mg2+, which increases the 
stability of the outer membrane (114, 285, 358), can correct for the difference in 
antibody binding between ChoP+ and ChoP- variants. Together, these data 
indicate that ChoP expression alters the physical properties of the outer 
membrane, and that these effects correlate with the reduction of antibody binding 
in ChoP+ phase variants.  
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ChoP structural requirements for its effect on antibody binding and outer 
membrane integrity 
ChoP is a zwitterionic molecule with a positively charged quaternary amine 
group, which may be important for its effect on antibody binding and the physical 
properties of the outer membrane. The structural components of ChoP that are 
required for its effect on antibody binding and the integrity of the outer membrane 
were examined using a strain that incorporated a ChoP analog, 
dimethylethanolamine phosphate [(CH3)2NCH2CH2PO4 -]. This ChoP analog 
differs from ChoP by a single methyl group, which reduces the positive charge on 
the amine group with minimal alteration of the overall structure. Incorporation of 
the ChoP analog into the LPS of the Rd constitutive ChoP+ strain H491 grown in 
CDM + dimethylethanolamine was confirmed by MS (not shown). H491 grown in 
CDM + dimethylethanolamine had a similar level of antibody binding as when the 
strain was grown in CDM alone (Figure 2E). In addition, while H491 grown in 
CDM + choline had increased EDTA resistance compared to when it was grown 
in CDM alone, H491 grown in CDM + dimethylethanolamine showed the same 
percent survival in EDTA as when it was grown in CDM alone (Figure 8B). While 
it cannot be ruled out that the single methyl group impacts the steric inhibition of 
antibody binding, these results suggest that the positively charged quaternary 
amine on ChoP is important for the reduced antibody binding and increased 
outer membrane integrity observed in ChoP+ phase variants. 
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Discussion 
 
 Understanding the requirements for H. influenzae colonization is integral 
to the effort to reduce the burden of NTHi-associated disease. H. influenzae is 
susceptible to antibody-dependent, classical pathway complement-mediated 
killing in vitro, and this may be an important mechanism for host control of H. 
influenzae in vivo. For example, human patients with primary antibody 
deficiencies have persistent colonization and higher rates of disease from NTHi 
strains (330).  In this light, bacterial factors that affect antibody recognition could 
play a major role in H. influenzae survival during colonization. In this study, it was 
found that ChoP+ phase variants have reduced binding of antibody, including 
antibody binding to LPS epitopes, as well as increased survival in the presence 
of antibody-dependent, complement-mediated killing. While there was no 
difference in C3 deposition or bacterial survival for ChoP+/- phase variants in the 
absence of antibody, the experiments conducted in the present study do no 
exclude the possibility that ChoP expression affects binding of other classical 
pathway complement components. The major bactericidal antibody from the 
serum sources in this study was IgG, which can reach the site of colonization 
through transcytosis (291, 322). Indeed, nasal lavage fluid from BALB/c mice 
contains IgG that binds H. influenzae targets, including LPS, and a role for 
complement in limiting H. influenzae colonization has also been demonstrated 
(440). Increased resistance to bactericidal antibody was observed for ChoP+ 
phase variants of multiple H. influenzae strains, despite the heterogeneity 
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observed in this bacteria (268). These data demonstrate a novel mechanism for 
evasion of antibody recognition by H. influenzae during colonization. It was also 
shown that adaptive immunity is required for the increase in the selection of 
ChoP+ phase variants during colonization. While the short-term colonization 
model used for the in vivo experiments demonstrates a role for ChoP expression 
in protection against natural antibodies, it was also shown that ChoP+ phase 
variants have reduced binding of antibody from pre-exposed, immune hosts. 
Taken together, these results suggest that ChoP expression provides a selective 
advantage at the mucosal surface during colonization, as ChoP+ bacteria are 
better protected against antibody binding and antibody-dependent clearance. 
ChoP is one of several LPS structural determinants whose attachment to 
the LPS is controlled by stochastic phase variation (264, 414). Other phase 
variable decorations to the LPS have been shown to have an effect on serum 
resistance. For example, loss of O-acetylation, sialylation, or the digalactoside 
residue Galα1,4Gal results in increased serum sensitivity, attributed to different 
mechanisms (83, 107, 172). The LPS of H. influenzae is highly heterogeneous 
(47), and phase variation of LPS epitopes may allow bacteria to quickly adapt to 
the repertoire of antibodies present in different host environments. While it was 
shown in the current study that ChoP+ phase variants have reduced binding of 
the mAb 6E4, the full scope of the LPS, or non-LPS, epitopes protected from 
antibody recognition by ChoP expression remains unknown. As mentioned 
previously, ChoP attachment to surface structures has been observed in several 
bacterial species. In addition to the LPS, ChoP has been found in bacteria on 
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teichoic acid, pili, and an elongation factor protein (15, 98, 407). It has also 
recently been shown that an effector protein injected by Legionella pneumophila 
modifies host regulatory factors with ChoP (15, 98, 407). The current study 
supplies another example of how the attachment of this ubiquitous molecule 
modulates the properties of its target. 
The importance of the molecular environment of the LPS for ChoP-
mediated protection against antibody binding was examined using a set of LPS 
mutants. It was found that two conserved inner core LPS structures (PEtn and 
HepIII) are required for the reduction of antibody binding in ChoP+ phase 
variants. This result could be due to the direct loss of epitopes that are normally 
protected against antibody binding by ChoP expression, or through an indirect 
effect of these structures on binding of antibody to other LPS epitopes. 
Previously, it was shown that changing the location of ChoP attachment affects 
sensitivity to CRP (228). In accordance with this data, we determined that the 
position of ChoP attachment to the LPS is important for the effect of ChoP on 
antibody binding in Rd. While the inner core structure of LPS is conserved 
among H. influenzae strains, ChoP can be attached to hexose extensions off of 
any of the three inner core heptoses or to a fourth heptose present in some NTHi 
strains (225, 235, 319). There are also NTHi strains with a partial duplication of 
the lic locus, resulting in the attachment of two ChoP residues to the LPS in 
ChoP+ phase variants (106). Each H. influenzae strain may have optimized its 
LPS structural arrangement to enable ChoP-mediated protection against 
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antibody binding. The variable position of ChoP also argues against its main 
function being sterically hindering antibody binding to other LPS epitopes. 
The finding that ChoP+ phase variants of H. influenzae are also less 
sensitive to trypsin digestion of outer membrane proteins led to the investigation 
of the effect of ChoP on the physical properties of the outer membrane. The 
reduced access of a non-antibody molecule to the membrane suggests that the 
effect of ChoP on antibody binding is due to a general effect on the outer 
membrane, rather than direct steric hindrance. This concept is supported by a 
recent study from this lab demonstrating that mutations in H. influenzae that 
change the distribution of phospholipids in the outer membrane result in 
decreased outer membrane stability and increased antibody binding to LPS 
epitopes (282).  
In support of the hypothesis that ChoP expression affects the physical 
properties of the outer membrane, it was shown that ChoP+ phase variants have 
reduced sensitization to treatments that may compromise the outer membrane, 
such as polymyxin B-induced EtBr permeability. Polymyxin B is a cationic peptide 
that targets negatively charged residues in the LPS (438). A previous study 
demonstrated that ChoP expression reduces sensitivity to killing by the cationic 
antimicrobial peptide LL-37 (229), further supporting a ChoP-mediated impact on 
the integrity of the outer membrane. While studies in several bacterial species 
have shown that lipid A modifications can affect antimicrobial resistance and 
membrane permeability (24, 270, 358, 400), the data presented in the current 
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paper demonstrate that modifications outside of the lipid A-KDO inner core 
region can also impact membrane integrity and barrier function. DSC has been 
used to determine the phase transition temperatures of phospholipid membrane 
systems as well as purified LPS from various bacterial strains (38, 179). In the 
current study, the phase transition temperature for purified LPS from a 
constitutive ChoP+ strain was found to be reduced compared to that for ChoP- 
LPS. A similar trend is observed in phospholipid membrane systems, where the 
addition of lipids containing ChoP reduce membrane permeability and the Tm 
(289). In DSC experiments using LPS isolated from Salmonella minnesota, it was 
found that mutants with reduced oligosaccharide extensions had a lower Tm, 
demonstrating that changes to the oligosaccharide, in addition to lipid A 
alterations, can affect the phase transition temperature (37, 114).  
It was shown in the current study that ChoP+ phase variants of H. 
influenzae have increased resistance to membrane disruption by EDTA. EDTA 
chelates the divalent cations that are important for the stabilization of the outer 
membrane through association with multiple negatively charged phosphate 
groups on the LPS (6, 285). It has been shown that EDTA treatment causes loss 
of outer membrane organization and shedding of LPS molecules, resulting in 
reduced membrane integrity (6, 393). The modification of outer membrane 
integrity correlated with an effect on antibody binding, as the addition of Mg2+ 
alone resulted in decreased antibody binding. While ChoP is a relatively small 
structural addition to H. influenzae LPS, the presence of the positively charged 
quaternary amine group may impact the outer membrane by altering charge 
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interactions. It was shown in this study that bacteria that incorporated 
dimethylethanolamine phosphate instead of ChoP did not have reduced antibody 
binding or increased EDTA resistance. These data indicate that the positively 
charged amine group, rather than the negatively charged phosphate group, is 
required for the effect of ChoP on outer membrane integrity and antibody binding. 
The expression of molecules with amine groups on lipid A, as well as KDO, has 
been shown to increase outer membrane stability in other bacteria (213, 316). 
Our study suggests a similar effect through modification of the outer core of the 
oligosaccharide with ChoP. This also supports the notion that a large part of the 
effect of ChoP on antibody binding is indirect, through alteration of outer 
membrane accessibility, rather than direct steric inhibition.  
In summary, these data indicate that ChoP expression increases the 
barrier function and integrity of the outer membrane, and these alterations 
correlate with a reduction in the accessibility and binding of antibody to ChoP+ 
phase variants. Phase variation of ChoP may be an important consideration in 
the design of NTHi vaccines targeting LPS epitopes, as selection for ChoP+ 
phase variants could abrogate vaccine effectiveness. In contrast, vaccines 
targeting ChoP would select for ChoP- phase variants, and thereby increase 
effective immune responses to other cell surface epitopes. While phase variation 
of LPS structures can directly alter the presence of specific epitope(s), these data 
suggest a novel mechanism whereby ChoP expression affects the ability of 
antibody to recognize bacterial targets by altering access to outer membrane 
antigens. 
77 
 
Materials and Methods 
 
Ethics Statement 
This study was conducted according to the guidelines outlined by National 
Science Foundation Animal Welfare Requirements and the Public Health Service 
Policy on the Humane Care and Use of Laboratory Animals. The protocol was 
approved by the Institutional Animal Care and Use Committee, University of 
Pennsylvania Animal Welfare Assurance Number A3079-01.  
 
Bacterial strains 
 All strains are listed in Table 1. Strains were grown in brain heart infusion media 
(Becton Dickinson Biosciences, Franklin Lake, NJ) supplemented with Fildes 
enrichment (Remel, Lenexa, KS) and 20 µg/mL β-Nicotinamide adenine 
dinucleotide hydrate (Sigma, St. Louis, MO), referred to as sBHI. When specified, 
strains were grown in CDM, prepared as previously described (252). CDM was 
supplemented with 300 µM of choline chloride or the choline analog N,N-
Dimethylethanolamine (Sigma) where indicated. Selection of ChoP and Galα1-
4Gal containing phase variants was performed by colony immunoblotting as 
previously described (417). Revertants of ChoP variants were selected in the 
same manner. Each ChoP phase variant population was determined to be over 
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98% ChoP+ or ChoP- by colony immunoblotting, and constitutive ChoP mutants 
were 100% ChoP+ (H491) or ChoP- (H446). The percentage of ChoP+ and 
ChoP- bacteria in each phase variant population remained constant during 
growth to log phase, as there is no selective pressure on ChoP expression in 
vitro. ChoP+ colonies transferred to a nitrocellulose membrane were detected 
using a 1:10,000 dilution of the monoclonal antibody TEPC-15 (Sigma) followed 
by a 1:10,000 dilution of alkaline phosphatase-conjugated anti-mouse IgA 
(Sigma). Colonies expressing the Galα1-4Gal structure were selected using a 
1:10,000 dilution of the monoclonal antibody 4C4 (401) followed by a 1:10,000 
dilution of alkaline phosphatase-conjugated anti-mouse IgG (Sigma). 
 
Mouse nasopharyngeal colonization 
Colonization studies were conducted as described previously (440). Briefly, mice 
were intranasally inoculated with 107 CFU/mL of bacteria that were first washed 
and diluted in phosphate-buffered saline (PBS). ChoP variants were grown 
separately, followed by combination at a 3:1 ratio of ChoP- : ChoP+ bacteria by 
volume prior to inoculation. Nasal lavage fluid was collected in 200 µl of PBS and 
plated onto sBHI containing 50 µg/mL streptomycin following three days of 
colonization. Bacterial counts obtained by nasal lavage were comparable to 
those collected by plating nasopharyngeal tissue homogenates. The percentage 
of ChoP+ colonies was determined through detection of ChoP by colony 
immunoblotting.   
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Flow cytometric analysis 
Antibody binding was detected by flow cytometry as previously described (282). 
Briefly, 200 µl reactions containing mid-logarithmic phase bacterial cells in 
Hank’s buffer without Ca2+ or Mg2+ (Gibco, San Diego, CA) supplemented with 
5% fetal calf serum (HyClone, Logan, UT) were incubated with primary antibody 
for 60 min at 37°C. Primary antibody sources included naïve BALB/c serum 
(1:200 dilution), NHS (1:200 dilution), IgG purified from NHS (Sigma, 4.8 µg), IgM 
purified from NHS (Sigma, 3.7 µg), normal human nasal secretions (1:200 
dilution), mAb 6E4 (1:100 dilution for H729, 1:500 dilution for Rd), and BRS (1:50 
dilution). Serum collected from BALB/c mice that had been intranasally 
inoculated at day 0, 7, and 14 with either PBS (naïve) or 107 CFU/mL of 
constitutive ChoP- type b strain H445 (immune) was also used as a source of 
primary antibody (1:20 dilution). Reactions mixtures were then washed and re-
suspended in 1:200 dilutions of secondary antibody, followed by incubation at 
4°C for 60 min. Secondary antibodies included goat anti-mouse IgG-FITC, goat 
anti-human IgG-FITC, goat anti-human IgA-FITC, goat anti-human IgM-FITC 
(Sigma), and goat anti-rabbit polyclonal C3-FITC (MP Biomedical Chappel, 
Irvine, CA). Reaction mixtures were then washed and re-suspended in PBS with 
1% bovine serum albumin and 0.5% paraformaldehyde prior to flow cytometric 
analysis on a BD FACS Calibur flow cytometer (Becton Dickinson Biosciences). 
A total of 50,000 cells were collected from each reaction mixture, and the MFI of 
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antibody binding was determined using FlowJo software (Tree Star, Ashland, 
OR).  
 
Bactericidal assays 
Assays were conducted in 200 µl reaction mixtures containing 20 µl of mid-
logarithmic phase bacterial cells (OD620 0.5) diluted to 105 CFU/mL in Hank’s 
buffer with Ca2+ and Mg2+ (Gibco). Following the addition of serum, reaction 
mixtures were incubated for 45 min at 37°C. One serum source was CRP-
depleted NHS, used at a 1:10 dilution for H233 and Eagan, a 1:5-1:10 dilution for 
other NTHi strains, and a 1:50 dilution for Rd. CRP was depleted from NHS using 
immobilized p-aminophenyl phosphoryl choline gel, which also results in 
depletion of anti-ChoP antibodies, according to the manufacturer’s protocol 
(Thermo Scientific, Rockford, IL). Another serum source was a 1:20 dilution of 
BRS, to which purified IgG from NHS was added (Sigma, 4.8 µg). IgG depletion 
of NHS was performed using a Protein G column (GE Healthcare Bio-Sciences, 
Uppsala, Sweden). IgG eluted from the Protein G column according to 
manufacturer’s instructions was also used as a source of purified IgG (0.25 
µg/mL) for bactericidal assays. Survival due to alternative pathway mediated 
killing alone was determined by comparing survival in BRS alone (no H. 
influenzae antibodies) and by chelating NHS with gelatin veronal buffer 
containing MgEGTA (Boston Bioproducts, Worcester, MA) (122). Serum pre-
absorption of anti-LPS antibodies was conducted by incubation of NHS (1:50 
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dilution) with 1 µg LPS overnight at 4°C. Baby rabbit serum was used as a 
source of complement without antibody at a 1:20 dilution for H233, a 1:10 dilution 
for H729, and a 1:25 dilution for Rd. Bactericidal assays with baby rabbit serum 
were supplemented with IgG purified from NHS (4.8 µg) for H233, or mAb 6E4 at 
a 1:10 dilution for H729 and a 1:100 dilution for Rd. Percent survival was 
determined relative to complement-inactivated serum, which was incubated for 
30 min at 56°C prior to use. Assays to determine EDTA sensitivity were 
performed by addition of EDTA (1-4 mM) to bacterial cells in sBHI diluted in 
Hank’s buffer with Ca2+ and Mg2+, followed by incubation for four hours at 37°C. 
Percent survival was determined relative to no-EDTA controls. 
 
LPS extraction 
LPS extractions were performed using the phenol-chloroform-petroleum ether 
method as previously described (112), with modifications (338). Briefly, bacterial 
pellets were washed sequentially in ethanol, acetone, and petroleum ether prior 
to lyophilization. The lyophilized samples were re-suspended and mixed 
overnight in a 2:5:8 extraction mixture of phenol: chloroform: petroleum ether. 
Following filtration and evaporation of chloroform and petroleum ether, LPS was 
precipitated from phenol in 5:1 mixture of acetone: diethyl ether. 
Ultracentrifugation was used to further purify LPS re-suspended in water, 
followed by lyophilization. 
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Trypsin digestion and Cy5 detection of surface proteins 
Partial digestion of outer membrane proteins with trypsin was performed as 
previously described (262). Briefly, 200 µl of mid-logarithmic phase bacterial cells 
(OD620 0.5) were washed and re-suspended in 10 mM Tris-HCL, pH 7.5. 
Following addition of 1mg/mL trypsin, bacteria were incubated for 2hrs at 37°C. 
The cells were then washed and re-suspended in 10 mM carbonate buffer prior 
to staining with Cy5 according to manufacturer’s instructions (GE Biosciences 
Amersham, Buckinghamshire, UK). Surface proteins with exposed lysines were 
labeled with 10 µl of Cy5 (40pmol) in the dark for 20 min, and reactions were 
stopped with 20 µl of 10 mM lysine. Cells were washed with 10 mM carbonate 
buffer and re-suspended in PBS with 1% bovine serum albumin prior to flow 
cytometric analysis on a BD FACS Calibur flow cytometer (BD Biosciences). A 
total of 50,000 cells were collected from each reaction mixture, and the MFI of 
antibody binding was determined using FlowJo software (Tree Star).  
 
EtBr uptake assay 
Ethidium bromide was used as a measure of outer membrane permeability as 
previously described (270). Bacterial cells grown to stationary phase (OD620 0.8) 
were re-suspended in PBS, with 15 µg/mL polymyxin B and 6 µM EtBr added 
directly prior to each measurement. Fluorescence was measured at an excitation 
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wavelength of 544 nm, an emission wavelength of 610 nm using FLUOstar 
OPTIMA (BMG Labtech, Ortenberg, Germany). EtBr uptake was expressed by 
RFU/s.  
 
DSC analysis of LPS phase transition temperature 
Purified LPS samples for each strain were diluted to 2 mg/mL in PBS, sonicated, 
and subjected to three cycles of incubation at 56°C for five min, vortexing 1 min, 
and cooling to 4°C. Where specified, MgCl2 was added to the PBS at 1:1 and 5:1 
[MgCl2]: [LPS] molar ratios. Following preparation, samples were stored at 4°C 
for several hours before running on the DSC instrument. Heat capacity profiles 
were determined at a scan rate of 60°C/hr over a temperature range of 10-60°C 
in a high-resolution differential scanning calorimeter (MCS, MicroCal, Amherst, 
MA). Three consecutive heating and cooling scans were measured per sample. 
PBS buffer-buffer references were subtracted from sample data, and 
concentration was normalized based on sample concentration. The Microcal 
ORIGIN software package was used to progress baselines. The gel-to-liquid 
crystalline phase transition temperature, Tm, was determined by integration from 
baseline to calculate the midpoint of the transition.  
 
MS analysis 
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Purified LPS samples were subjected to mild acid hydrolysis and electrospray 
ionization-mass spectrometry (ESI-MS) was performed as previously described 
(226). 
 
Statistical analysis 
Differences between groups were assessed for statistical significance using an 
unpaired Student’s t-test (GraphPad PRISM4, GraphPad Software, La Jolla, CA).  
 
Gene reference numbers 
The reference numbers for genes mentioned in the text include: opsX (0261), 
lpsA (0765), orfH (0523) and lpt6 (0258, 0259) from the Rd database for the 
published genome sequence (102), as well as lic1A (950399) and lic1D (950403) 
GeneID from the NCBI GenBank database. 
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Table 1. List of strains used in this study 
 
Strain Description Reference  
H233 NTHi chronic bronchitis clinical isolate A860516 (394) 
H632 NTHi otitis media clinical isolate SR7332.P1, Sma (243) 
H707 NTHi COPDb (non-exacerbation) clinical isolate (282) 
H708 NTHi COPD (non-exacerbation) clinical isolate (282) 
H725 NTHi COPD (exacerbation) clinical isolate (282) 
H729 NTHi COPD (exacerbation) clinical isolate (282) 
Rd Type d, unencapsulated isolate (5) 
H446 Rd with lic1D::Kmc, constitutive ChoP- (228) 
H457 (H3)d Rd with lic1D (Eagan) (228) 
H491 (H1)e Rd with lic1AΔ(CAAT)n, constitutive ChoP+ (228) 
lpsA Rd lpsA::Km (170) 
lpt6 Rd lpt6::Km (428) 
opsX Rd opsX::Km (170) 
orfH Rd orfH::Km (170) 
Eagan Type b clinical isolate  (413) 
H625 Eagan, unencapsulated isolatef (165) 
H445 Eagan with lic1D:Km, constitutive ChoP- (228) 
aSm, spontaneous streptomycin resistant mutant, bCOPD, chronic obstructive pulmonary disease, 
cKm, contains kanamycin resistance cassette, dH3, ChoP attached to hexose extension from 
HeptoseIII, eH1, ChoP in natural position (for Rd) attached to hexose extension from HeptoseI, 
ftype b- spontaneous mutant lacking both copies of the cap locus 
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Figure 1. Adaptive immunity is required for selection of ChoP+ phase variants 
during colonization. BALB/c or BALB/c (severe combined immune deficiency, or 
SCID) mice were intranasally inoculated with 107 CFU/mL of a 3:1 mixture of 
ChoP-:ChoP+ phase variants of NTHi strain H632. The percentage of ChoP+ 
phase variants was determined by colony immunoblotting of the inoculum (input, 
white bars) and the nasal lavage fluid following three days of colonization (output, 
stippled bars). Values are derived from five mice per group ± SD, ***p<.0001. 
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Figure 2. ChoP expression decreases antibody binding to the bacterial surface. 
Flow cytometric analysis was used to quantify antibody binding to bacterial cells. 
Representative histogram of BALB/c serum IgG binding to phase variants of 
NTHi strain H233, and the mean fluorescence intensity (MFI) for binding to H233 
phase variants and revertants of the originally selected phase variants (A). MFI of 
IgG binding from the serum of naïve (intranasally inoculated with PBS) or 
immune (intranasally inoculated with constitutive ChoP- type b strain H445) 
BALB/c mice to phase variants of type b (unencapsulated) strain H625 (B). The 
MFI of normal human serum (NHS) IgG binding to phase variants of NTHi strains 
H233 and H729 (C) and purified IgG for strain H233 (D). The MFI of NHS IgG 
binding for Rd constitutive ChoP+ strain H491 grown in CDM alone (grey bar) or 
supplemented with choline ((CH3)3N+CH2CH2, black bar) or 
dimethylethanolamine ((CH3)2NCH2CH2, stippled bar), (E). The MFI of IgA 
binding for phase variants of H233 using NHS (F) or pooled human nasal 
secretion IgA binding (G). The MFI of IgM purified from NHS binding for phase 
variants of H233 and Rd (H). The MFI of C3 binding from BRS to phase variants 
of H233 in the presence or absence of purified IgG (from NHS) (I). ChoP+ 
variants are shown in black bars, ChoP- variants are shown in grey bars. Values 
are derived from at least three independent experiments ± SD, *p<.05, **p<.01, 
***p<.001. 
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Figure 3. ChoP expression protects against bactericidal antibody. Percent 
survival in C-reactive protein (CRP)-depleted NHS (relative to complement-
inactivated control) is shown for phase variants of NTHi strain H233 and 
revertants of the originally selected phase variants (A). Percent survival in 
purified IgG from NHS with BRS (complement source) for phase variants of H233 
(B). Percent survival in CRP-depleted NHS for constitutive ChoP+ and ChoP- 
mutants in Rd, phase variants of type b strain Eagan, and multiple NTHi strains 
(C). Percent survival of NTHi strain H233 ChoP- phase variant in NHS, IgG-
depleted NHS, or in IgG-depleted NHS supplemented with purified IgG, is shown 
as indicated (D). ChoP+ variants are shown in black bars, ChoP- variants are 
shown in grey bars. Values are derived from at least three independent 
experiments ± SD, *p<.05, **p<.01, ***p<.001. 
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Figure 4. ChoP expression reduces binding of LPS bactericidal antibody. Rd LPS 
structure with arrows indicating sites of truncations for LPS biosynthesis mutants 
(A). Percent survival (relative to complement-inactivated control) for Rd 
constitutive ChoP- strain H446 in NHS that was absorbed with: purified Rd LPS 
from the constitutive ChoP+ mutant, the constitutive ChoP- mutant, or an opsX 
mutant (B). Flow cytometric analysis of the MFI of mAb 6E4 binding to phase 
variants of NTHi strain H729 and constitutive ChoP+ and ChoP- mutants in Rd 
(C). Percent survival in BRS (complement source) and mAb 6E4 for phase 
variants of NTHi strain H729 and constitutive ChoP+ and ChoP- mutants in Rd 
(D). ChoP+ variants are shown in black bars, ChoP- variants are shown in grey 
bars. Values are derived from at least three independent experiments ± SD, 
*p<.05, **p<.01, ***p<.001. 
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Figure 5. Core LPS structures are required for ChoP-mediated protection against 
antibody binding. Flow cytometric analysis of the MFI of IgG binding to phase 
variants of Rd LPS mutant strains lpsA, orfH, and lpt6 following incubation in 
BALB/c serum (A) or NHS (B). Percent survival in CRP-depleted NHS (relative to 
complement-inactivated control) for phase variants of Rd mutant strains (C). 
ChoP+ variants are shown in black bars, ChoP- variants are shown in grey bars. 
Values are derived from at least three independent experiments ± SD, *p<.05, 
**p<.01. 
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Figure 6. Position of ChoP affects ChoP-mediated protection against antibody 
binding. Flow cytometric analysis of the MFI of IgG binding to phase variants of 
Rd lic1D exchange mutants; H491 with Rd lic1D (HeptoseI, or H1), and H457 
with Eagan lic1D (HeptoseIII, or H3), from BALB/c serum (A) or NHS (B). Percent 
survival (relative to complement-inactivated control) was determined following 
incubation in CRP-depleted NHS (C).  ChoP+ variants are shown in black bars, 
ChoP- variants are shown in grey bars. Values are derived from at least three 
independent experiments ± SD, *p<.05, **p<.01. 
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Figure 7. ChoP expression affects outer membrane accessibility and barrier 
function. Flow cytometric analysis of the MFI of Cy5 binding to outer membrane 
surface proteins following trypsin digestion for phase variants of NTHi strain 
H233 and revertants of the originally selected phase variants and constitutive 
ChoP+ and ChoP- mutants in Rd (A). Rate of ethidium bromide (EtBr) uptake, 
expressed in relative fluorescent units per second (RFU/s), in the presence of 
polymyxin B for phase variants of NTHi strain H233 and revertants and 
constitutive ChoP+ and ChoP- mutants in Rd (B). ChoP+ variants are shown in 
black bars, ChoP- variants are shown in grey bars. Values are derived from at 
least three independent experiments ± SD, *p<.05, **p<.01, ***p<.001. 
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Figure 8. ChoP expression increases outer membrane integrity. Percent survival 
following incubation in EDTA was determined for ChoP+ (black solid), ChoP- 
(grey solid), and ChoP-,Galα1-4Gal+ (grey dashed) phase variants of NTHi strain 
H233 (A). Percent survival in EDTA for Rd constitutive ChoP+ strain H491 grown 
in CDM alone (grey solid), or supplemented with choline (black solid) or with 
dimethylethanolamine (grey dashed) (B). Percent survival in EDTA for Rd lic1D 
exchange mutants, Rd lic1D (H1) (C) and Eagan lic1D (H3) (D). Flow cytometric 
analysis of the MFI of NHS IgG binding in the presence of 0-50 mM Mg2+ for 
ChoP+ (black bars) and ChoP- (grey bars) phase variants of NTHi strain H233 
(E). Values are representative of three independent experiments performed in 
duplicate ± SD (A-D), or are derived from three independent experiments ± SD 
*p<.05, **p<.01 (E). 
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Abstract 
 
Non-typeable Haemophilus influenzae (NTHi), a common commensal of the 
human pharynx, is also an opportunistic pathogen if it becomes established in 
the lower respiratory tract (LRT). In comparison to colonizing isolates from the 
upper airway, LRT isolates, especially those associated with exacerbations of 
chronic obstructive pulmonary disease, have increased resistance to the 
complement- and antibody-dependent, bactericidal effect of serum. To define the 
molecular basis of this resistance, mutants constructed in a serum resistant 
strain using the mariner transposon were screened for loss of survival in normal 
human serum. The loci required for serum resistance contribute to the structure 
of the exposed surface of the bacterial outer membrane. These included loci 
involved in biosynthesis of the oligosaccharide component of lipooligosaccharide 
(LOS), and vacJ, which functions with an ABC transporter encoded by yrb genes 
in retrograde trafficking of phospholipids from the outer to inner leaflet of the cell 
envelope. Mutations in vacJ and yrb genes reduced the stability of the outer 
membrane and were associated with increased cell surface hyrophobicity and 
phospholipid content. Loss of serum resistance in vacJ and yrb mutants 
correlated with increased binding of natural immunoglobulin M in serum as well 
as anti-oligosaccharide mAbs. Expression of vacJ and the yrb genes was 
positively correlated with serum resistance among clinical isolates. Our findings 
suggest that NTHi adapts to inflammation encountered during infection of the 
LRT by modulation of its outer leaflet through increased expression of vacJ and 
yrb genes to minimize recognition by bactericidal anti-oligosaccharide antibodies. 
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Author Summary 
 
Haemophilus influenzae generally colonizes the human upper respiratory tract. 
When isolated from the lower respiratory tract, this opportunistic pathogen is 
associated with inflammatory conditions such as pneumonia and exacerbations 
of chronic obstructive pulmonary disease (COPD). Here we show that one of the 
adaptations made by H. influenzae isolated from the lower respiratory tract is 
increased resistance to the bactericidal effect of antibody and complement. To 
define the mechanism for increased resistance, mutants were screened to 
identify the complete set of genes required to inhibit killing by antibody and 
complement. These included multiple genes that all contribute to biosynthesis of 
the organism's surface oligosaccharide (lipooligosaccharide), which is targeted 
by bactericidal antibody. Our results also revealed a novel function for additional 
genes that maintain the lipid asymmetry of the surface membrane and thereby 
limit recognition of the pathogen by anti-oligosaccharide antibodies. 
 
Introduction 
 
The mucosal surface of the human nasopharynx is serially colonized by different 
strains of Haemophilus influenzae (268). When host factors allow this 
opportunistic pathogen to gain access to the normally sterile parts of the 
respiratory tract, inflammatory diseases such as otitis media, sinusitis or 
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pneumonia may result (272). Widespread immunization against encapsulated 
strains with the type b polysaccharide has greatly reduced the incidence of 
invasive disease by H. influenzae in children. However, non-typeable strains 
(NTHi), which do not express a capsule, remain amongst the most common 
etiologic agents of localized infectious diseases of the airway in all age groups 
(389). The damaged airways in adults with chronic obstructive pulmonary 
disease (COPD) are especially susceptible, and identification of a newly acquired 
NTHi isolate in sputum is temporally associated with exacerbations of disease 
symptoms and decline in pulmonary function (14, 344). COPD ranks as the 
fourth leading cause of death in the US and is rapidly becoming recognized as a 
public health problem of similar proportions in other parts of the world (279, 297). 
Characteristics of the organism that allow it to transition from its 
commensal state in the upper airway and survive the inflammatory milieu of the 
lower respiratory tract (LRT) and elsewhere are poorly understood. In particular, 
during early infection this predominantly extracellular pathogen will be exposed to 
increasing levels of natural (i.e. pre-existing) antibody and complement produced 
locally or extravasated from serum. For encapsulated H. influenzae, the thick 
polysaccharide coat protects the organism from recognition by immunoglobulin, 
the activation of complement and complement-dependent bactericidal activity. 
For gram-negative bacteria, the exposed surface is its outer membrane, an 
asymmetric lipid bilayer consisting of an outer leaflet of lipid A attached to a 
polysaccharide (LPS) and an inner leaflet of phospholipid (183, 189, 285). For H. 
influenzae, LPS is referred to as a lipooligosaccharide (LOS) because of its more 
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limited number of attached sugars. There is marked strain to strain heterogeneity 
in the presence and linkages of these sugars and oligosaccharide epitopes these 
residues generate indicating that antigenic variation may contribute to immune 
evasion by NTHi (339, 375). Structural features of the surface oligosaccharide 
that inhibit complement-dependent killing have been analyzed extensively (83, 
95, 164, 415). The expression of many of these oligosaccharide components is 
controlled by highly repetitive DNA sequences and, as a consequence of slipped 
stranded mispairing, the expression of oligosaccharide structures is turned on 
and off at high frequency (413, 415). While this would predict that the presence 
of bactericidal antibody and complement would select for variants with increased 
resistance, many of these structures decorating the surface oligosaccharide are 
present on both serum sensitive and resistant isolates. Therefore, our current 
understanding does not fully account for why only some NTHi are serum 
resistant and how this phenotype correlates with the pathogenicity of the species. 
In this study, we addressed whether increased resistance to the 
complement-mediated bactericidal activity of normal human serum is a 
characteristic of isolates from the LRT. We then used a whole genomic approach 
to identify the genes required for the expression of serum resistance among 
these isolates. We describe an important role for genes involved in trafficking of 
phospholipids in evading natural antibody and the expression of serum 
resistance by NTHi. 
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Results 
 
Lung isolates have increased serum resistance and decreased binding of natural 
IgM 
Collections of recent clinical isolates maintained with minimal in vitro passage 
were compared for their ability to survive following a 60 min incubation in 5% 
normal human serum (NHS). Bactericidal activity was complement-dependent, 
since killing was not observed in controls using heat-inactivated serum. Sputum 
isolates from the lower respiratory tract (LRT) (n=22) were significantly more 
serum resistant than colonizing strains (n=25) cultured from the upper respiratory 
tract (Fig. 1A). Among the LRT isolates, those obtained at the time of a COPD 
exacerbation were the most serum resistant. Next, we examined whether 
differences in serum resistance correlated with the binding of immunoglobulin 
present in normal human serum as measured by flow cytometry. There was no 
difference between serum resistant and serum sensitive isolates in binding of IgG 
(Fig. 1B1). In contrast, the serum sensitive strains bound significantly more IgM 
than serum resistant strains (Fig. 1B2). There was no difference between serum 
resistant and serum sensitive strains in killing by baby rabbit serum (2.5%), which 
lacks natural antibody to H. influenzae, as a source of complement (Fig. 1C). 
Addition of IgM, but not IgG, purified from NHS to baby rabbit serum significantly 
enhanced killing of serum sensitive, but not serum resistant isolates (Fig. 1C). 
Together these results demonstrate 1) an association between serum resistance 
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and the ability of NTHi to infect the LRT and 2) that resistant isolates bind less 
natural, bactericidal IgM. 
 
Genetic basis of increased serum resistance 
In order to identify the complete set of genes required for serum resistance in 
NTHi, we screened mariner transposon mutants generated in strain R2866, a 
previously described serum resistant isolate for which the whole genome 
sequence was available, for increased susceptibility to NHS (423). A total of 
6912 mutants were individually screened to provide ~4-fold representation of 
open reading frames. Genomic DNA from candidates showing <10% survival 
was back transformed into the parent, R2866, and these back transformants 
were tested to confirm that the insertion mutation conferred a serum sensitive 
phenotype. Sixty serum sensitive mutants (representing 0.87% of the total strains 
screened) were identified and for these the mariner insertion site was defined. 
We focused on the genes (13 total and 12 of ‘known’ function) for which there 
was more than a single ‘hit’ (Table 1). Eight loci, including lgtC, galE, waaQ, 
lic2A, lex2B, lpsA, yhxB and galU, function in the biosynthesis of the surface 
oligosaccharide and these were not considered further (170). The most striking 
effect on serum resistance (Fig. 2A) was observed with mutations in HI0718 
(encoding VacJ, a putative lipoprotein), and in a separate operon with ‘hits’ in 
HI1083, HI1085, and HI1086 (encoding orthologs of other gram-negative 
species; YrbB, a putative NTP binding protein; YrbD, an ABC transporter 
periplasmic protein; and YrbE, an ABC transporter permease, respectively). 
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VacJ, YrbD and YrbE each share homology (>60% sequence identity) with 
members of the E. coli Mla transport system, which have been proposed to 
function in preventing phospholipid accumulation in the outer leaflet and thereby 
maintain the lipid asymmetry and the barrier function of the gram-negative outer 
membrane (234). A double mutant in vacJ and the ABC transporter gene yrbE 
had a similar serum sensitive phenotype to that of each mutant, which confirmed 
that these may act in the same pathway. The effect on vacJ is unlikely to be 
caused by a polar effect of the insertion mutation, since a mutant in the 
immediate downstream gene, HI0719, maintained serum resistance (data not 
shown). There was no effect of vacJ or yrb genes on LOS or outer membrane 
protein profiles as assessed following separation using tricine gel electrophoresis 
followed by silver staining (data not shown). 
 
vacJ and yrb ABC transporter genes contribute to serum resistance and IgM 
binding 
After incubation in baby rabbit serum, no significant difference was observed in 
the binding of rabbit complement factor 3 between wild type and vacJ mutant 
(data not shown) indicating a requirement for antibody in the differential 
susceptibility of the mutants. To determine whether vacJ and yrbE, B and D 
mediate serum resistance by affecting antibody binding, we compared the 
deposition of IgG and IgM purified from NHS by flow cytometry. No detectible 
effect of these mutations on the binding of IgG was observed (data not shown). 
In contrast, there was a significant increase in the binding of IgM to the mutants 
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(Fig. 2B and 2C). To determine if increased binding of IgM was sufficient to 
account for loss of serum resistance of the mutants, IgM purified from human 
serum was used with 2.5% baby rabbit serum as a complement source. Under 
these conditions each of the mutants was more susceptible to IgM dependent 
killing (data not shown). To define the complement pathway affected, the survival 
of the mutants was studied in the presence of Mg-EGTA buffer, which inhibits the 
classical pathway. When the classical pathway was inhibited, a significant 
increase in the survival of each mutant was observed (Fig. 2D). The requirement 
for the classical pathway of complement showed that the anti-bacterial effect of 
IgM was not caused by agglutination. Together these results demonstrated that 
vacJ and yrbE, B and D are needed for serum resistance in R2866 by limiting the 
binding of natural IgM that promotes killing via the classical pathway of 
complement activation. 
 
vacJ and yrb ABC transporter genes affect binding of anti-LOS antibody 
Next, we considered the target of bactericidal, natural IgM affected by mutations 
in vacJ and yrb ABC transporter genes. We performed FACS analysis to 
compare the binding of murine mAbs 4C4 and TEPC-15, which bind specifically 
to LOS components, Galα1-4Gal and phosphorylcholine, respectively. Since 
these are both phase variable LOS epitopes, we first enriched for mAb 4C4 or 
TEPC-15 positive cells by colony immunoblotting. Mutations in vacJ and the yrb 
ABC transporter genes significantly increased the binding of mAbs 4C4 and 
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TEPC-15 (Fig. 3A and 3B). Furthermore, mAb 4C4 was bactericidal in the 
presence of normal mouse serum as a source of complement and each mutant 
was significantly more sensitive compared to the parent strain. (Fig. 3C). We 
then investigated whether vacJ affects the antibody binding to cell surface 
proteins by flow cytometry in two different ways. First, we compared binding of 
the mAb 7B11 to an exposed epitope on outer membrane protein P2 on strain 
H782 (143). However, the mutation in vacJ in strain H782 did not alter the 
binding of mAb 7B11 (data not shown). Second, we labeled exposed lysine 
residues on cell surface proteins by treating whole bacteria with the fluorescent 
dye Cy5. There was no difference in the levels of bound Cy5 between wild type 
and vacJ mutant (data not shown). Our data suggested that vacJ affects binding 
of antibody to exposed LOS but not outer membrane protein epitopes. Since 
mAb 4C4 is IgG and TEPC-15 is IgA, the effect on antibody binding and killing 
was not specific to IgM. This suggests that our observations about natural 
antibody in NHS could be because the bactericidal antibody targeting LOS is 
predominantly IgM. 
 
vacJ and yrb ABC transporter genes affect outer membrane stability 
To test whether vacJ and yrb ABC transporter genes affect the integrity of the 
outer membrane, we analyzed the sensitivity of the mutants to small antimicrobial 
compounds, including vancomycin (MW 1449), novobiocin (MW 613), bacitracin 
(MW 1423), and polymyxin-B (MW 1302). There was no difference in sensitivity 
to these compounds compared to the parent strain suggesting that the outer 
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membrane barrier of the mutants is largely intact (data not shown). We then 
addressed the stability of the outer membrane by the addition of EDTA, which 
chelates divalent cations and compromises the outer leaflet by interrupting 
intermolecular associations between LOS phosphate groups. A concentration of 
25 mM EDTA had no effect on the parent strain, but resulted in a >3-log 
decrease in viability for each of the mutants (Fig. 4A). Similarly, the mutants were 
sensitive to the detergent deoxycholate at a concentration 4-fold lower than that 
required to inhibit growth of the parent strain (data not shown). Our observations 
of increased sensitivity to EDTA and deoxycholate demonstrated that the stability 
of the outer membrane was impaired in the mutants. Next, we compared the 
physical properties of the outer leaflet of the mutants by measuring the rate of 
uptake of 1-N-phenylnaphthylamine (NPN), a probe that changes fluorescence 
upon transfer from a hydrophilic to hydrophobic environment. We predicted that 
higher phospholipid content would increase the hydrophobic character of the cell 
surface of the mutants. As shown in Fig. 4B, vacJ and yrbE mutants had more 
rapid NPN uptake than the wild type strain, demonstrating that both mutants 
have increased surface hydrophobicity. In addition, we directly compared the 
content of surface exposed phospholipids by treating whole cells with 
phospholipase C and then detecting released diacylglycerol using thin layer 
chromatography (Fig. 4C). In comparison to the parent strain, amounts of 
released diacylglycerol were increased in vacJ (spot density increased 219%) 
and yrbE (spot density increased 143%) mutants, showing that the amount of 
surface phospholipid accessible to phospholipase C treatment was increased in 
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the mutants. The similar results for each mutant provided further evidence that 
vacJ and yrb genes act in the same pathway and were consistent with their 
previously proposed function in E. coli in excluding phospholipids from the outer 
leaflet described (234). Together our findings suggested that maintaining the 
asymmetry of the outer leaflet by the exclusion of phospholipids is important in 
limiting recognition of surface oligosaccharide epitopes by antibody. 
 
Expression of vacJ and yrb ABC transporter genes correlates with serum 
resistance in clinical isolates 
To investigate the relationship between outer leaflet stability and serum 
resistance in NTHi, we compared the sensitivity of serum resistant and serum 
sensitive clinical isolates to EDTA. As shown in Fig. 5A, serum resistant isolates 
were significantly more resistant to EDTA than serum sensitive isolates. We then 
determined whether differences in serum resistance and resistance to EDTA 
correlated with the expression of vacJ and yrb genes by qRT-PCR. As shown in 
Fig. 5B, vacJ expression was ~5-fold higher in serum resistant strains compared 
to serum sensitive isolates. In addition, yrbE and yrbD expression was ~3-fold 
higher in serum resistant compared to serum sensitive isolates (Fig. 5C and 5D). 
To further investigate the relationship between serum resistance and vacJ 
expression, we serially passaged strain H725, a serum sensitive clinical isolate, 
in 2.5% NHS to select for variants with an increasing capacity to resist the 
bactericidal effect of serum. With each passage H725 became more serum 
resistant and this adaptation was associated with a stepwise increase in vacJ 
106 
expression and resistance to EDTA (Fig. 6A–C). Our data suggest that among 
clinical isolates differences in serum resistance correlate with the level of 
expression of vacJ and its effect on stability of the outer leaflet of NTHi. 
 
Discussion 
 
Although generally co-existing in a commensal relationship with its host, NTHi is 
able to survive the robust inflammatory response it induces in normally sterile 
sites in the respiratory tract such as the lung. Since humans are serially 
colonized beginning early in childhood, prior exposure to NTHi, as well as to 
other microbial species that induce cross reactivity, provides an abundant source 
of natural antibody (89, 292). Individuals with defects in generating antibody are 
particularly susceptible to recurrent respiratory tract infection with NTHi (293). To 
survive the inflammatory response in the LRT, this pathogen has to evade the 
effects of the host's pool of pre-existing antibody, which when bound to the 
bacterial surface activates complement and induces lytic killing. In this report we 
used a serum killing assay to show that survival of NTHi isolated from the LRT is 
associated with increased resistance to the complement-dependent bactericidal 
effect of antibody. Additional evidence in support of this conclusion is the finding 
that serum resistance was highest among the isolates obtained at the time of 
COPD exacerbations when clinical signs of inflammation, such as increased 
production of sputum, are more pronounced. Although antibodies of other 
isotypes can be bactericidal, we found that most of the natural bactericidal 
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antibody present in NHS is IgM. Our findings demonstrate that serum killing 
correlates with binding of natural IgM followed by activation of the classical 
pathway of complement. Observations on the prominence of anti-LOS IgM in the 
bactericidal activity of NHS correlate with previous reports looking at natural 
bactericidal antibody present in animal sera (85). Findings in the current study 
are also consistent with prior reports from this laboratory using a mouse model of 
airway infection showing that complement and natural antibody protect the host 
from NTHi (440). 
Previous analysis of serum resistance in NTHi has been limited by the 
marked heterogeneity within and between strains. This is largely caused by the 
rapid variation in the expression of surface antigens targeted by natural antibody 
and demonstrates the ability of the organism to escape antibody-dependent, 
complement-mediated killing. Several specific oligosaccharide structures that 
contribute to serum resistance have been described. Some strains express 
siayltransferases that use serum CMP-NANA to cap the oligosacchaide with 
sialic acid, which inhibits the activation of complement through the alternative 
pathway (95). The disaccharide Galα1-4Gal, which mimics the human Pk blood 
group antigen, blocks recognition by anti-LOS antibodies (415). The 
oligosaccharide structures requiring the galactosyltransferase LgtC affects 
expression of Galα1-4Gal modulating deposition of C4b and activation of the 
classical pathway (164). These oligosaccharide decorations are each variably 
expressed within and between strains. Our finding that 8 of the 13 genes 
necessary for the expression of serum resistance in a highly serum resistant 
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NTHi strain function in biosynthesis of the surface oligosaccharide highlights its 
central role in this phenotype and the pathogenicity of the organism. In addition, 
we demonstrate that the oligosaccharide is the major target of bactericidal 
human antibody. This may explain the predominance of natural IgM in targeting 
the NTHi oligosaccharide, since antibody to LPS antigens is dominated by IgM 
generated by B-1 cells (314). For example, a large proportion of B-1 cells 
generate IgM reactive with phosphorylcholine (31). 
The selection for a more serum resistant phenotype in the LRT correlated 
with increased expression of vacJ and yrb genes, which alter cell surface 
characteristics and thereby limit the binding of bactericidal antibody. The 
identification of VacJ and an ABC transporter with related function as necessary 
for the expression of serum resistance shows that surface characteristics other 
than structural components of the oligosaccharide contribute to serum resistance 
of NTHi. The lipoprotein VacJ was previously identified as a virulence 
determinant contributing to intracellular survival by Shigella flexneri (372). The 
group of Silhavy proposed that VacJ acts with the Mla ABC transporter to 
maintain the lipid asymmetry of the outer membrane by recycling phospholipids 
from the outer leaflet back to the inner leaflet (234). In E. coli, mutants lacking 
these genes were more sensitive to the presence of SDS plus EDTA added to 
solid media, but not to antibiotics that need to access targets in the periplasmic 
space. These observations indicated that 1) stability of the outer leaflet 
generated through intermolecular bridging of LPS by divalent cations was 
compromised by the accumulation of phospholipids and 2) the permeability 
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barrier of the outer leaflet remains largely intact in the mutants. We observed 
similar characteristics of mutants in vacJ and Mla ABC transporter homologs in 
NTHi. In addition, we provided direct evidence that vacJ and yrb genes function 
in determining key characteristics of the cell surface (i.e. its hydrophobicity) and 
that these genes affect amounts of surface exposed phosholipid. The increase in 
antibody binding and killing seen in these mutants provides a new insight into 
how these physical characteristics of the outer membrane contribute to serum 
resistance. Our results suggest that the intramolecular forces bridging LOS 
molecules also serve to limit binding of antibodies to the oligosaccharide. Thus, 
when phospholipids are more thoroughly excluded (high expression of vacJ and 
yrb genes), LOS molecules are more tightly packed and accessibility of LOS 
epitopes is restricted (serum resistance). Whereas when phospholipids 
accumulate in the outer leaflet (low expression of vacJ and yrb genes), 
intermolecular associations of LOS molecules are interrupted allowing for 
increased access of oligosaccharide epitopes recognized by bactericidal 
antibodies (serum sensitivity). 
Interestingly, the expression of vacJ and yrb genes, which are required for 
serum resistance, is variable within and between NTHi strains. Serum resistant 
isolates demonstrated increased levels of transcription compared to serum 
sensitive isolates and serial passage of a sensitive isolate in serum selected for 
increased resistance and resulted in a higher level of vacJ expression. Thus, 
differences in transcription of vacJ are another factor accounting for the marked 
differences in serum resistance that characterizes this species. It is somewhat 
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surprising that for many clinical isolates levels of vacJ expression is low enough 
to affect the stability of the outer membrane. This suggests that some level of 
phospholipid accumulation in the outer leaflet is tolerated by NTHi and implies 
that there must be an advantage to a less stable, more hydrophobic outer 
membrane, particularly during colonization when restricting recognition by 
antibody may be less critical for survival. It appears, however, that this fitness 
advantage is lost during infection of the lung when increased vacJ and yrb gene 
expression is selected for. Because NTHi resides in the respiratory tract where it 
is not exposed to the detergent effect of bile in the intestine, the physical 
requirements of its outer membrane may be different from the paradigm 
described in the classic studies based on enteric bacteria (286). 
In conclusion, we show that resistance to the bactericidal effect of 
immunoglobulin together with complement correlates with the ability of NTHi to 
infect the human LRT. Analysis of a serum resistant isolate revealed that genes 
contributing to the biosynthesis of its surface oligosaccharide are required for this 
phenotype. In addition, we describe a novel mechanism for serum resistance 
whereby NTHi limits the binding of bactericidal anti-LOS antibody by increasing 
the exclusion of surface phospholipids. 
 
Materials and Methods 
 
Bacterial strains and growth conditions 
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Strains used in this study are listed in Table 2. COPD strains. Strains were 
isolated from expectorated sputum samples as part of a prospective study at the 
Buffalo VA Medical Center. COPD exacerbation strains fulfilled the following 
criteria: 1) First isolation of the strain in an adult with COPD based on molecular 
typing of isolates recovered from monthly sputum cultures; 2) NTHi is the only 
potential pulmonary pathogen isolated in the sputum sample; 3) simultaneous 
onset of clinical symptoms of an exacerbation (increased sputum volume, 
increased sputum purulence and increased shortness of breath compared to 
baseline symptoms). Non-exacerbation strains were from patients with COPD 
during clinically stable periods who fulfilled criteria 1 and 2 but symptoms 
unchanged from baseline upon acquisition of the strain. Upper respiratory tract 
strains. 25 NTHi strains were isolated from throat cultures of 25 healthy children 
attending 17 different day care centers (92, 363). Each isolate had a different 
pulse-field gel electrophoresis pattern and was confirmed to be H. influenzae 
(and not non-hemolytic H. haemolyticus) based on previous criteria (247, 268). 
The absence of bexA and bexB confirmed that the isolates were not capsule-
negative variants. 
 Strains were routinely grown at 37°C in brain heart infusion broth (Becton 
Dickinson) supplemented with 2% Fildes enrichment (Remel) and 20 µg/ml β-
NAD hydrate (NAD; Sigma). H782 was created from strain Rd by transformation 
with a PCR product from outer membrane protein P2 locus of strain 2019 
followed by screening for expression of the surface epitope recognized by mAb 
7B11 epitope (143). 
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Ethics statement 
The strains from adults with COPD were obtained from subjects enrolled in a 
study at the Buffalo VA Medical Center that was approved by the IRB of the VA 
Western NY Healthcare System. All subjects provided written informed consent. 
Strains collected from healthy children in day care, under protocols reviewed by 
IRB Health at the University of Michigan, were deemed EXEMPT on the basis of: 
EXEMPTION #4 (45 CFR 46.101(b)(4)), because the data were collected and 
analyzed without personal identifiers attached to the bacterial isolates. 
 
In vitro transposon mutagenesis, DNA transformation and transposon library 
construction 
Mariner mutants of strain R2866 were created by in vitro transposon 
mutagenesis as previously described (210). Briefly, in vitro transposition 
reactions were carried out on NTHi genomic DNA treated with purified MarC9 
transposase and pEMspec (240). To repair gaps, reactions were ethanol-
precipitated and resuspended in the gap repair buffer [50 mM Tris (pH 7.8)], 10 
mM MgCl2, 1 mM DTT, 100 nM dNTP, and 50 ng of BSA] and then treated with 
T4 DNA polymerase (Invitrogen) and E. coli DNA ligase (Invitrogen) (3). DNA 
was transformed into competent R2866 by the method of Herriott et al (161) and 
transformants where selected for on sBHI agar (1%) plates containing 
spectinomycin (100 µg/ml). 
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Identification of serum sensitive transposon mutants 
To identify NTHi genes essential for serum resistance, mariner transposon 
mutants were screened in a 96-well serum bactericidal assay. Following growth 
from single colonies in 200 µl sBHI, mutants were diluted to 105 CFU/ml and 10 
µl of the culture solution was added to 90 µl consisting of 55 µl PBS, 30µl Hank's 
buffer (Ca2+, Mg2+) and 5 µl of normal human serum (NHS). Serum was 
obtained from a single donor for the initial screen to minimize variability in 
screening large numbers of mutants. Bacteria were incubated at 37°C for 1 h 
with shaking before the reaction was stopped at 4°C. Controls included serum 
from the same donor treated at 56°C for 30 min to inactivate complement. 
Mutants showing >90% killing in the primary screen were further tested to 
minimize false positives. Genomic DNA was used to back transform competent 
R2866 and three spectinomycin resistant colonies were picked and rescreened in 
the bactericidal assay. The site of the transposon insertion was determined for 
mutants in which 3/3 back transformants were serum sensitive. 
 
Arbitrary primed PCR and nucleotide sequence 
The primers used for inverse PCR are listed in Table 2. The first round of PCR 
was performed in a final volume of 50 µl. Primers (0.5 µmol/reaction mixture) 
ARB1 paired with mag2F3 (transposon) were used in PCR under the following 
conditions: 1 cycle of 95°C for 8 min; 6 cycles of 95°C for 30 s, 30°C for 30 s, and 
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72°C for 1.5 min; 30 cycles of 95°C for 30 s, 45°C for 30 s, and 72°C for 2 min; 
and 72°C for 5 min. A second round of PCR was performed with primers (0.5 
µmol/reaction) ARB2 paired with the internal mag2F4 (transposon) primer under 
the following conditions: 1 cycle of 95°C for 8 min, 30 cycles of 95°C for 45 s, 
55°C for 45 s, and 72°C for 1.5 min, followed by 72°C for 10 min. PCR products 
were purified with the QIAGEN PCR cleanup kit and then used for nucleotide 
sequence analysis. 
 
Construction of ΔvacJ::KmR mutant 
The vacJ gene and flanking regions were amplified from strain R2866 using 
primers Hi_vacJ_H3_F2 and Hi_vacJ_R1 and cloned into pCR2.1TOPO vector. 
The entire vacJ gene was deleted by inverse PCR using Hi_vacJ_B1_F1 and 
Hi_vacJ_B1_R1 primers introducing a BamHI site. The resulting ΔvacJ fragment 
was subcloned into pUC19 and the kanamycin-resistance cassette from pUC4K 
was then inserted using BamHI creating pUCΔvacJ::KmR. This plasmid was 
used to transform strains R2866 and 69G3 strains creating single and double 
ΔvacJ::KmR mutants. Disruption of vacJ was confirmed by PCR using primers 
vacJ_ F9 and Hi_vacJ_R7 located outside of the originally cloned region. 
 
Serum bactericidal assays 
To test clinical isolates in bactericidal assays, serum was collected, pooled and 
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stored at -80°C from 5 healthy adult volunteers. Assays were performed with 20 
µl of a suspension of midlog phase organisms (OD620 0.3–0.4) diluted to 105 
CFU/ml in Hank's buffer with Ca2+ and Mg2+ (GIBCO, Auckland, New Zealand), 
10 µl of NHS, 110 µl of PBS and 60 µl of Hank's buffer with Ca2+ and Mg2+. 
After incubation for 60 min at 37°C with rotation, the assay was stopped by 
cooling to 4°C and dilutions were made for quantitative culture. To inhibit the 
classical pathway of complement, veronal buffer (pH 7.4) containing 70 mM 
NaCl, 140 mM glucose, 0.1% gelatin, 7 mM MgCl2, and 10 mM Mg-EGTA was 
substituted for Hank's buffer (246). To calculate the percent survival, viable 
counts were compared to controls in which complement activity had been 
eliminated by heat-inactivation at 56°C for 30 min. IgG was removed from NHS 
using a protein G column according to the manufacturer's instructions (GE 
Healthcare, Uppsala, Sweden). The flow-through of IgG column was used for 
purification of IgM. Purified IgM was obtained by using IgM purification column 
according to the manufacturer's instructions (GE Healthcare, Uppsala, Sweden). 
The concentration of purified IgG and IgM were determined by the Micro BCA 
protein assay (Pierce Chemical Co.) and a titrated enzyme-linked 
immunosorbent assay (ELISA). Where indicated, three-four week old baby rabbit 
serum was used as a complement source (Pel-Freez Biologicals, Rogers, AR). 
 
Colony immunoblotting 
Colonies lifted onto nitrocellulose were immunoblotted to separate phase variants 
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as previously described (417). Briefly, the LOS and ChoP epitope on colonies 
lifted onto nitrocellulose were detected using mAbs 4C4 against Galα1-4Gal 
(141) and TEPC-15 (Sigma) against phosphorylcholine followed by alkaline 
phosphatase–conjugated anti– mouse IgG and IgA, respectively. Single colonies 
of a uniform phenotype were selected and confirmed by repeated 
immunoblotting. 
 
Labeling of surface proteins 
200 µl of a suspension of midlog phase organisms, R2866 and vacJ mutant, 
(OD620 0.5) was pelleted, washed twice with 1 ml of 10 mM carbonate buffer 
(pH 8.5), and then resuspended in 200 µl of buffer (10 mM carbonate, 1 M urea). 
Surface-exposed lysine residues were labeled with 10 µl of Cy5 (400 pmol, GE 
Healthcare) on ice in the dark for 20 min (196). Reactions were stopped by 
addition of 20 µl of 10 mM lysine. The resulting pellets were washed twice with 
500 µl of carbonate buffer, centrifuged, and resuspended in 200µl 1% BSA. Cy5 
binding on bacteria was analyzed by flow cytometry with 10,000 events analyzed 
per sample. 
 
Deposition of complement factor 3 
R2866 and vacJ mutant were grown to an OD620 ~0.5. The bacterial suspension 
(200 µl) was pelleted and resuspended in Hank's buffer with Ca2+ and Mg2+ 
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(GIBCO, Auckland, New Zealand) with 5% fetal calf serum (HyClone) and 
incubated with 5µl of baby rabbit sera for 1°h. Bacteria were pelleted and 
resuspended in Hanks' buffer plus 5% fetal calf serum containing a 1:100 dilution 
of a FITC-conjugated polyclonal goat anti-rabbit C3 antibody (MP Biomedical 
Cappel, Irvine, CA) for 60 min at 4°C in dark and analyzed by flow cytometry. 
 
Quantitative real-time RT-PCR 
Total cellular RNA was extracted from mid-log phase grown NTHi clinical isolates 
by using the RNeasy mini Kit (QIAGEN). To eliminate genomic DNA, samples 
were incubated with 20 U of RNase-free DNase (QIAGEN) for 20 min at 25°C 
using the RNeasy columns, according to the manufacturer's instructions. 1 to 1.5 
µg RNA was used for reverse transcription in a 20 µl reaction with the high-
capacity cDNA reverse transcription kit (Applied Biosystems) together with 
random primers and 20 U RNase inhibitor (Promega). 1 µl of cDNA from this 
reaction was used as template with 0.5 µM primers (vacJ-F: 5′-
TCCGTGGGCATTAGTGAAAT-3′; vacJ-R:5′-
AATTCTGCATTATTGAGATTTTTCG-3′; yrbD-F:5′-
TACTGTGACGGCAACTTTCG-3′; yrbD-R:5′-AATCGCGATGCTTACTTTCG-3′; 
yrbE-F:5′-TCGTGTTAATCGATTTTTCTGC-3′; yrbE-R:5′- 
CAGGGCCTAATTCTCGTAAAAG-3′) and SYBR Green PCR Master Mix in a 20-
µl reaction (Applied Biosystems). Standard runs of the reactions on fast optical 
96-well reaction plates (Applied Biosystems) were carried out using the 
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StepOnePlus Real-Time PCR system (Applied Biosystems). The gyrA gene 
(primers gyr-F: 5′-GCGTGTTGTGGGTGATGTAA-3′; and gyr-R: 5′- 
GTTGTGCCATACGAACGATG-3′) was used as the internal standard gene for 
RNA quantity normalization (124). Quantitative comparison was obtained through 
the ΔΔCT method as described at 
http://www3.appliedbiosystems.com/cms/groups/mcb_support/documents/genera
ldocuments/cms_041435.pdf. 
 
Antibody binding assays 
200 µl of mid-logarithmic-phase bacterial cells (OD620 0.5) were pelleted and 
resuspended in 200 µl of Hanks' buffer without Ca2+ and Mg2+ (Gibco) 
supplemented with 5% fetal calf serum (HyClone). Primary antibodies (1:200 for 
heat inactivated NHS, 1:50 for mAb 4C4, 1:1000 for mAb TEPC-15, and 1:100 
for mAb 7B11) were added to reaction and then incubated at 37°C for 60 min. 
Bacteria were pelleted and incubated with Hanks' buffer without Ca2+ and Mg2+ 
plus 5% fetal calf serum containing a 1:200 dilution of the appropriate secondary 
antibody; goat anti-human IgG-FITC conjugate (Sigma), goat anti-human IgM 
FITC conjugate (Sigma), anti-mouse IgG-FITC conjugate (Sigma), anti-mouse 
IgA-FITC conjugate (Sigma) for 60 min at 4°C in the dark. Reaction mixtures 
were then washed and resuspended in 200 µl of PBS containing 1% bovine 
serum albumin and 0.5% paraformaldehyde. A total of 50,000 cells were 
collected for each sample. All samples were subjected in full volume to flow 
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cytometry analysis on a BD FACS Calibur flow cytometer (BD Biosciences), and 
groups were compared using FlowJo software (Tree Star). 
 
Growth inhibition assays 
Ethylenediaminetetraacetate (EDTA) was added to 500 µl of an overnight culture 
in sBHI broth (25 mM final concentration) and incubated at 37°C for 4 h under 
aeration prior to obtaining viable counts. The minimum inhibitory concentration of 
vancomycin, novobiocin, bacitracin, polymyxin-B and deoxycholate was 
determined by broth microdilution method. Briefly, 96-well plates containing 2-
fold dilution of chemical were prepared in sBHI and wells were inoculated with 
~5×105 cfu/ml of overnight bacterial cultures. Viable counts were determined 
after incubation for 18–24 h at 37°C. 
 
NPN uptake assay 
1-N-phenylnaphthylamine (NPN) (Sigma) uptake assay was performed as 
described previously (241). Briefly, bacteria were grown to OD620 0.5 in sBHI 
broth. Pellets were washed and resuspended in 5 mmol/L HEPES buffer (pH 
7.2). NPN was dissolved in acetone for a 500 µmol/L stock solution and diluted to 
40 µmol/L in HEPES buffer. The NPN solution (50 µl) was added after 15 s to the 
bacterial suspension (150 µl) for a final NPN concentration of 10 µmol/L. 
Fluorescence was monitored for a total of 90 s using the PTi fluorescence 
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system (Photon Technology International), with excitation at 350 nm, emission at 
420 nm, and slit width of 2 nm. 
 
Phospholipase C treatment 
Phospholipase C treatment and thin layer chromatography (TLC) were performed 
as described previously (128). 1 L of each bacterial culture were grown in sBHI 
broth to OD620 0.5 and centrifuged ×5000 g for 20 min. Pellets were washed 
once and resuspended in a sucrose-PBS-MgCl2 buffer [0.4M sucrose, 1×PBS, 
15 mM MgCl2, (pH 7.5)] to a final volume of 1.8 ml. 200 µl aliquots of bacterial 
suspension were treated with 5u of phospholipase C from Bacillus cereus 
(Sigma) for 20 min at 37°C. Reactions were stopped by adding 600 µl CHCl3-
methanol 1:2 (v/v). The lipids were extracted by the method of Bligh and Dyer 
(30). Lipid samples were normalized to protein content and separated by TLC on 
glass backed silica gel 60 plates (Merck) with CHCl3-Acetone 94:4 (v/v) solvent 
system and were stained by iodine. The standard was 10 µg of 1,2-diglycerides 
from pig liver (Serdary Research Lab). 
 
Statistical analysis 
All data were analyzed using StatView software (Abacus Concepts, Cary, NC). 
The significance of differences between or among groups was examined using 
ANOVA followed by Tukey or Dunnett post-tests. 
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Table 1. List of sites with multiple transposon insertions affecting serum 
resistance in strain R2866. 
 
 
*NCBI Reference Sequence: NC_000907.1 (Haemophilus influenzae Rd KW20, complete 
genome). 
#NCBI Reference Sequence: NZ_AADP01000001 and NZ_AADP01000002 (Haemophilus 
influenzae R2866 whole genome). 
 
HI no. 
* 
Gene 
name 
Protein_id# Function 
0258 lgtC NP_438427* UDP-galactose-LOS-galactosyltransferase 
0351 galE ZP_00156190.2 UDP-glucose 4-epimerase 
0461  ZP_00156296.2 Hypothetical protein 
0523 waaQ ZP_00349685.1 ADP-heptose-lipooligosaccharide heptosyltransferase III 
0550 lic2A ZP_00156370.1 UDP-galactose-LOS-galactosyltransferase 
0653 lex2B ZP_00156456.1 UDP-glucose-LOS-glucosyltransferase 
0718 vacJ ZP_00156519.2 Lipoprotein (associated to retrograde PLs trafficking) 
0740 yhxB ZP_00156601.1 phosphomannomutase 
0765 lpsA ZP_00203076.1 LOS-glycosyltransferase 
0812 galU ZP_00156667.2 UTP-glucose-1-phosphate uridylyltransferase 
1083 yrbB ZP_00156925.2 Putative NTP binding protein 
1085 yrbD ZP_00156927.2 ABC transporter periplasmic protein 
1086 yrbE ZP_00203123.1 ABC transporter permease 
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Table 2. The list of strains, plasmids and primers used in this study. 
Strains, plasmids, 
primers 
Description Reference 
Strains   
Rd Rough type d isolate, genome sequence reference 
strain 
(102) 
2019 Clinical isolates of nontypeable H. influenzae (302) 
R2866 NTHi clinical isolate from the bloodstream (423) 
32F2 R2866 vacJ disrupted by mariner Tn This study 
49E3 R2866 yrbD ABC transporter periplasmic protein 
disrupted by mariner Tn 
This study 
66B5 R2866 yrbB NTP binding protein disrupted by mariner 
Tn 
This study 
69G3 R2866 yrbE ABC transporter perimease disrupted by 
mariner Tn 
This study 
H782 Rd transformed with DNA of 2019 to express m7B11 
epitope on OMP P2 
This study 
H725 Clinical isolate of NTHi from lower respiratory tract This study 
H816 H782 transformed with DNA of 32F2 to disrupt vacJ This study 
vacJ::Km R2866 transformed with pUCΔvacJKmR to disrupt vacJ This study 
vacJ::Km,ΔyrbE 69G3 transformed with pUCΔvacJKmR to disrupt vacJ This study 
Plasmids   
pEMspec Contains mariner Tn carrying SpecR cassette (240) 
pUCΔvacJKmR vacJ replaced with KmR cassette from pUC4K This study 
Primers   
ARB1 GGCCACGCGTGCACTAGTAC (N)10 TACNG (250) 
ARB2 GGCCACGCGTGCACTAGTAC (250) 
MAG2F3 GGAATCATTTGAAGGTTGGTA (155) 
MAG2F4 ACTAGCGACGCCATCTATGTG (155) 
Hi_vacJ_H3_F2 AAGCTTAAAATGTAGCAGGTAAACGTCG This study 
Hi_vacJ_R1 ACGTAATGCCATCGTTTTAGAC This study 
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Hi_vacJ_B1_F1 CGGGATCCTAAACAGAAAAGTGCGGTAAAAATT This study 
Hi_vacJ_B1_R1 CGGGATCCTTTTAATCCTTACATAAATATGGGATTAT
TC 
This study 
Hi_vacJ_F9 CGTGCGTTCTTTAATGACTCTCG This study 
Hi_vacJ_R7 CAATGTGAAGTGGAAAAGCCCC This study 
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Figure 1. Characterization of clinical isolates. (A) Comparison of serum sensitivity 
between lower and upper respiratory tract isolates. Survival was determined over 
60 min in 5% normal human serum and expressed relative to controls in which 
complement was inactivated. Groups included lower respiratory tract isolates 
from patients with chronic obstructive pulmonary disease (COPD) at the time of 
clinical exacerbation (black bars; n = 11); isolates from patients with COPD during 
clinically stable periods (grey bars; n = 11); and upper respiratory tract colonizing 
strains (white bars; n = 25). Values are the mean of three determinations in 
triplicate ± SEM. (B) Comparison of antibody binding in serum resistant (>50% 
survival in pooled NHS, black bars; n = 10) and serum sensitive (<50% survival in 
pooled NHS, white bars; n = 10) isolates. B1 and B2 show percent of IgG and IgM 
bound following incubation in 5% heat-inactivated NHS as determined by flow 
cytometry, respectively. (C) Serum IgM contributes to bactericidal killing of 
clinical isolates of NTHi. Strains were incubated with or without IgG (C1, 0.25 
µg/ml) or IgM (C2, 0.07µg/ml) purified from NHS for 60 min in 2.5% baby rabbit 
serum as a complement source. Percent survival was calculated by viable counts 
with and without antibody. The mean values of two independent experiments in 
triplicate are shown ± SD, *P<0.05, **P<0.01, ***P<0.001. Serum sensitive (SS), 
Serum resistant (SR). 
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Figure 2. Characterization of vacJ and yrb mutants. (A) Effect of mutations in 
vacJ and genes of the yrb ABC transporter on serum resistance of strain R2866. 
Survival was determined over 60 min in 5% normal human serum and expressed 
relative to controls in which complement was inactivated. (B) Representative 
histogram comparing the binding, as measured by fluorescence intensity (x-axis), 
of total IgM purified from normal human serum to parent strain (WT) or vacJ by 
flow cytometry. Control performed without IgM (C) Percent IgM binding for each 
mutant was determined by calculating the percentage of 50,000 events with an 
increase in mean fluorescence intensity following incubation in 5% heat-
inactivated normal human serum compared to no serum controls. (D) Survival of 
mutants in 10% normal human serum in the presence (black bars) or absence 
(white bars) of Mg-EGTA to inhibit the classical pathway of complement 
activation. Values represent two independent experiments in triplicate ± SD. 
*P<0.05, **P<0.01, ***P<0.001. 
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Figure 3. Effect of vacJ and yrb mutants on antibody binding and bactericidal 
activity. Binding of (A) mAb 4C4 to the LOS structure Galα1-4Gal or (B) mAb 
TEPC-15 to the LOS structure phosphorylcholine was compared by flow 
cytometry for the mutants indicated. Percent mAb binding for each mutant was 
determined by calculating the percentage of 50,000 events with an increase in 
mean fluorescence intensity compared to no primary antibody controls. (C) Effect 
of mutations in vacJ and genes of the yrb ABC transporter on the bactericidal 
effect of mAb 4C4. Bactericidal assays were performed with (white bars) or 
without (black bars) mAb with 5.0% normal mouse serum as a complement 
source. Values represent two independent experiments in triplicate ± SD. 
*P<0.05, ***P<0.001. 
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Figure 4. Effect of mutations in vacJ and genes of the yrb ABC transporter on 
outer membrane characteristics. (A) To compare outer membrane stability, 
following overnight culture of the strain indicated, viable counts were obtained 
after incubation at 37°C for 4 h in the presence (white bars) or absence (black 
bars) of 25 mM EDTA. Values represent two independent experiments in 
triplicate ± SD. *P<0.05. (B) To compare surface hydrophobicity, the rate of 
uptake of membrane permeant 1-N-phenylnaphthylamine (NPN) was monitored 
by fluorescence. NPN was added at the time indicated and a representative 
experiment shown. (C) To compare amounts of surface phospholipids, 
diacylglycerol (boxed area) released by phospholipase C treatment of whole 
bacteria was detected by thin layer chromatography. Lane 1; diacylglycerol 
(standard), Lane 2 and 3; R2866 (wild type), Lane 4 and 5; 32F2 (vacJ mutant), 
Lane 6 and 7; 69G3 (yrbE mutant). 
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Figure 5. Membrane stability and vacJ and yrb expression among clinical 
isolates. (A) Outer membrane stability of serum sensitive (n=31) compared to 
serum resistant (n=16) clinical isolates. Following overnight culture, viable counts 
were obtained after incubation at 37°C for 4 h with or without 25 mM EDTA. 
Values represent two independent experiments in triplicate ± SD. *P<0.05, 
Serum sensitive (SS), Serum resistant (SR). (B) Relative expression of vacJ 
mRNA, (C) yrbD and (D) yrbE by qRT-PCR in serum sensitive (white bar, n=7) 
and serum resistant isolates (black bar, n=7). Error bars indicate SD, **P<0.01. 
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Figure 6. Repeated serum treatment selects for serum resistance, increased 
vacJ expression, and increased outer membrane stability. (A) Serum sensitive 
clinical isolate H725 was treated three times in 2.5% NHS and survival quantified 
after the passage indicated. (B) Following each passage in the bactericidal assay 
survivors were tested for relative expression of vacJ mRNA by qRT-PCR and (C) 
survival in the presence of 25 mM EDTA. Values represent two independent 
experiments in triplicate ± SD.*P<0.05, ***P<0.001. 
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Summary 
 
The lipopolysaccharide (LPS) of H. influenzae is highly variable. Much of the 
structural diversity is derived from phase variation, or high frequency on-off 
switching, of molecules attached during LPS biosynthesis. In this study, we 
examined the dynamics of LPS phase variation following exposure to human 
serum as a source of antibody and complement in multiple H. influenzae isolates. 
We show that lic2A, lgtC, and lex2A switch from phase-off to phase-on following 
serial passage in human serum. These genes, which control attachment of a 
galα1-4gal di-galactoside structure (lic2A and lgtC phase-on) or an alternative 
glucose extension (lex2A phase-on) from the same hexose moiety, reduce 
binding of bactericidal antibody to conserved inner core LPS structures. The 
effects of the di-galactoside and alternative glucose extension were also 
examined in the context of the additional LPS phase variable structures 
phosphorylcholine (ChoP) and sialic acid. We found that di-galactoside, the 
alternative glucose extension, ChoP, and sialic acid each contribute 
independently to bacterial survival in the presence of human complement, and 
have an additive effect in combination. We propose that LPS phase variable 
extensions serve to shield conserved inner core structures from recognition by 
host immune components encountered during infection. 
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Introduction 
 
The gram-negative bacterium Haemophilus influenzae has established the 
human nasopharynx as its niche. Between 20-60% of the population is colonized 
asymptomatically by H. influenzae, and colonization is thought to be a pre-
requisite for respiratory tract diseases including pneumonia, otitis media, and 
exacerbations of chronic obstructive pulmonary disease (COPD), (148, 231, 275, 
277). While the Hib vaccine protects against type-b H. influenzae, there is still a 
significant burden of disease caused by non-typeable H. influenzae (NTHi) 
strains (2, 391). Evasion of the host immune system is critical to the persistence 
of H. influenzae in the nasopharynx. H. influenzae is susceptible to classical 
pathway complement-mediated lysis, and components of this pathway including 
complement and antibody are present on the mucosal surface (440). The 
lipopolysaccharide, or LPS, is a major source of both intra- and interstrain 
surface variation in H. influenzae (47, 375).  
 Several of the genes required for the expression of LPS structures in H. 
influenzae are phase variable due to the presence of tetranucleotide repeats 
(107, 137, 163, 171). Slipped-strand mispairing, which occurs with these tandem 
repeats, creates stochastic on-off switching of gene expression. The result is 
high frequency (102-103 times per generation) phase variation of LPS 
modifications, as changes in the number of tetranucleotide repeats shifts the 
reading frame in and out of frame (translational switch), (413). As there are 
several phase variable genes controlling attachment of LPS structures, the 
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population of a given H. influenzae strain contains many different phase variants 
with distinct LPS structural configurations. In addition, the distribution of these 
genes varies among isolates. The selective pressure of host immune 
components can enrich for phase variants that are resistant to recognition and 
clearance. This has been demonstrated previously in the case of the phase 
variable structure ChoP, where attachment to the LPS is dependent on the lic1 
locus, of which lic1A contains the tetranucleotide repeats determining phase 
variant status (417). Bacteria with ChoP-modified LPS (lic1A phase-on variants) 
are targets of C-reactive protein (CRP), which initiates complement-mediated 
killing of ChoP expressing bacteria (416). In environments with high CRP levels, 
such as in the blood, there is selection against bacteria with ChoP-modified LPS. 
However, lic1A phase-on variants are enriched during colonization, as ChoP 
expression reduces antibody binding and complement-mediated killing (384, 
416). ChoP and several other LPS phase variable structures increase bacterial 
survival in the presence of human serum, although the dynamics of these effects 
and how they relate to each other has not previously been explored. We sought 
to conduct a comprehensive analysis of the LPS phase variable structures that 
contribute to the evasion of complement-mediated killing in H. influenzae. Our 
findings highlight the independent and additive effects of several phase variable 
LPS structures on bacterial evasion of recognition by host immune components 
present at the mucosal surface.  
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Results 
 
LPS structural requirements for evasion of complement-mediated lysis  
We sought to determine the minimal LPS structural components required for 
bacterial resistance to human antibody and complement-mediated lysis. Initial 
analysis was conducted with mutants in the H. influenzae strain Rd, which is a 
type-d, unencapsulated strain with a minimally complex LPS structure compared 
to most NTHi isolates (see Table 1 for a full list of strains and mutants used in 
this study). We first examined the targets of human antibody binding by flow 
cytometry. We found that an opsX- mutant in Rd, which has a severely truncated 
inner core oligosaccharide, has increased binding of naturally acquired human 
IgG compared to bacteria with outer core oligosaccharides (Fig. 1A,B). This was 
demonstrated in a lic1D- background, as the lic1D-dependent attachment of 
ChoP to the LPS has previously been shown to reduce antibody binding (53), 
and we sought to determine whether additional LPS structures play a similar role. 
The phenotype of the lic1D- mutant is similar to that of a wild-type, ChoP phase-
off variant. The difference in antibody binding between opsX- and lic1D- strains 
was maintained in the presence or absence of digestion with trypsin, suggesting 
that antibody binds to non-proteinaceous structures, and this is blocked by the 
presence of LPS outer core extensions (aside from ChoP).  
Next, human serum was used as a source of antibody and complement for 
bactericidal assays, and survival was determined relative to complement-
inactivated controls. Serum was depleted of CRP to prevent killing of ChoP 
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phase-on bacteria. The Rd opsX- mutant was sensitive to human serum 
compared to the lic1D- strain. Surviving colonies from these bactericidal assays 
were then grown and re-exposed to human serum, under the same conditions as 
in the original bactericidal assays. This was repeated several times, to determine 
if the level of serum resistance changed following serial passage in human 
serum. The opsX- mutant remained constitutively serum sensitive (Fig. 1C). 
Selective truncations of Rd oligosaccharide structures were used to establish the 
requirements for evasion of complement-mediated lysis. Serial passage of 
bacteria in human serum results in selection for increased resistance in an lpsA- 
mutant, which lacks hexose extensions from the third inner core heptose (HepIII) 
of Rd (Fig. 1A,D). In Rd, ChoP is attached to the hexose extension from HepI, 
leading us to hypothesize that increased bacterial survival was due to the 
enrichment of lic1A phase-on variants in the resistant population, compared to 
the original population. To determine phase variant status, the 5’ end of the lic1A 
gene was sequenced from genomic DNA isolated from the original and resistant 
bacterial populations, and the tetranucleotide repeats within these sequences 
were enumerated. We found that while the original population was lic1A phase-
off, the more resistant population was predominantly lic1A phase-on (Table 2). 
This result was corroborated by colony immunoblotting using the ChoP-specific 
antibody TEPC-15 to distinguish between lic1A phase-on and lic1A phase-off 
colonies. By colony immunoblotting, the original population was phenotypically 
<2% lic1A phase-on, while the serum resistant population was >94% lic1A 
phase-on (data not shown). Previous work has documented the selection for 
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lic1A phase-on variants in vivo following colonization in animal models and 
humans, validating this in vitro approach for phase variant analysis (384, 416). 
The Rd lpsA-, lic1D- mutant, in contrast, remained constitutively sensitive to 
human serum (Fig. 1E).  
Serial passage in human serum results in selection for increased serum 
resistance in the lgtF- mutant, which lacks the hexose extensions from the first 
inner core heptose (HepI) of Rd (Fig. 1A,F). As there is no possibility for ChoP 
attachment in the absence of lgtF, this resistant population potentially contains 
changes in phase variable genes other than lic1A that affect resistance to 
antibody and complement. A screen of all ten known genes with tetranucleotide 
repeats (not including lic1A) in Rd (305) was performed to compare phase 
variants in the original and serum resistant bacterial populations of the lgtF- 
mutant (see Table 3 for all primers used for tetranucleotide repeat sequence 
analysis). The only gene with altered phase variant status was lic2A, which was 
phase-off in the original population, and phase-on in the serum resistant 
population (Table 2). The expression of lic2A results in the attachment of a 
galactose residue to the LPS, which enables further hexose extensions in the 
presence of other phase-on LPS biosynthesis genes (Fig. 1A). Therefore, the 
lic1D-, lic2A- mutant contained the minimal LPS truncations required for 
constitutive sensitivity to human serum in Rd (Fig. 1G). These data established 
that selection for ChoP or galactose phase-on variants is necessary for evasion 
of complement-mediated killing in this strain.  
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In order to extend these observations to a H. influenzae strain with a more 
complex LPS structure, survival in human serum was examined for selective LPS 
truncation mutants in the NTHi clinical isolate R2846 (Fig. 2A). Serial passage of 
the R2846 lic1D-, lpsA- mutant in human serum results in selection for a 
population with increased resistance, while the lic1D-, lgtF- mutant is 
constitutively serum sensitive (Fig. 2B,C). Sequence analysis of the LPS phase 
variable genes present in the lic1D-, lpsA- mutant determined that the serum 
resistant population of this strain was lic2A phase-on, compared to lic2A phase-
off in the original population, as with Rd (Table 2). However, unlike in the Rd 
strain, both the original and serum resistant populations of R2846 were also lgtC 
phase-on. The expression of lic2A and lgtC results in attachment of a di-
galactoside structure, galα1-4gal. The proximal galactose of this di-galactoside is 
added in lic2A phase-on variants, and the distal galactose is added in lic2A and 
lgtC phase-on variants. The galα1-4gal structure is also present in humans in the 
form of P blood group antigens, and, therefore, is not a target of human antibody 
(28, 401). Interestingly, selection for lic2A phase-on variants was observed even 
though in R2846 galactose is attached to a glucose extension from HepI, rather 
than HepIII as in Rd (Fig. 2A). Therefore, the R2846 lic1D-, lic2A- mutant (also 
lex2A-; see below) contains the minimal LPS truncations required for constitutive 
sensitivity to human serum in this strain (Fig. 2D). In the absence of functional 
lic2A, there is no possibility for attachment of either galactose, regardless of lgtC 
phase variant status. Our analysis of LPS structures contributing to evasion of 
complement-mediated killing in two separate H. influenzae strains revealed that 
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selection for either ChoP or galactose phase-on variants aids bacterial survival in 
the presence of human serum. 
 
Variable LPS hexose extensions increase bacterial survival in human serum 
The contribution of hexose oligosaccharide extensions to serum resistance was 
examined in a lic1D- background of multiple strains, as the role of ChoP 
expression has previously been described for several H. influenzae isolates (53). 
Experiments with lic1D- mutants were conducted in serum without CRP 
depletion, as the presence of CRP does not affect survival of these strains. Serial 
passage in human serum results in selection for lgtC phase-on variants in the Rd 
lic1D- strain (Figure 3A, Table 2). As the original and serum resistant populations 
in this strain background were also lic2A phase-on, the serum resistant 
population expressed the di-galactoside structure. Similarly, serial passage in 
human serum resulted in selection for variants expressing the di-galactoside 
structure in the R2846 lic1D- strain (Fig. 3B, Table 2). Of note, sequence 
analysis of the original and serum resistant populations of R2846 included all 
LPS phase variable genes used in the first Rd screen as well as three additional 
LPS phase variable genes found in R2846 that are not present in Rd; lex2A, 
oafA, and losA1 (which has a eight base pair repeat). We also performed 
sequence analysis on bacterial populations from each passage in between the 
original and serum resistant populations of Rd and R2846 lic1D- strains to 
determine the timing of the change in phase variant status. We confirmed that 
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either lgtC (Rd) or lic2A (R2846) switched to phase-on in the round of passage in 
human serum corresponding to the shift in resistance (data not shown).  
To extend these observations to other relevant H. influenzae strains, 
lic1D- mutants of the NTHi clinical isolate 2019 and a capsule- variant of the 
type-b strain Eagan were also exposed to human serum. Without capsule, Eagan 
is significantly less resistant to complement-mediated lysis (287). In both strains, 
serial passage in human serum resulted in selection for a resistant population 
(Fig. 3C,D). The serum resistant population of 2019 was lic2A phase-on, 
compared to the lic2A phase-off original population (Table 2). In Eagan, the 
serum resistant population was both lic2A and lgtC phase-on, compared to the 
lic2A and lgtC phase-off original population (Table 2). Thus, passage in human 
serum results in selection for expression of the components of the same di-
galactoside structure in four distinct H. influenzae strains. 
 LPS mutants in lic2A and lgtC were used to confirm the contribution of the 
di-galactoside to survival in the presence of human serum. The mAb 4C4 
specifically recognizes galα1-4gal, and was used for phenotypic confirmation of 
lic2A- mutants by Western blotting (data not shown). In the Rd lic1D- 
background, the lic2A and lgtC phase-on strain was the most serum resistant, 
the lic2A phase-on, lgtC- mutant had an intermediate level of serum resistance, 
and the lic2A- mutant was the least serum resistant (Fig. 4A). These data show 
that both lic2A and lgtC contribute individually to bacterial survival. In the R2846 
lic1D- background, the lic2A and lgtC phase-on strain was also more serum 
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resistant than the lic2A- mutant (Fig. 4B). We constructed the Rd and R2846 
lic1D-, lic2A- mutants using two separate background strains; the serum resistant 
population (lic2A and lgtC phase-on) and the original population (lic2A and lgtC 
phase-off). The lic2A- mutants had the same phenotype in both background 
strains, supporting the proposition that phase variation of lic2A and lgtC accounts 
for the only difference between the original and serum resistant populations. 
Similar results were also observed for Eagan and 2019 (Fig. 4C,D). In 2019, the 
lic2A and lgtC phase-on variant population was isolated using the mAb 4C4, as 
the resistant population isolated after passage in human serum was lic2A phase-
on, lgtC phase-off. Similar to Rd, in 2019 both lic2A and lgtC contribute 
individually to bacterial survival in the presence of human serum. These results 
demonstrate that each galactose extension on LPS in lic2A and lgtC phase-on 
variants contributes independently to the evasion of complement-mediated killing 
in multiple H. influenzae strains. 
In a minority of cases, serial passage of the R2846 lic1D- strain in human 
serum resulted in selection for a resistant population that was lex2A phase-on 
instead of lic2A phase-on (Table 2). The expression of lex2A in R2846 results in 
the attachment of glucose to the same hexose moiety as galactose is attached to 
when lic2A is phase-on (Fig. 2A). The R2846 lex2A phase-on strain was more 
serum resistant than a lex2A- mutant (Fig. 4B). In order to determine whether the 
presence of ChoP affects selection for di-galactoside or the alternative glucose 
extension controlled by lex2A expression, we also exposed lic1A phase-on H. 
influenzae strains to serial passage in human serum. In R2846, the lic1A phase-
142 
on serum resistant population was lic2A phase-on in one experiment, and lex2A 
phase-on in another (Table 2). In Rd, serial passage of the lic1A phase-on strain 
in human serum resulted in selection for a lic2A phase-on serum resistant 
population (Table 2). These results demonstrate that LPS hexose extensions 
contribute to evasion of complement-mediated killing independent of ChoP 
expression.  
 
Di-galactoside expression reduces antibody binding and classical pathway 
complement-mediated killing 
H. influenzae is susceptible to alternative and classical pathway complement-
mediated lysis. We have previously shown that ChoP attachment to the LPS 
reduces antibody binding to the bacterial surface, increasing survival in the 
presence of complement (53). To determine whether modification of the LPS with 
di-galactoside or the alternative glucose extension affects antibody binding, flow 
cytometry was used to measure binding of human serum IgG to the bacterial 
surface. The Rd lic2A and lgtC phase-on variant population had the lowest 
amount of IgG binding, the lic2A phase-on, lgtC- strain had an intermediate 
amount of IgG binding, and the lic2A- mutant had the most IgG binding (Fig. 5A). 
Bactericidal assays in human serum with or without IgG depletion were used to 
determine whether the difference in antibody binding correlated with a difference 
in classical pathway complement-mediated killing. The Rd lic2A- mutant was 
killed in the presence, but not the absence, of human IgG, while the lic2A and 
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lgtC phase-on variant was resistant in either condition (Fig. 5B). Similar results 
were observed for bactericidal assays conducted with purified human IgG either 
added or not added to a complement source that lacks antibody to H. influenzae, 
baby rabbit serum (BRS), (Fig. S1A). In contrast, there was no difference in IgM 
binding or bactericidal activity between lic2A and lgtC phase-on variants and 
lic2A- mutants (data not shown). A further comparison between alternative and 
classical pathway complement-mediated killing was performed using Mg-EGTA 
treated human serum. Mg-EGTA treatment inhibits classical and lectin, but not 
alternative pathway complement-mediated lysis (104). The Rd lic2A- mutant was 
sensitive to normal human serum, but not Mg-EGTA-treated human serum, 
confirming that the classical pathway, rather than the alternative pathway, is 
responsible for the sensitivity of the lic2A- mutant (Fig. S1B). Similar results were 
observed for the R2846 lic2A and lgtC phase-on strain versus the lic2A- mutant 
(Fig. 5C,D and Fig. S1C,D). Collectively, these data show that di-galactoside 
expression reduces IgG binding and bactericidal activity in multiple strains of H. 
influenzae. 
 The LPS mAb 6E4, which binds to an inner core LPS epitope that includes 
the KDO structure (360), was used to determine the effect of di-galactoside 
expression on antibody binding to LPS. Previously, we showed that ChoP 
expression reduces mAb 6E4 binding and killing in the presence of complement 
(53). Titration of mAb 6E4 was used to determine an antibody concentration 
where binding between modified and un-modified LPS could be differentiated by 
flow cytometry. R2846 retains mAb 6E4 binding in an lgtF- mutant (data not 
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shown), which is missing all HepI extensions (Fig. 2A), suggesting that the di-
galactoside itself is not required for mAb 6E4 recognition of LPS. Serial passage 
of the R2846 lic1D- strain in mAb 6E4 and a complement source (BRS) resulted 
in selection for a resistant population (Fig. 6A). Sequence analysis determined 
that the mAb 6E4 resistant population was lic2A phase-on (Table 2). These 
results are consistent with the changes observed following serial passage of 
R2846 in human serum. Bactericidal assays with LPS mutants were conducted 
to confirm the role of di-galactoside in evasion of mAb 6E4-mediated killing. The 
R2846 lic2A and lgtC phase-on strain is the most resistant to killing by mAb 6E4 
and complement, the lic2A phase-on, lgtC- mutant has an intermediate level of 
resistance, and the lic2A- mutant is the least resistant (Fig. 6B). These data show 
that both lic2A and lgtC contribute to survival in the presence of the mAb 6E4 
and complement. Next, flow cytometry was used to examine the amount of mAb 
6E4 binding to the bacterial surface. Consistent with the bactericidal assay data, 
there was evidence for an individual contribution of both lic2A and lgtC in the 
reduction of mAb 6E4 binding (Fig. 6C). These results show that di-galactoside 
expression reduces the binding and bactericidal activity of an anti-LPS antibody 
that requires an inner core LPS structure for bacterial recognition. 
 Serial passage in both human serum and mAb 6E4 with complement 
resulted in selection for di-galactoside expression. We next compared the lic2A 
and lgtC phase-on variants isolated following serial passage in human serum to 
those isolated after serial passage in mAb 6E4 with complement. First, the 
R2846 lic2A and lgtC phase-on population isolated after serial passage in human 
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serum had reduced binding of mAb 6E4 compared to the lic2A- mutant (Fig. 
S2C). Similar results were also observed for Rd (Fig. S2D). Second, the R2846 
lic2A and lgtC phase-on population isolated after serial passage in mAb 6E4 and 
complement had increased survival in the presence of human serum, compared 
to the lic2A- mutant (Fig. S2E). These results demonstrate that di-galactoside 
expressing variants isolated following exposure to different antibody sources 
recognizing inner core LPS epitopes have the same resistance profile in the 
presence of complement.  
We also found that lex2A contributes to evasion of antibody binding to the 
bacterial surface. In the R2846 lic1D- strain, the lex2A phase-on population had 
reduced binding of human IgG compared to the lex2A- mutant (Fig. S2A). Upon 
repetition of the experiment where the R2846 lic1D- strain was serially passaged 
in mAb 6E4 and complement, one of the mAb 6E4 resistant populations was 
lex2A phase-on instead of lic2A phase-on (Table 2). Flow cytometry confirmed 
that the lex2A phase-on population had reduced mAb 6E4 binding compared to 
the lex2A- mutant (Fig. S2B). These data show that in addition to contributing to 
evasion of killing in human serum, both di-galactoside and the alternative glucose 
extension from the same hexose moiety reduce antibody binding to the bacterial 
surface. The expression of these phase variable hexose extensions protects H. 
influenzae against antibody binding conserved inner core LPS structures. 
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LPS phase variable structures have independent and additive effects on bacterial 
survival in the presence of complement 
LPS phase variable structures including ChoP and di-galactoside contribute to 
evasion of antibody-dependent, complement-mediated lysis. We wanted to 
determine next whether the effects of these structures on bacterial survival are 
independent, additive, or both. Selection for di-galactoside expressing variants in 
the presence or absence of ChoP (Table 2) suggests that these two 
modifications contribute to survival independently, but may have an additive 
effect in combination. Included in the subsequent analysis was another phase 
variable LPS structure, sialic acid (Neu5Ac). The modification of LPS with sialic 
acid increases resistance to alternative pathway complement-mediated killing in 
H. influenzae (95). H. influenzae must acquire sialic acid from the environment 
(346), so the presence or absence of sialic acid was controlled by 
supplementation of growth media with Neu5Ac. This approach was validated 
using a siaP- mutant, which inactivates the sialic acid transporter SiaPQM TRAP, 
preventing sialic acid uptake and LPS attachment (346). The Rd lic1D-, siap- 
mutant remained constitutively sensitive to human serum, regardless of the 
presence of Neu5Ac, while the Rd lic1D- strain had increased survival in human 
serum with Neu5Ac added to growth media (data not shown).  We found that in 
the presence of human serum and Neu5Ac, there was selection for increased 
serum resistance in the Rd lic1D- strain, and sequence analysis determined that 
this population was lgtC phase-on (Table 2). As lic2A was phase-on in the 
original and serum resistant populations, serial passage in human serum with 
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sialic acid selected for di-galactoside expressing variants. These results suggest 
there is an independent, but additive effect of di-galactoside and sialic acid 
expression on bacterial resistance to human serum.  
To examine the dynamics of ChoP, di-galactoside, and sialic acid 
expression on bacterial survival, mutants were compared with phase variant 
populations following exposure to various concentrations of human serum. 
Human serum was used in increasing concentrations to resolve additive 
contributions of separate phase variable structures to bacterial survival. For the 
Rd lic1D- strain, there was an independent and additive effect of sialic acid and 
di-galactoside attachment to the LPS on serum resistance (Fig. 7A). Repetition of 
this experiment in Rd lic1A phase-on variants showed that there is also an 
independent and additive contribution of sialic acid and di-galactoside in the 
presence of ChoP (Fig. 7B). This experiment indicates that there is an additive 
effect for all three LPS modifications; ChoP, di-galactoside, and sialic acid each 
contribute to evasion of complement-mediated lysis, and can do so in 
combination for maximum serum resistance. In the R2846 lic1D- background, di-
galactoside, the alternative glucose extension, and sialic acid each had an 
independent and additive effect on bacterial survival in human serum, similar to 
results observed for Rd (Fig. 7C). In addition to the di-galactoside, we tested the 
effect of a single galactose on bacterial survival in the presence or absence of 
sialic acid. We found that Rd and R2846 lic2A phase-on, lgtC- mutants also had 
an additive effect on bacterial survival in human serum in combination with sialic 
acid (Fig. S3A). In R2846 lic1A phase-on variants, an independent and additive 
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contribution of sialic acid, the alternative glucose extension (lex2A phase-on) and 
ChoP was observed (Fig. 7D). We found that there was no difference in survival 
for lex2A and lgtC phase-on variants compared to a lex2A phase-on, lgtC- 
mutant, demonstrating there is no contribution of lgtC in combination with lex2A 
in R2846 (Fig. S3B). Evidence for an independent and additive effect of sialic 
acid and di-galactoside attachment to LPS was also observed in the lic1D- 
backgrounds of Eagan and 2019 (Fig. S3C,D). These experiments demonstrate, 
in four distinct H. influenzae isolates, that phase variable LPS structures can 
contribute individually to evasion of complement-mediated lysis, and have an 
additive effect on bacterial survival in combination.  
 
Discussion 
 
During colonization and disease, H. influenzae must evade killing by host 
immune components including antibody and complement (440). In this study, 
normal human serum was used to provide a source of antibody and complement 
for bactericidal assays, intended to test the effect of these factors at the mucosal 
surface. While several studies have highlighted individual LPS phase variable 
genes that contribute to bacterial survival following exposure to human serum 
(136, 168, 415), a comprehensive analysis of their combined effects has not 
been described. We hypothesize that LPS phase variation allows bacteria to 
evade recognition and killing by host immune components in vivo through 
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selective enrichment of resistant bacteria from a mixed population. A recent 
study conducted by M. Apicella and colleagues at the University of Iowa explored 
this hypothesis using experimental human colonization with the NTHi clinical 
isolate 2019, which was also tested in the current study (303). They found that 
the population of bacteria isolated from healthy volunteers following six days of 
colonization was enriched for lic1A and igaB (an IgA1 protease-encoding gene) 
phase-on variants. The selection for lic1A phase-on variants during human 
colonization confirms previous data in animal models and the observation that 
clinical samples of H. influenzae are enriched for ChoP−expressing variants 
(239, 384, 416). IgA1 protease expression is phase variable due to the presence 
of a seven base pair repeat in igaB (93). Selection for bacteria expressing the 
IgA1 protease underlines the importance of antibody evasion at the mucosal 
surface.  
In the human carriage study there was also an increase in the lex2A 
phase-on variant population, although this did not achieve statistical significance 
after six days of colonization. While the di-galactoside encoding genes lic2A and 
lgtC remained phase-off during the course of the carriage study, it may take 
longer periods of colonization to see enrichment in di-galactoside expressing 
bacteria. Alternatively, modification of LPS with di-galactoside or the alternative 
glucose extension may be more important during inflammation. In a study of 
phase variant populations from clinical samples, bacteria isolated from 
asymptomatic patients and patients with pneumonia were all lic1A phase-on 
variants (415). Interestingly, while lic2A and lgtC expression in asymptomatic 
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patients was variable, both genes were phase-on in every isolate obtained from 
patients with pneumonia. As we demonstrate in the current study that there is an 
additive effect for ChoP and di-galactoside expression, ChoP expression may be 
sufficient for successful colonization, while both ChoP and di-galactoside could 
be required for survival in a more inflammatory milieu. Human colonization 
studies are critical for the analysis of the in vivo contribution of LPS phase 
variable structures because the repertoire of antibodies differs between humans 
and animals used to model H. influenzae colonization and disease. For example, 
while the di-galactoside structure galα1-4βgal is found in human P blood group 
antigens (281), this structure isn’t present in rodents. As a result, rodents are 
capable of making antibody specific for this di-galactoside, and infection selects 
against lic2A and lgtC phase-on bacteria (83, 415).   
 We demonstrate in the current study that both components of the di-
galactoside and the alternative glucose extension from the same hexose moiety 
contribute to bacterial survival in the presence of complement (Fig. 4). In some 
strains, lex2A expression controls attachment of a galactose rather than glucose, 
which allows for subsequent di-galactoside attachment (73). In this way, all three 
phase variable structures controlled by lic2A, lgtC, and lex2A expression could 
have an additive effect on evasion of antibody binding and complement-mediated 
lysis (136). Of note, selection for lex2A phase-on variants was a more rare 
occurrence in R2846 than selection for lic2A phase-on variants (Table 2). Also, 
while lex2A is also present in Eagan, selection for lex2A phase-on variants was 
not observed. It is possible that due to the additive effect of lic2A and lgtC, which 
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does not occur for lex2A and lgtC, selection for di-galactoside expression is more 
favorable for bacterial evasion of complement-mediated killing.  
Serial passage of bacteria in human serum resulted in the identification of 
changes in lic2A, lex2A, and lgtC tetranucleotide repeats in several H. influenzae 
strains (Table 2). Despite the LPS structural differences and varying levels of 
initial serum resistance of these strains, the same genes were found to contribute 
to bacterial resistance. However, there were no repeat shifts detected for lic3A 
(Rd or R2846), oafA (R2846), or losA1 (R2846). Expression of lic3A results in 
sialic acid attachment to the LPS. As all bacterial populations tested were lic3A 
phase-on, we controlled sialic acid expression by selective addition of Neu5Ac to 
growth media. We found that sialic acid increased bacterial survival in human 
serum for all H. influenzae strains included in the present study. While previous 
work has demonstrated that oafA and losA1 can contribute to bacterial survival in 
serum (84, 107), in this study we did not isolate any oafA or losA1 phase-off 
variants, so these genes could not be fully accounted for in our analysis. In a 
previous study from this laboratory, a screen of genes contributing to serum 
resistance in the NTHi clinical isolate R2866 found that several LPS biosynthesis 
genes, including lic2A, lgtC, and lex2A, are important for bacterial survival in 
human serum (282). In addition to these, a role for vacJ and its associated genes 
was described, where increased vacJ transcription reduced IgM binding. In 
contrast, we did not observe a change in vacJ expression between serum 
sensitive and resistant populations of Rd (data not shown). While other 
spontaneous mutations between the original and resistant populations isolated in 
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this study cannot be ruled out without full genome sequence analysis, our data 
suggests the difference in survival is due solely to the change in repeat number 
of the identified LPS phase variable genes.  
Previous work has shown that ChoP attachment to the LPS reduces 
antibody binding through an effect on the physical properties of the outer 
membrane, reducing membrane accessibility (53). For example, lic1A phase-on 
bacteria are more resistant to EDTA treatment, which is a measure of outer 
membrane stability. In contrast, di-galactoside expression does not affect EDTA 
sensitivity (53). Also, ChoP has a more global effect on antibody binding, while 
di-galactoside expression reduced binding of IgG, but not IgM, to the bacterial 
surface (Fig. 5), suggesting these two LPS modifications affect sensitivity to 
antibody binding through different mechanisms. The contribution of lgtC 
expression to bacterial survival has been previously explored in the NTHi strain 
R2866. It was found that lgtC phase-on bacteria have reduced deposition of the 
complement protein C4b, compared to lgtC- mutants (164). Reduction in C4b 
and IgG binding decreases sensitivity to classical pathway complement-mediated 
killing, and both could contribute to resistance. In the current study, we found that 
the di-galactoside and alternative glucose extension from the same hexose 
moiety each reduce binding of human IgG and the mAb 6E4, which binds an 
inner core LPS structure that includes KDO (Fig. 5,6, Fig. S2). We also showed 
that human IgG recognizes conserved inner core LPS structures, as there was 
increased antibody binding to the truncated opsX- mutant compared to bacteria 
with more complete oligosaccharide extensions (Fig. 1B). These data suggest 
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that LPS hexose structures affect antibody binding indirectly, possibly through 
steric hindrance. The attachment of sialic acid to the LPS, in contrast to ChoP 
and di-galactoside, affects the alternative pathway of complement-mediated lysis. 
It was shown previously that bacteria with sialylated LPS have delayed 
deposition of complement components on the outer membrane compared to 
those without sialic acid (95). While ChoP, di-galactoside, the alternative glucose 
extension, and sialic acid attachment to LPS affect host recognition in different 
ways, all contribute to survival in the presence of complement (Fig. 7). The use of 
divergent mechanisms may contribute to the ability of these phase variable 
molecules to have an additive effect on resistance to complement-mediated 
killing.  
 The LPS structural variations introduced by the attachment of ChoP, di-
galactoside, the alternative glucose extension, and sialic acid may contribute to 
survival in other in vivo contexts that have yet to be explored. However, each of 
these structures is phase variable, which suggests there are also host 
environments for which expression is not favorable for survival. For ChoP, it has 
been shown that C-reactive protein (CRP) can recognize ChoP-modified LPS 
and initiate classical pathway complement-mediated killing (416). In the case of 
di-galactoside and sialic acid, however, the disadvantages during infection are 
less clear. Galactins, which bind several galactose-associated LPS residues, 
have the potential to recognize these structures (332, 399). In many H. 
influenzae strains, the residue GalNAc, which is recognized by some galectins, 
can be attached to the terminal end of hexose extensions including the galα1-
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4gal di-galactoside. Galactin binding can initiate immune responses resulting in 
bacterial clearance (332). Also, it has been shown that lic2A expression 
increases susceptibility of H. influenzae to infection with the bacteriophage 
HP1c1 (435). The galactose that is attached to the LPS in lic2A phase-on 
variants is likely part of the receptor required for phage predation. Host immune 
and microbial factors that target H. influenzae LPS modifications can thereby 
also provide a negative selective pressure for phase variants in some host 
environments. 
 In summary, we show that exposure to human antibody and complement 
drives selection for bacteria expressing phase variable LPS structures including 
the galα1-4gal di-galactoside and the alternative glucose extension attached to 
the same hexose moiety. Selection for di-galactoside expression was observed 
in several distinct H. influenzae strains, and the attachment of di-galactoside or 
the alternative glucose extension reduces antibody binding to the LPS. Each of 
the phase variable structures including ChoP, sialic acid and di-galactoside are 
outer core modifications with reduced host recognition through molecular mimicry 
(90, 334, 401). While LPS modifications provide a source of surface variation in 
H. influenzae, there is a limited repertoire of structural conformations and 
epitopes achieved by phase variation alone. Instead, phase variation of LPS 
outer core structures may serve to shield conserved inner core structures from 
antibody binding and complement deposition. LPS modifications including ChoP, 
sialic acid, di-galactoside, and the alternative hexose extension each contribute 
to bacterial survival in the presence of antibody and complement, and have an 
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additive effect in combination. The additive effect of each of these LPS phase 
variable structures is supportive of the hypothesis that in the presence of human 
antibody and complement, survival favors bacteria with the most highly 
decorated LPS. Phase variation ensures that H. influenzae populations are 
staged for rapid enrichment of the most-fit variants for successful colonization. 
 
Experimental procedures 
 
Bacterial strains and growth conditions 
See Table 1 for a full list of all H. influenzae strains and mutants of these strains 
included in the present study. Bacteria were grown in brain heart infusion media 
(Becton Dickinson Biosciences, Franklin Lake, NJ) supplemented with 2% Fildes 
enrichment (Remel, Lenexa, KS) and 20 µg ml-1 β-Nicotinamide adenine 
dinucleotide hydrate (Sigma, St. Louis, MO). Strains with multiple mutations (ex. 
lic1D-, lpsA-) were created through transformation of one mutant strain with 
genomic DNA of the second mutant strain. All mutants constructed for the 
present study were back-transformed and confirmed by PCR analysis.  
For the lex2A mutant, a spectinomycin resistance cassette was inserted to 
disrupt gene function. The lex2A gene and flanking regions was amplified from 
R2846 with the primer pair lex2A amplify (Supplementary Table 1) and cloned 
into the pCRTM 2.1-TOPO® vector, according to manufacturer’s instructions 
(Invitrogen, Grand Island, NY). A region of lex2A was deleted by inverse PCR 
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with the primer pair lex2A XmaI (Supplementary Table 1), introducing an XmaI 
site.  The spectinomycin gene aad9 was inserted at the XmaI site following 
amplification with the primer pair aad9 (Supplementary Table 1). The resulting 
plasmid used to transform R2846. The siaP- mutant was constructed as 
previously described (346). Briefly, the siaP gene (carried by the pUC19 plasmid) 
was disrupted by deletion of a BglII restriction fragment, and a kanamycin 
resistance cassette from the pUC4Kan plasmid was inserted. The resulting 
plasmid was used to transform the Rd lic1D- strain. In R2846, lic1A phase-on 
colonies were identified by colony immunoblotting with the mAb TEPC-15, as 
described previously (417). The TEPC-15 enriched lic1A phase-on population is 
> 98% lic1A phase-on. Similarly, the mAb 4C4 was used for detection and 
enrichment of lic2A and lgtC phase-on variants of 2019. Binding of mAb 4C4 was 
also used for phenotypic verification of lic2A- mutant strains, as was TEPC-15 
binding for lic1D- strains. 
 
Flow cytometric analysis 
Flow cytometry was used to detect antibody binding to the bacterial surface as 
described previously (282). Briefly, 200 µl reactions were conducted in Hank’s 
buffer without Ca2+ or Mg2+ (Gibco, San Diego, CA) supplemented with 5% fetal 
calf serum (HyClone, Logan, UT) with a 20 µl of mid-logarithmic phase bacterial 
cells (OD620 0.5) diluted to 105 CFU ml-1. Reactions were incubated with primary 
antibody for 60 min at 37°C. Primary antibody sources consisted of purified IgG 
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from NHS (4.8 µg) and mAb 6E4 (1:200 dilution). A Protein G column (GE 
Healthcare Bio-Sciences, Uppsala, Sweden) was used to purify IgG from NHS. 
An alternative source of purified IgG from a mixed NHS pool was obtained from 
Sigma. Reactions were washed and re-suspended in 1:200 dilutions of 
secondary antibody, followed by incubation at 4°C for 60 min. Secondary 
antibody sources included goat anti-human IgG-FITC and goat anti-mouse IgG-
FITC (Sigma). After secondary incubation, reactions were washed and re-
suspended in PBS with 1% bovine serum albumin and 0.5% paraformaldehyde 
prior to analysis on a BD FACS Calibur flow cytometer (Becton Dicksinson 
Biosciences). A total of 50,000 cells were collected, and MFI was determined 
using FlowJo software (Tree Star, Ashland, OR). Partial digestion of outer 
membrane proteins with trypsin was performed, where specified, as described 
previously (53). Briefly, 200 µl reactions containing 20 µl of mid-logarithmic 
phase bacterial cells (OD620 0.5) diluted to 105 CFU ml-1 in 10 mM Tris-HCL, pH 
7.5 were washed and re-suspended in 1 mg ml-1 trypsin. Following incubation for 
2 hrs at 37°C, cells were washed and re-suspended in Hank’s buffer for flow 
cytometry as described above. 
 
Bactericidal assays 
Bactericidal assays were conducted as described previously (53). Briefly, 200 µl 
reaction mixtures in Hank’s buffer were incubated for 45 min at 37°C following 
addition of serum. Serum sources included NHS, CRP-depleted NHS, and baby 
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rabbit serum (BRS) to which the mAb 6E4 (1:200 dilution) or purified IgG from 
NHS (4.8 µg/200 µl reaction) was added. NHS was obtained from a single donor 
to provide a consistent repertoire of human antibody, although representative 
experiments were repeated with similar results from other NHS donors. Where 
specified, Neu5Ac (Sigma) was added to growth media prior to bactericidal 
assays to a final concentration of 0.1 mg ml-1. CRP was depleted from NHS for 
bactericidal assays conducted with lic1A phase-on variants with immobilized p-
aminophenyl phosphoryl choline gel (Thermo Scientific, Rockford, IL). Percent 
survival was determined relative to complement-inactivated serum, which was 
obtained by incubation of NHS for 30 min at 56°C. For serial passage in NHS or 
mAb 6E4 and BRS, 5-25 surviving colonies were picked and grown for the 
subsequent bactericidal assay, performed under the same conditions. 
Inactivation of classical and lectin pathways of complement was accomplished by 
chelation of NHS with gelatin veronal buffer containing MgEGTA (50 µM final 
concentration in NHS), (Boston Bioproducts, Worcester, MA). EDTA sensitivity 
was compared by addition of EDTA (1-4 mM) to bacterial cells in Hank’s buffer 
followed by incubation for four hrs at 37°C. Percent survival was determined 
relative to no-EDTA controls. 
 
Sequence analysis of bacterial populations 
Genomic DNA was isolated from multiple colonies of each population (original 
and post exposure to NHS or mAb 6E4 with BRS) for sequence analysis. Primers 
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listed in Table 3 were used to amplify a portion of the target gene and 
surrounding sequence that included the tetranucleotide (or in the case of losA1, 
octonucleotide) repeat. The number of repeats was counted from each sequence 
and used to determine reading frame status as in frame (ON) or out of frame 
(OFF), as listed in Table 2.  
 
Statistical analysis 
Differences between experimental groups were assessed for statistical 
significance with an unpaired Student’s two-tailed t-test (GraphPad Prism 4, 
GraphPad Software, La Jolla, CA). 
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Table 1. H. influenzae strains used in this study 
Strain Mutant (-) or phase-ON variant Reference 
aRd    
 opsX- (170) 
 lpsA-  (170) 
 lgtF-  (282) 
 lic2A-  (282) 
 lgtC-  (282) 
 lic1D-  (228) 
 lic1A-ON  (53) 
 lic1D-, siaP-  (346) 
 lic1D-, lpsA- This study 
 lic1D-, lic2A- This study 
 lic1D-, lic2A-ON, lgtC- This study 
 lic1D-, lic2A-ON, lgtC-ON This study 
 lic1A-ON, lic2A-ON, lgtC-ON This study 
bR2846   
 lic1D- This study 
 lic1A-ON This study 
 lic1D-, lpsA- This study 
 lic1D-, lgtF- This study 
 lic1D-, lic2A-, lex2A- This study 
 lic1D-, lic2A-, lex2A-ON This study 
 lic1D-, lex2A-ON, lgtC-ON This study 
 lic1D-, lic2A-ON, lgtC-, lex2A- This study 
 lic1D-, lic2A-ON, lgtC-ON, lex2A- This study 
 lic1A-ON, lex2A-ON This study 
   
c2019    
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 lic1D- This study 
 lic1D-, lic2A- This study 
 lic1D-, lic2A-ON, lgtC- This study 
 lic1D-, lic2A-ON, lgtC-ON This study 
dEagan cap-   
 lic1D- This study 
 lic1D-, lic2A- This study 
 lic1D-, lic2A-ON, lgtC-ON This study 
   
a. Type d, unencapsulated variant, avirulent strain  
b. NTHi clinical isolate from patient with otitis media  
c. NTHi clinical isolate from patient with chronic obstructive pulmonary disease 
d. Type-b, spontaneous capsule- derivative of the clinical isolate Eagan 
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Table 2. Exposure to NHSa drives selection for LPS phase variants in H. 
influenzae 
Strain Serial passage Gene No. Repeats (Reading frame) 
Times 
observed 
Rd      
lpsA- NHS lic1A 17 (OFF)b → 18 (ON) 3/3 
lgtF- NHS lic2A 23 (OFF) → 22 (ON) 3/3 
lic1D- NHS lgtC 21 (OFF) → 22 (ON) 3/3 
lic1D- Neu5Ac + NHS lgtC 21 (OFF) → 22 (ON) 4/4 
lic1A-
ONc NHS lic2A 21 (OFF) → 22 (ON) 3/3 
     
R2846     
lpsA- NHS lic2A 24 (OFF) → 25 (ON) 3/3 
lic1D- NHS lic2A 24 (OFF) → 25 (ON) 6/7 
  lex2A 16 (OFF) → 14 (ON) 1/7 
lic1D- mAb 6E4 + BRSd lic2A 24 (OFF) → 25 (ON) 3/4 
  lex2A 16 (OFF) → 14 (ON) 1/4 
lic1A-
ONc NHS lic2A 24 (OFF) → 25 (ON) 1/2 
  lex2A 16 (OFF) → 14 (ON) 1/2 
     
2019     
lic1D- NHS lic2A 17 (OFF) → 16 (ON) 3/3 
     
Eagan 
(cap-)     
lic1D- NHS lic2A 17 (OFF) → 16 (ON) 4/4 
  lgtC 23 (OFF) → 24 (ON) 4/4 
163 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
a. NHS, normal human serum    
b. Refers to the reading frame of the indicated gene as in frame (ON) or out of frame (OFF) 
  based on the number of tetranucleotide repeats  
c. Bactericidal assays with lic1A-ON variants were conducted with CRP-deleted NHS 
d. BRS, baby rabbit serum 
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Table 3. Primers used in this study 
Target gene (repeat)a Direction Sequence  Reference 
lic1A (CAAT) F 5'-AGCTAACCGAGCTTGGGTAAAA-3' This study 
 R 5'-AAATCATTGTGGCACGGACG-3'  
lic2A (CAAT) F 5'-CAAGTGATTTATCCCCACGCGCCA-3' (415) 
 R 5'-CGTTCTTTTTCCAATCCGCTTGTT-3'  
lgtC (GACA) F 5'-TTTCATATCAAGAATATAAAAATT-3' (415) 
 R 5'-GGTTTTGAAGAAAAAGGCGAA-3'  
lex2A (GCAA) F 5'-GGCGGAATTATGTTAATCAC-3' (83) 
 R 5'-GCTTGCATATAAGCTTTTCG-3'  
oafA (GCAA) F 5'-TTCCAGAATTACTTGTAGGATCTTTG-3' (83) 
 R 5'-CATTAAAAACAAGCAGGAAAATAATAG-3'  
lic3A (CAAT) F 5'-CTCAGCCTTTCGGCACCCCG-3' This study 
 R 5'-GGCATCAAAGGCGGGTAGCTTGT-3'  
losA1 (CGAGCATA) F 5'-TCGAGCATCCATTTTCCCACT-3' This study 
 R 5'-TGCCCTCAAAGAGATCCAACG-3'  
hgp hemoglobin and 
hemoglobin-
haptoglobin binding 
protein, HI_0635 
(CCAA) 
F 5'-TCATCAACCCCTCGAACTGC-3' This study 
 R 5'-TCGTCAAGATCCTGTTGCCC-3'  
hgp hemoglobin and 
hemoglobin-
haptoglobin binding 
protein, HI_0661 
(CCAA) 
F 5'-CTTTGCCCAAAACGTCCAGC-3' This study 
 R 5'-ACGTGCTTGCCTATTCCGTT-3'  
hgp hemoglobin and 
hemoglobin-
haptoglobin binding 
protein, HI_1565 
(CCAA) 
F 5'-TTATGCTTGGGCTAACGGCA-3' This study 
 R 5'-CCGGTTTCATAGCGCACAAG-3'  
hgp hemoglobin and 
hemoglobin-
haptoglobin binding 
protein, HI_0712 
F 5'-TTCAGCTTGACGAAGCCCAT-3' This study 
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hgp hemoglobin and 
hemoglobin-
haptoglobin binding 
protein, HI_0712 
(CCAA) 
F 5'-TTCAGCTTGACGAAGCCCAT-3' This study 
 R 5'-TCCGCTGGGAAAGTCACATC-3'  
Drug/metabolite 
exporter, HI_0687 
(TTTA) 
F 5'-GCAGTTATTGGTTGGGCTGC-3' This study 
 R 5'-GCATCCCATAAAAGCCAGCG-3'  
mod type III 
restriction/modification 
system methylase,  
HI_1058 (TGAC) 
F 5'-TTTTGCGTCAAAAAGCCGGT-3' This study 
 R 5'-TGTGTATTGAATGGCGGGCA-3'  
Putative 
glycosyltransferase, 
HI_1386 (CCAA) 
F 5'-TTGGAGAAGATGGCAAAGGCT-3' This study 
 R 5'-TGAAGTCACTACCGCAACGG-3'  
a. Sequence of the tandem repeat present within the sequence amplified for each target gene 
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Figure 1. LPS structural requirements for resistance to human serum in the strain 
Rd. LPS structure proposed for Rd (169), with arrows indicating extensions 
dependent on LPS biosynthesis genes (black, bold), or phase variable genes 
(grey, bold), and dashed line indicating the border between inner and outer core 
LPS structures (A). Mean fluorescence intensity (MFI) for binding of purified 
human IgG to the surface of the Rd lic1D- strain compared to the opsX- mutant, 
with or without trypsin digestion (B). Bactericidal assays, where survival in human 
serum is determined relative controls with the same serum heat-inactivated to 
eliminate complement activity. Survival following serial passage in human serum 
is indicated for Rd and Rd mutants (C-G) in 3% normal human serum (NHS). 
Data shown are means and SEM (representative experiment in triplicate shown 
for D-G). Statistical analysis (n ≥ 3) was performed by an unpaired t-test; 
**P<0.01, ***P<0.001. 
 
167 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. LPS structural requirements for resistance to human serum in the strain 
R2846. LPS structure proposed for NTHi clinical isolate R2846 (225), with arrows 
indicating extensions dependent on LPS biosynthesis genes (black, bold), or 
phase variable genes (grey, bold), and dashed line indicating the border between 
inner and outer core LPS structures (A). Also included in parentheses is the 
phase variable gene responsible for the proposed alternative glucose extension 
(grey, bold), which can be attached to the same hexose moiety as the di-
galactoside. Bactericidal assays for the serial passage in in 5% normal human 
serum (NHS), with survival following the round of serum exposure indicated, for 
R2846 mutants (B-D). Data shown are means and SEM (representative 
experiments in triplicate).  
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Figure 3. Exposure to human serum drives selection for resistant populations in 
multiple strains of H. influenzae. Bactericidal assays following serial passage of 
bacteria in human serum, with the round of serum exposure indicated, for Rd 
lic1D- (A, 3% normal human serum, NHS), R2846 lic1D- (B, 4% NHS), Eagan 
cap-, lic1D- (D, 2% NHS), and 2019 lic1D- (F, 4% NHS). Data shown are means 
and SEM (representative experiments in triplicate). 
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Figure 4. Contribution of LPS hexose extensions to survival in human serum. 
Bactericidal assays in human serum for lic2A, lgtC, and lex2A (R2846 only) 
phase-on variants (ON) and mutants (-) in Rd lic1D- (A, 2% normal human 
serum, NHS), R2846 lic1D- (B, 4% NHS), Eagan cap-, lic1D- (C, 1% NHS), and 
2019 lic1D- (D, 4% NHS). Data shown are means and SEM. Statistical analysis 
(n ≥ 3) was performed by an unpaired t-test; *P<0.05, ***P<0.001. 
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Figure 5. Di-galactoside expression protects against human IgG binding and 
bactericidal activity. Histogram of purified human IgG binding to lic2A and lgtC 
phase-on variants (black), a lic2A phase-on, lgtC- mutant (dark grey), and a 
lic2A- mutant (light grey) in Rd lic1D- (A). Graphical summary of IgG mean 
fluorescence intensity (MFI) is also shown. Bactericidal assays in IgG-depleted 
human serum with or without purified human IgG added back, as indicated, for 
lic2A and lgtC phase-on variants and lic2A- mutants in Rd lic1D- (B, 2% IgG-
depleted normal human serum, NHS). Histogram of purified human IgG binding 
to lic2A and lgtC phase-on variants (black) and a lic2A- mutant (grey) of R2846 
lic1D- (C), with a graphical summary of IgG MFI. Bactericidal assays in IgG-
depleted human serum with or without purified IgG added back, as indicated, for 
lic2A and lgtC phase-on variants and lic2A- mutants in R2846 lic1D- (D, 4% IgG-
depleted NHS). Data shown are means and SEM. Statistical analysis (n ≥ 3) was 
performed by an unpaired t-test; *P<0.05, **P<0.01, ***P<0.001. 
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Figure 6. Di-galactoside expression protects against binding and bactericidal 
activity of the anti-LPS mAb 6E4. Bactericidal assays for the serial passage of 
R2846 lic1D- in mAb 6E4 and baby rabbit serum (BRS), with the round of 
exposure indicated (A, 15% BRS, 0.5% mAb 6E4; representative experiment in 
triplicate). Bactericidal assays in mAb 6E4 and BRS for lic2A and lgtC phase-on 
variants and mutants (B, 15% BRS, 0.5% mAb 6E4). Histogram and graphical 
summary for binding of mAb 6E4 to lic2A and lgtC phase-on variants and 
mutants in R2846 lic1D- (C). Data shown are means and SEM. Statistical 
analysis (n ≥ 3) was performed by an unpaired t-test; *P<0.05, **P<0.01, 
***P<0.001. 
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Figure 7. Di-galactoside, sialic acid, and ChoP have independent and additive 
effects on bacterial survival in human serum. Bactericidal assays in human 
serum for lic2A, lgtC, and lex2A (R2846 only) phase-on variants (ON) or mutants 
(-), with or without sialic acid (Neu5Ac) added to growth medium (+). Results are 
shown for Rd lic1D- (A), a lic1A phase-on variant population of Rd (B), R2846 
lic1D- (C), and a lic1A phase-on variant population of R2846 (D). Bactericidal 
assays were performed at the concentration of normal human serum (NHS) 
indicated and in the case of lic1A phase-on variants, serum was first depleted of 
C-reactive protein. Data shown are means and SEM. Statistical analysis (n ≥ 3) 
was performed by an unpaired t-test; *P<0.05, **P<0.01, ***P<0.001. 
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Supplementary Table 1. Primers used for the construction of H. influenzae 
mutants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 1. Primers used for the construction of H. influenzae mutants 
Target 
gene Direction Sequence Reference 
lex2A 
amplify F 5'-ACCCCTTTGCATTCAACCGCT-3' This study 
 R 5'-CCGAATGGTTCTGCGGAGGGC-3'  
lex2A XmaI F 5'-GCGGCGGGGCCCGCTTGCTTGCCAAGACTATC-3' This study 
 R 5'-GCGGCGGGGCCCGCAAGCAAGCAAAGAGTGAC-3'  
aad9 F 
5'-
GCGGCGGGGCCCATCGATTTTCGTTCGTGAATACATGT
T-3' This study 
 R 
5'-
GCGGCGGGGCCCTATGCAAGGGTTTATTGTTTTCTAAA
ATCTGA-3'  
siaP F 5’-GTTCACACAGGAGCGAAT-3’ (346) 
 R 5’-TACAGAGTATGCTGCTGC-3’  
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Supplemental Figure 1. Di-galactoside expression protects against classical 
pathway complement-mediated killing. Bactericidal assays in baby rabbit serum 
(BRS) with or without purified IgG for lic2A and lgtC phase-on variants and lic2A- 
mutants in Rd lic1D- (A, 4% BRS). Bactericidal assays in human serum with or 
without Mg-EGTA treatment for lic2A and lgtC phase-on variants and lic2A- 
mutants in Rd lic1D- (B, 2% normal human serum, NHS). Bactericidal assays in 
BRS with or without purified IgG in R2846 lic1D- (C, 15% BRS). Bactericidal 
assays in human serum with or without Mg-EGTA-treatment in R2846 lic1D- (D, 
4% NHS). Data shown are means and SEM. Statistical analysis (n ≥ 3) was 
performed by an unpaired t-test; *P<0.05, ***P<0.001. 
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Supplemental Figure 2. Di-galactoside expressing variants have dual resistance 
to human IgG binding and mAb 6E4 binding and bactericidal activity. Histogram 
and graphical summary of human IgG (A) and mAb 6E4 (B) binding to lex2A 
phase-on variants (black) compared to a lex2A- mutant (grey) in R2846 lic1D-, 
with graphical MFI summaries. Summary of mean fluorescence intensity (MFI) 
for mAb 6E4 binding to lic2A and lgtC phase-on variants isolated following 
passage in normal human serum (NHS) compared to lic2A- mutants in R2846 
lic1D- (C) and Rd lic1D- (D). Bactericidal assays in human serum for lic2A and 
lgtC phase-on variants isolated following passage in mAb 6E4 and BRS 
compared to lic2A- mutants in R2846 lic1D- (E, 4% NHS). Data shown are 
means and SEM. Statistical analysis (n ≥ 3) was performed by an unpaired t-test; 
*P<0.05, ***P<0.001. 
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Supplemental Figure 3. Additive and independent effects on bacterial survival in 
human serum for LPS modifications in multiple H. influenzae strains. Bactericidal 
assays in human serum for a Rd lic2A phase-on, lgtC- mutant (2% normal 
human serum, NHS) and a R2846 lic2A phase-on, lgtC- mutant (4% NHS) with 
or without sialic acid (Neu5Ac) added (+) to growth medium (A). Also, bactericidal 
assays in human serum for lex2A and lgtC phase-on variants compared to a 
lex2A phase-on, lgtC- mutant and a lex2A-, lgtC- mutant in R2846 lic1D- (B, 4% 
NHS).  Individual and collective contributions of lic2A, lgtC and sialic acid 
(Neu5Ac) modifications in Eagan cap-, lic1D- (C) and 2019 lic1D- (D). 
Bactericidal assays were performed at the concentration of normal human serum 
(NHS) indicated. Data shown are means and SEM. Statistical analysis (n ≥ 3) 
was performed by an unpaired t-test; *P<0.05, **P<0.01, ***P<0.001. 
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Model for the role of phase variation during Haemophilus influenzae colonization 
 
 H. influenzae must evade host recognition in order to successfully 
colonize the human respiratory tract. Antibody and complement are immune 
components present at the mucosal surface, and are important for the control of 
H. influenzae colonization and disease (78, 146, 202, 330). We have shown that 
the phase variable LPS structure phosphorylcholine (ChoP) is one of the 
bacterial factors that contributes to protection against host recognition (Chapter 
3), (53). ChoP attachment to the LPS alters the physical characteristics of the 
outer membrane, resulting in reduced membrane accessibility. The altered 
membrane accessibility of ChoP phase-on variants limits antibody binding to the 
bacterial surface, and increases survival in the presence of complement. ChoP 
phase-on variants are also less susceptible to cationic antimicrobial peptides 
(229). Through a screen to identify NTHi genes required for complement 
resistance, we characterized an additional structure on the outer membrane that 
affects membrane accessibility in H. influenzae. The expression of vacJ and the 
associated yrb genes increase the expression of an ABC transporter that 
recycles phopsholipids from the outer leaflet of the outer membrane to the inner 
leaflet (Chapter 4) (282). In the absence of this activity, the outer membrane is 
less stable and there is increased antibody binding to LPS epitopes. ChoP and 
the vacJ/yrb associated transporter system are two examples of how alterations 
in membrane stability affect accessibility of host antibody to bacterial targets.  
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 Aside from the vacJ and yrb genes, the remaining hits identified in the 
screen for complement resistance determinants were LPS biosynthesis genes, 
several of which were phase variable. We next examined the dynamics of phase 
variation in H. influenzae, and found that serial exposure to human antibody and 
complement drives selection for phase variants expressing ChoP, the galα1-4gal 
di-galactoside, and an alternative glucose extension (Chapter 5). Each of these 
structures, in addition to another LPS phase variable molecule, sialic acid, 
contributed independently to bacterial survival in the presence of complement. 
Finally, we observed an additive effect for ChoP, the di-galactoside, and sialic 
acid in combination. Phase variants with the most outer core LPS modifications 
had the highest level of complement resistance. 
 These data inform our model of how LPS phase variation in H. influenzae 
contributes to bacterial survival during human colonization and disease. We 
hypothesize that phase variation of LPS structures aids in the evasion of host 
recognition. Unlike most bacteria, H. influenzae has a limited number of two-
component regulatory systems, where environmental triggers stimulate gene 
regulation; only four two-component systems have been identified and three of 
these have been characterized (72, 366, 369). Instead, H. influenzae has a 
number of phase variable genes, creating both intra- and interstrain surface 
diversity. Importantly, phase variation occurs in ‘contingency’ genes, not 
housekeeping genes, and affects bacterial survival during exposure to different 
host conditions (263). Phase variation of surface structures allows H. influenzae 
to spread survival risk among a heterogeneous population, enabling rapid 
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selection of the most-fit phase variants. This form of ‘bet-hedging’ is a specific 
evolutionary strategy, designed for survival in an environment where survival 
determinants are rapidly changing (309). Evolutionary theorists have modeled 
conditions for the evolution and maintenance of phase variation using H. 
influenzae as an example, and found that broad survival conditions select for the 
adoption of this strategy in bacteria (294).  
The repertoire of host antibody present during colonization and disease 
development is a diverse and rapidly changing immune pressure on H. 
influenzae. In addition to antibody, complement levels increase dramatically 
during inflammation, which itself influences the type and amount of antibodies 
present on the mucosal surface (146). Over time, affinity maturation alters the 
repertoire of antibodies secreted (265). Phase variation of surface structures 
allows for the selective enrichment of bacteria with reduced antibody binding and 
complement deposition. However, any phase variant population resulting from a 
given selection event will still contain alternative phase variants, allowing rapid 
selection in the face of a different host immune response. We hypothesize that 
over the course of colonization and disease development, phase variants are 
constantly enriched for or selected against due to the immune pressures of 
antibody binding and complement-mediated lysis (see model in Figure 1).  
Several of the phase variable LPS structures expressed by H. influenzae 
mimic host epitopes, and are not readily recognized by human antibody (90, 334, 
401). We propose that, rather than create a source of antigenic variation, phase 
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variation of outer core LPS structures serves to shield conserved inner core 
structures from antibody binding. In this way, outer core LPS phase variants 
protect inner core structures from immune recognition, promoting bacterial 
survival without alteration of the conserved portion of the LPS. To summarize, in 
our model the phase variation of LPS structures allows H. influenzae to evade 
recognition by human antibody and complement, and this contributes to the 
successful colonization of this extracellular pathogen. 
 
Multifunctional roles of phase variable LPS structures 
 
Each of the phase variable LPS modifications discussed in this work 
reduces host recognition through a different mechanism. This divergence may 
contribute to the ability of each of these phase variable molecules to have an 
additive effect on bacterial survival in combination. For example, while sialic acid 
attachment to the LPS decreases alternative pathway complement-mediated 
lysis (95), the expression of the di-galactoside structure and the alternative 
glucose extension reduce antibody binding, contributing to survival in the context 
of classical pathway complement-mediated lysis (Chapter 5). Also, it was shown 
previously that the expression of lgtC, which is responsible for the attachment of 
the distal galactose residue of the di-galactoside structure, reduces binding of the 
complement protein C4b (164). The reduction of C4b binding and antibody 
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binding are two separate ways to affect classical pathway complement-mediated 
lysis, and both likely contribute to survival.  
In contrast, ChoP has a more general effect on the physical properties of 
the outer membrane (53). In addition to reducing antibody binding and 
complement-mediated killing, ChoP expression increases bacterial survival in the 
presence of cationic antimicrobial peptides (229). Also, ChoP expression affects 
binding of IgG, IgM, and IgA, while di-galactoside expression affects binding of 
IgG, but not IgM. The mechanisms of the effect of oafA and other phase variable 
structures, such as los1A, have yet to be characterized. Some phase variable 
structures in H. influenzae are also phase variably expressed in other bacteria, 
including ChoP and the galα1-4gal di-galactoside structure (407, 431). However, 
the effects of these phase variable structures are not always equivalent. For 
example, sialylation in Neisseria increases factor H deposition, which helps to 
protect against complement-mediated lysis, but has no effect on factor H binding 
to H. influenzae (95, 310). Understanding the mechanisms of how each phase 
variable molecule contributes to bacterial survival is important for the design of 
strategies to minimize their effectiveness. 
While we have shown that bacteria with the maximum number of outer 
core LPS extensions have the greatest resistance against antibody and 
complement-mediated killing, each of the structures we have highlighted is not 
constitutively expressed. A phase variable expression profile suggests there are 
also host environments for which these structures are detrimental to bacterial 
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survival. This concept has been explored in detail for the phase variation of 
ChoP. ChoP phase-on bacteria are recognized by C-reactive protein (CRP), 
which initiates complement-mediated killing (416). In environments with high 
levels of CRP, such as in the blood, ChoP phase-on variants are killed more 
readily than ChoP phase-off variants. In human serum, ChoP phase-off bacteria 
predominate, unless CRP is depleted from the serum (416). The conditions 
favoring fimbriae phase-on and phase-off variants have also been explored. H. 
influenzae isolated from the nasopharynx are highly fimbriated, while bacteria 
isolated from the bloodstream do not have fimbriae (254, 408). There may be 
immune components in the blood that recognize fimbriae and are less abundant 
on the mucosal surface, or their effect is not as detrimental as a lack of fimbriae 
for increased epithelial cell adherence on the mucosal surface. Another example 
of selection against phase-on variants is the increase in phase-off variants of the 
HMW1 and HMW2 adhesins over time in COPD patients, which correlates with 
increased anti-HMW1 and HMW2 titers in patients (51). In this case, antibody 
recognition of a phase variable structure is associated with selection against 
variants expressing that structure. 
While the benefits and detriments of ChoP expression and some outer 
membrane proteins have been explored, the negative consequences of the other 
phase variable LPS structures remain unclear. One example of a potential 
disadvantage is an increase in susceptibility to phage infection. LPS structures 
are critical for phage recognition in several bacterial strains (181, 432). In H. 
influenzae, lic2A phase-on variants are more susceptible to infection with the 
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HP1c1 phage than lic2A- mutants (435). The in vivo consequences of phage 
predation are difficult to assess. Not all phages are lytic, and phage 
transformation results in exchange of genetic material that could be either 
advantageous or disadvantageous for survival. However, perhaps lic2A phase-on 
variants are selected against when there is an increase in lytic HP1c1 phage 
populations. Another potential consequence for the expression of LPS phase 
variable structures is recognition by host galectins. These molecules recognize 
structures found on the outer core of the LPS of H. influenzae, such as GalNAc 
(399). Galectin recognition, while not directly bactericidal, can increase immune 
responses resulting in bacterial clearance (332). In addition to phase variation, 
there may be consequences for the differential regulation of genes controlling the 
expression of other outer membrane structures. For example, vacJ expression is 
not always up-regulated, suggesting there may be advantages in some 
circumstances for reduced outer membrane stability, or at least less phospholipid 
turnover (282). In Escherichia coli, mutants in the Tat protein export system have 
increased membrane permeability and susceptibility to antimicrobial agents, but 
are also more resistant to phage infection (364). However, it is unclear what 
outer membrane protein or LPS structures were responsible for these effects in 
tat- mutants. Clearly, there is a need to further study the consequences of phase 
variable expression on bacterial survival in different host environments. 
  
Bacterial targets of host antibody 
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 Surface exposed structures on the outer membrane of H. influenzae are 
targets for recognition by host antibodies. Outer membrane proteins are 
susceptible to antibody binding, and immunization with purified outer membrane 
proteins can induce protein-specific antibodies (32, 175, 386). The only currently 
licensed vaccine with efficacy against NTHi disease contains the protein D outer 
membrane protein (307). However, it is unclear whether the efficacy against 
NTHi disease in protein D-immunized individuals is from direct protein D 
recognition and bacterial clearance, or from blocking its enzymatic activity. 
Protein D is a glycerophosphodiester phosphodiesterase, and is critical for 
uptake of choline from glycerophosphocholine, the major source of choline on the 
mucosal surface (90). Immunization against protein D prevents its enzymatic 
activity, and bacteria have reduced ChoP expression (185, 385). Therefore, 
individuals immunized against protein D may inhibit ChoP expression in 
colonizing bacteria, which reduces bacterial survival in the presence of natural 
host antibody and complement (53).  
 The LPS is also a major target of human antibody. In an experiment where 
purified LPS was used to deplete anti-LPS antibodies through incubation in 
serum (serum pre-absorption), it was found that IgM from rabbits binds primarily 
to LPS structures, rather than outer membrane proteins (85). Similar results were 
found in human serum, where the majority of the bactericidal activity was due to 
IgG recognition of LPS structures on H. influenzae (53). Studies where mice 
were immunized with heat-killed H. influenzae have led to the isolation of 
monoclonal antibodies capable of binding both LPS phase variable structures, 
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such as the galα1-4gal di-galactoside, and structures comprising the inner core 
region of the LPS (33, 34). 
 Our hypothesis, based on the evidence presented in this work, is that 
phase variation of LPS modifications protects conserved inner core structures 
from antibody recognition. We have shown two separate examples of phase 
variable structures that restrict recognition of inner core structures (Chapter 5), 
(53). These studies used LPS truncation mutants paired with defined monoclonal 
antibodies that had known epitope specificities. However, it is unclear whether 
LPS phase variation also affects outer membrane protein recognition. The most 
prominent candidate for this is ChoP, which has a general affect on membrane 
accessibility. While there may be a minor role for ChoP in reducing recognition of 
outer membrane proteins, we found that the majority of antibodies affected by 
ChoP expression targeted LPS structures. 
 Screens of H. influenzae strains have identified LPS biosynthesis genes 
as the major determinants of bacterial survival (427). For example, in the screen 
to identify genes necessary for complement resistance in NTHi (Chapter 4), all 
hits, other than the vacJ and associated yrb genes, affected LPS biosynthesis 
(282). Several LPS biosynthesis genes were also identified in a similar screen for 
complement resistance determinants in the same NTHi strain (211). One of the 
hits identified in both screens was a previously uncharacterized gene that 
encodes a hypothetical protein. This protein, R2866_0112, was found to be 
important for LPS outer core extensions, and mutants have increased IgM 
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binding to the bacterial surface as well as reduced virulence in a murine model of 
otitis media (211). A screen of H. influenzae genes required for short-term 
persistence in murine lungs determined that both metabolism genes and LPS 
biosynthesis genes were critical for bacterial survival (115). While these studies 
have identified many important LPS biosynthesis genes, some of which were hits 
in multiple screens, several of these genes cause severe LPS truncations when 
disrupted. The individual contributions to bacterial survival for each LPS structure 
affected by these mutations require further investigation.  
It remains unclear if the list of genes affecting bacterial survival in the 
presence of host antibody and complement is complete. While we have shown a 
major role for LPS phase variable genes, there is still the possibility of minor 
contributions from other genes. For example, the outer membrane protein P6 
affects outer membrane stability and increases survival in serum, and may 
therefore also affect antibody accessibility to the LPS or other outer membrane 
proteins (276). Modifications affecting the charge of the LPS may also be 
important for host recognition, as it has been shown that the sensitivity of 
Salmonella typhimurium mutants to antimicrobial peptides is related to the 
charge of the LPS in each mutant (311). In H. influenzae, mutation of htrB, which 
reduces lipid A acylation, results in increased sensitivity to the β-defensin HBD-2 
(365). However, the potential effects of such mutations on antibody recognition 
remain largely undefined. 
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 The study of the effect of phase variation on host recognition is reliant 
upon a source of antibodies that can bind H. influenzae surface structures. 
However, there is a major problem with the use of animal models for this 
purpose. While animal models of H. influenzae colonization and disease are 
useful for the investigation of many virulence factors in vivo, they are not ideal for 
the study of antibody evasion. The best example for why this is a problem is the 
differential recognition of the di-galactoside structure galα1-4gal in humans 
versus rodents. This di-galactoside mimics host glycoconjugates, specifically P 
blood group antigens, and humans do not make antibodies capable of 
recognizing these structures. However, the linkage of this structure is different in 
rodents, which make antibodies that bind the galα1-4gal di-galactoside on H. 
influenzae (33). The expression of the di-galactoside, therefore, is only 
advantageous in avoiding antibody recognition when exposed to human, not 
rodent, antibody (388). This example highlights the concern with a reliance on 
animal models for vaccination studies. It is clear that experiments incorporating 
human antibodies should be included in the design and testing of all H. 
influenzae vaccine candidates, as information from rodent models may be 
misleading. The group of M. Apicella and colleagues has developed a new 
experimental model of human NTHi colonization (303). This model will likely be 
useful for the study of bacterial factors that contribute to survival in the human 
nasopharynx. Importantly, a caveat of using human antibodies and the human 
carriage model in screening vaccination candidates is the lack of naïve hosts, as 
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it is estimated that all humans have been exposed to H. influenzae by adulthood, 
and colonization occurs early in life (113). 
 
Vaccine design for protection against NTHi carriage and disease 
 
While the Hib vaccine has been extremely successful in limiting invasive 
H. influenzae disease, there is still a large burden of respiratory tract disease 
associated with H. influenzae infection (2, 275). Acute otitis media infections and 
COPD exacerbations often are recurrent, as patients acquire new strains (148, 
296). Otitis media-prone children produce less serum IgG against outer 
membrane proteins including protein D and P6, suggesting the frequency of otitis 
media events could be reduced through the stimulation of a more protective 
immune response (191). The primary objective for control of NTHi related 
disease is reducing colonization. Our model for the importance of phase variation 
in evasion of host recognition suggests that LPS phase variation should be 
considered during vaccine design. While there is currently no evidence that 
suggests LPS phase variation affects recognition of outer membrane proteins, 
several vaccine candidates include LPS structural targets (140, 167). Phase 
variation of the vaccine targets themselves, or other LPS structures that interfere 
with epitope recognition, should be considered.  
 Another issue related to the development of LPS-based vaccines for 
protection against NTHi disease is the stimulation of a protective immune 
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response. Similar to capsular antigens, LPS is a T cell independent epitope. 
Therefore, effective vaccination will likely require conjugation to a protein. In a 
murine model of otitis media, serum depleted of antibodies targeting outer 
membrane proteins was less protective following passive immunization than 
whole serum or serum without antibodies to LPS structures, suggesting that LPS 
antibodies are not protective (16). However, other studies have shown that 
protective anti-LPS antibodies can be generated using protein conjugate 
vaccines (167, 429). Our studies have identified a critical role for IgG and IgM in 
the recognition of LPS structures and killing in the presence of complement. 
While IgA is the most abundant natural antibody present on the mucosal surface, 
antigen-specific IgG and IgM generated following immunization can be isolated 
from the serum and respiratory tract (202, 379). The seven-valent S. pneumoniae 
conjugate vaccine, which reduces bacterial carriage, induces production of 
serum IgG as well as salivary IgA and IgG (291). It is likely that mucosal IgG and 
IgM will be required for protection against NTHi colonization.  
 Given our model for the importance of phase variation in shielding inner 
core epitopes, one strategy for future vaccination efforts is the inclusion of 
multiple LPS targets. For example, a vaccine could be designed to stimulate the 
production of antibodies that bind a phase variable structure as well as the inner 
core epitope it normally shields from recognition. In this way, phase-on and 
phase-off variants would both be vaccine targets. The initial promise of the 
protein D vaccine could also be expanded upon, perhaps by more direct 
targeting of ChoP. While natural anti-ChoP antibodies are low affinity, 
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conjugation to a protein carrier allows for stimulation of protective IgG anti-ChoP 
antibodies (379, 387).  
 
Future directions 
 
 This work has focused on the impact of phase variation on bacterial 
survival in the presence of human antibody and complement. However, these are 
only some of the many immune components encountered by H. influenzae during 
colonization (Chapter 1). Moving forward, the role of phase variation should be 
explored in other contexts. This may reveal as yet uncharacterized advantages, 
and disadvantages, for the different phase variant molecules present in H. 
influenzae.  
 One area that requires further research is the effect of phase variation on 
recognition by immune cells, such as macrophages and neutrophils. Neutrophils 
are important for limiting H. influenzae colonization (440), and the effect of phase 
variation on neutrophil recognition has yet to be characterized. TLR4 stimulation 
is primarily lipid A-dependent, although it has been shown that core 
oligosaccharide is recognized by other pattern recognition receptors (66). While 
still largely unexplored, it is possible that phase variation affects cell-mediated, in 
addition to cell-free, immune responses. 
Bacterial factors affecting transmission of H. influenzae to new hosts is 
another area requiring further investigation. For example, we hypothesize that 
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some phase variants have enhanced survival during the selective bottleneck of 
transmission. Unfortunately, there is no transmission model for H. influenzae to 
address such hypotheses. Transmission in humans would be even more difficult 
to track, due to the common carriage of H. influenzae (similar to the issue of a 
lack of naïve hosts). However, studies of infants and their caregivers or children 
in daycare settings are potential environments to address such questions through 
epidemiological data.  
 In addition to transmission to new hosts, phase variation could affect 
transmission to new anatomical sites within the same host. For example, some 
phase variants may be more successful during invasion of the middle ear, 
leading to otitis media, or the lung, which can cause bronchitis or COPD 
exacerbations (272). We have shown that upper respiratory tract isolates are 
more susceptible to IgM binding than lower respiratory tract isolates, and that this 
correlates with reduced vacJ expression (282). However, there may be other 
bacterial factors that contribute to survival in these different host environments. 
Even within the same host site, such as the nasopharynx, the repertoire of 
immune components is constantly changing. For example, there may be 
differences in survival conditions for bacteria on the un-inflamed versus inflamed 
mucosal surface. H. influenzae can induce inflammation in several ways 
(Chapter 1), and during inflammation there is increased leakage of serum 
components to the mucosal surface from the airway vasculature (135). There is 
also evidence that while ChoP is important for initial colonization, di-galactoside 
expression is perhaps more critical for long-term colonization or for survival 
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under inflammatory conditions (415). Bacterial factors contributing to survival 
during initial inflammation following bacterial exposure may also be important in 
the setting of chronic inflammatory diseases, such as COPD (409).  
 Finally, H. influenzae and its human host are not the only factors involved 
in the host-pathogen dynamic. In addition to phage predation of H. influenzae, 
discussed previously, there are also a number of bacteria in the respiratory tract 
flora that compete with H. influenzae for space and survival. For example, some 
H. influenzae strains are resistant to bacteriocins produced by competing 
bacteria (257). In a co-colonization study, neutrophil recruitment induced by H. 
influenzae colonization contributes to the clearance of S. pneumoniae (230). H. 
influenzae can also promote the survival of other bacteria. For example, quorum 
sensing molecules produced by H. influenzae promote the persistence of another 
prevalent nasopharyngeal bacterium, Moraxella catarrhalis, in a murine model of 
otitis media (8). The role of phase variation in evasion of host immunity may only 
be a starting point for how these important molecules contribute to bacterial 
survival. 
 
Concluding remarks 
 
 The evolution and maintenance of phase variable LPS biosynthesis genes 
in H. influenzae indicates the importance of these features in the promotion of 
bacterial survival. Phase variation of LPS structures allows bacteria to quickly 
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adapt to a range of different host conditions. In this work, we show the 
importance of LPS phase variation in bacterial evasion of antibody and 
complement-mediated lysis. We hypothesize phase variable outer core LPS 
structures shield conserved inner core structures from host recognition during 
colonization. While the mechanisms of how each phase variable LPS structure 
affects antibody and complement recognition are diverse, these modifications 
have an additive effect on bacterial survival in combination. The impact of phase 
variation on antibody and complement recognition of bacteria is important to 
consider in the efforts to design a vaccine to protect against both NTHi 
colonization and infection. While there is clearly a role for phase variation in 
evasion of host recognition, the impact of these phase variable structures on 
other aspects of the host immune response against H. influenzae, including the 
potential disadvantages of their expression, remain important areas for future 
investigation. We conclude that the phase variation of LPS structures is a critical 
strategy for the successful colonization of the extracellular bacterium H. 
influenzae. 
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Figure 1. Model for the role of phase variation in evasion of antibody and 
complement-mediated lysis. Representation of bacteria with inner core LPS 
structures (blue) modified with phase variable structures including 
phosphorylcholine (ChoP, orange circles), the galα1-4gal di-galactoside (Di-gal, 
green triangles), and sialic acid (Neu5Ac, purple plus signs). The bacteria with 
the maximum number of outer core modifications have the greatest resistance to 
antibody and complement mediated lysis (top). Heterogeneous populations 
enriched for highly modified LPS (right) or minimally modified LPS (left) are 
selected depending on the host immune components present (bottom). 
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